Altered	O
replication	O
timing	O
of	O
the	O
HIRA	B-GeneOrGeneProduct
/	O
Tuple1	B-GeneOrGeneProduct
locus	O
in	O
the	O
DiGeorge	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
Velocardiofacial	I-DiseaseOrPhenotypicFeature
syndromes	I-DiseaseOrPhenotypicFeature
.	O

DiGeorge	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
Velocardiofacial	I-DiseaseOrPhenotypicFeature
syndromes	I-DiseaseOrPhenotypicFeature
(	O
DGS	B-DiseaseOrPhenotypicFeature
/	O
VCFS	B-DiseaseOrPhenotypicFeature
)	O
are	O
endowed	O
by	O
a	O
similar	O
complex	O
phenotype	O
including	O
cardiovascular	B-DiseaseOrPhenotypicFeature
,	O
craniofacial	I-DiseaseOrPhenotypicFeature
,	O
and	I-DiseaseOrPhenotypicFeature
thymic	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
,	O
and	O
are	O
associated	O
with	O
heterozygous	O
deletions	O
of	O
22q11	O
chromosomal	O
band	O
.	O

The	O
Typically	O
Deleted	O
Region	O
in	O
the	O
22q11	O
.	O
21	O
subband	O
(	O
here	O
called	O
TDR22	O
)	O
is	O
very	O
gene	O
-	O
dense	O
,	O
and	O
the	O
extent	O
of	O
the	O
deletion	O
has	O
been	O
defined	O
precisely	O
in	O
several	O
studies	O
.	O

However	O
,	O
to	O
date	O
there	O
is	O
no	O
evidence	O
for	O
a	O
mechanism	O
of	O
haploinsufficiency	O
that	O
can	O
fully	O
explain	O
the	O
DGS	B-DiseaseOrPhenotypicFeature
/	O
VCFS	B-DiseaseOrPhenotypicFeature
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
candidate	O
gene	O
HIRA	B-GeneOrGeneProduct
/	O
Tuple1	B-GeneOrGeneProduct
mapping	O
on	O
the	O
non	O
-	O
deleted	O
TDR22	O
,	O
in	O
DGS	B-DiseaseOrPhenotypicFeature
/	O
VCFS	B-DiseaseOrPhenotypicFeature
subjects	O
presents	O
a	O
delayed	O
replication	O
timing	O
.	O

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cell	O
ratio	O
showing	O
the	O
HIRA	B-GeneOrGeneProduct
/	O
Tuple1	B-GeneOrGeneProduct
locus	O
localised	O
toward	O
the	O
nuclear	O
periphery	O
.	O

It	O
is	O
known	O
that	O
replication	O
timing	O
and	O
nuclear	O
location	O
are	O
generally	O
correlated	O
to	O
the	O
transcription	O
activity	O
of	O
the	O
relative	O
DNA	O
region	O
.	O

We	O
propose	O
that	O
the	O
alteration	O
in	O
the	O
replication	O
/	O
nuclear	O
location	O
pattern	O
of	O
the	O
non	O
-	O
deleted	O
TDR22	O
indicates	O
an	O
altered	O
gene	O
regulation	O
hence	O
an	O
altered	O
transcritpion	O
in	O
DGS	B-DiseaseOrPhenotypicFeature
/	O
VCFS	B-DiseaseOrPhenotypicFeature
.	O
Manganese	B-GeneOrGeneProduct
superoxide	I-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
(	O
Mn	B-GeneOrGeneProduct
-	O
SOD	I-GeneOrGeneProduct
)	O
gene	O
polymorphisms	O
in	O
urolithiasis	B-DiseaseOrPhenotypicFeature
.	O

Polymorphism	O
in	O
manganese	B-GeneOrGeneProduct
superoxide	I-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
gene	O
(	O
Mn	B-GeneOrGeneProduct
-	O
SOD	I-GeneOrGeneProduct
)	O
is	O
a	O
new	O
approach	O
to	O
identify	O
its	O
probable	O
association	O
with	O
urolithiasis	B-DiseaseOrPhenotypicFeature
.	O

Oxidative	O
stress	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
stone	B-DiseaseOrPhenotypicFeature
formation	I-DiseaseOrPhenotypicFeature
in	O
the	O
renal	O
system	O
.	O

MnSOD	B-GeneOrGeneProduct
is	O
one	O
of	O
the	O
primary	O
enzymes	O
that	O
directly	O
scavenges	O
potential	O
harmful	O
oxidizing	O
species	O
.	O

A	O
valine	B-SequenceVariant
(	O
Val	I-SequenceVariant
)	O
to	I-SequenceVariant
alanine	I-SequenceVariant
(	O
Ala	I-SequenceVariant
)	O
substitution	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
16	I-SequenceVariant
,	O
occurring	O
in	O
the	O
mitochondrial	O
targeting	O
sequence	O
of	O
the	O
MnSOD	B-GeneOrGeneProduct
gene	O
,	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
urolithiasis	B-DiseaseOrPhenotypicFeature
risk	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
association	O
of	O
MnSOD	B-GeneOrGeneProduct
gene	O
polymorphism	O
with	O
the	O
risk	O
of	O
urolithiasis	B-DiseaseOrPhenotypicFeature
.	O

We	O
investigated	O
the	O
MnSOD	B-GeneOrGeneProduct
in	O
66	O
stone	B-DiseaseOrPhenotypicFeature
-	O
forming	I-DiseaseOrPhenotypicFeature
adults	O
and	O
72	O
healthy	O
volunteers	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
and	O
genotyping	O
was	O
performed	O
with	O
PCR	O
-	O
based	O
methods	O
.	O

Then	O
PCR	O
products	O
were	O
cut	O
by	O
BsaW1	O
.	O

Products	O
were	O
run	O
on	O
3%	O
agarose	B-ChemicalEntity
gel	O
,	O
246	O
bp	O
regions	O
were	O
1	O
-	O
Ala	O
-	O
9	O
,	O
164	O
and	O
82	O
bp	O
products	O
were	O
determined	O
as	O
2	O
Val	O
-	O
9	O
.	O

Chi	O
-	O
square	O
test	O
was	O
used	O
for	O
comparison	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
.	O

In	O
the	O
control	O
group	O
the	O
homozygote	O
Ala	O
allele	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
patient	B-OrganismTaxon
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
distribution	O
of	O
Ala	O
/	O
Val	O
and	O
homozygote	O
Val	O
alleles	O
in	O
the	O
patient	B-OrganismTaxon
group	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

MnSOD	B-GeneOrGeneProduct
genotype	O
determination	O
may	O
provide	O
a	O
tool	O
to	O
identify	O
individuals	O
who	O
are	O
at	O
risk	O
of	O
urolithiasis	B-DiseaseOrPhenotypicFeature
.	O

This	O
experiment	O
also	O
provides	O
data	O
about	O
antioxidant	O
status	O
and	O
stone	B-DiseaseOrPhenotypicFeature
formation	I-DiseaseOrPhenotypicFeature
.	O
Identification	O
of	O
PVT1	B-GeneOrGeneProduct
as	O
a	O
candidate	O
gene	O
for	O
end	B-DiseaseOrPhenotypicFeature
-	O
stage	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
in	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
using	O
a	O
pooling	O
-	O
based	O
genome	O
-	O
wide	O
single	O
nucleotide	O
polymorphism	O
association	O
study	O
.	O

To	O
identify	O
genetic	O
variants	O
contributing	O
to	O
end	B-DiseaseOrPhenotypicFeature
-	O
stage	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
ESRD	B-DiseaseOrPhenotypicFeature
)	O
in	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
analysis	O
of	O
115	O
,	O
352	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
pools	O
of	O
105	O
unrelated	O
case	O
subjects	O
with	O
ESRD	B-DiseaseOrPhenotypicFeature
and	O
102	O
unrelated	O
control	O
subjects	O
who	O
have	O
had	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
for	O
>	O
or	O
=	O
10	O
years	O
without	O
macroalbuminuria	O
.	O

Using	O
a	O
sliding	O
window	O
statistic	O
of	O
ranked	O
SNPs	O
,	O
we	O
identified	O
a	O
200	O
-	O
kb	O
region	O
on	O
8q24	O
harboring	O
three	O
SNPs	O
showing	O
substantial	O
differences	O
in	O
allelic	O
frequency	O
between	O
case	O
and	O
control	O
pools	O
.	O

These	O
SNPs	O
were	O
genotyped	O
in	O
individuals	O
comprising	O
each	O
pool	O
,	O
and	O
strong	O
evidence	O
for	O
association	O
was	O
found	O
with	O
rs2720709	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
000021	O
;	O
odds	O
ratio	O
2	O
.	O
57	O
[	O
95%	O
CI	O
1	O
.	O
66	O
-	O
3	O
.	O
96	O
]	O
)	O
,	O
which	O
is	O
located	O
in	O
the	O
plasmacytoma	O
variant	O
translocation	O
gene	O
PVT1	B-GeneOrGeneProduct
.	O

We	O
sequenced	O
all	O
exons	O
,	O
exon	O
-	O
intron	O
boundaries	O
,	O
and	O
the	O
promoter	O
of	O
PVT1	B-GeneOrGeneProduct
and	O
identified	O
47	O
variants	O
,	O
11	O
of	O
which	O
represented	O
nonredundant	O
markers	O
with	O
minor	O
allele	O
frequency	O
>	O
or	O
=	O
0	O
.	O
05	O
.	O

We	O
subsequently	O
genotyped	O
these	O
11	O
variants	O
and	O
an	O
additional	O
87	O
SNPs	O
identified	O
through	O
public	O
databases	O
in	O
319	O
-	O
kb	O
flanking	O
rs2720709	B-SequenceVariant
(	O
approximately	O
1	O
SNP	O
/	O
3	O
.	O
5	O
kb	O
)	O
;	O
23	O
markers	O
were	O
associated	O
with	O
ESRD	B-DiseaseOrPhenotypicFeature
at	O
P	O
<	O
0	O
.	O
01	O
.	O

The	O
strongest	O
evidence	O
for	O
association	O
was	O
found	O
for	O
rs2648875	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0000018	O
;	O
2	O
.	O
97	O
[	O
1	O
.	O
90	O
-	O
4	O
.	O
65	O
]	O
)	O
,	O
which	O
maps	O
to	O
intron	O
8	O
of	O
PVT1	B-GeneOrGeneProduct
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
PVT1	B-GeneOrGeneProduct
may	O
contribute	O
to	O
ESRD	B-DiseaseOrPhenotypicFeature
susceptibility	O
in	O
diabetes	B-DiseaseOrPhenotypicFeature
.	O
Roles	O
of	O
G1359A	B-SequenceVariant
polymorphism	O
of	O
the	O
cannabinoid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
(	O
CNR1	B-GeneOrGeneProduct
)	O
on	O
weight	B-DiseaseOrPhenotypicFeature
loss	I-DiseaseOrPhenotypicFeature
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O

BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
1359	B-SequenceVariant
G	I-SequenceVariant
/	O
A	I-SequenceVariant
)	O
of	O
the	O
CB1	B-GeneOrGeneProduct
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	B-SequenceVariant
to	I-SequenceVariant
A	I-SequenceVariant
at	I-SequenceVariant
nucleotide	I-SequenceVariant
position	I-SequenceVariant
1359	I-SequenceVariant
in	O
codon	B-SequenceVariant
435	I-SequenceVariant
(	O
Thr	I-SequenceVariant
)	O
,	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O

Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O

OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(	O
G1359A	B-SequenceVariant
)	O
of	O
CB1	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	B-DiseaseOrPhenotypicFeature
loss	I-DiseaseOrPhenotypicFeature
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	B-OrganismTaxon
with	O
obesity	B-DiseaseOrPhenotypicFeature
was	O
analyzed	O
.	O

Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
,	O
an	O
anthropometric	O
evaluation	O
,	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	B-SequenceVariant
and	O
A1359A	B-SequenceVariant
as	O
a	O
group	O
and	O
wild	O
type	O
G1359G	B-SequenceVariant
as	O
second	O
group	O
,	O
with	O
a	O
dominant	O
model	O
.	O

Results	O
:	O
Forty	O
seven	O
patients	B-OrganismTaxon
(	O
50%	O
)	O
had	O
the	O
genotype	O
G1359G	B-SequenceVariant
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(	O
50%	O
)	O
patients	B-OrganismTaxon
G1359A	B-SequenceVariant
(	O
41	O
patients	B-OrganismTaxon
,	O
43	O
.	O
6%	O
)	O
or	O
A1359A	B-SequenceVariant
(	O
6	O
patients	B-OrganismTaxon
,	O
6	O
.	O
4%	O
)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O

In	O
wild	O
and	O
mutant	O
type	O
groups	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
fat	O
mass	O
,	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O

In	O
mutant	O
type	O
group	O
,	O
resistin	B-GeneOrGeneProduct
(	O
4	O
.	O
15	O
1	O
.	O
7	O
ng	O
/	O
ml	O
vs	O
.	O

3	O
.	O
90	O
2	O
.	O
1	O
ng	O
/	O
ml	O
:	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
leptin	B-GeneOrGeneProduct
(	O
78	O
.	O
4	O
69	O
ng	O
/	O
ml	O
vs	O
66	O
.	O
2	O
32	O
ng	O
/	O
ml	O
:	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
(	O
1	O
.	O
40	O
1	O
.	O
9	O
pg	O
/	O
ml	O
vs	O
0	O
.	O
81	O
1	O
.	O
5	O
pg	O
/	O
ml	O
:	O
P	O
<	O
0	O
.	O
05	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(	O
A1359	B-SequenceVariant
)	O
with	O
a	O
decrease	O
of	O
resistin	B-GeneOrGeneProduct
,	O
leptin	B-GeneOrGeneProduct
and	O
interleukin	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
secondary	O
to	O
weight	B-DiseaseOrPhenotypicFeature
loss	I-DiseaseOrPhenotypicFeature
.	O
CRYBA3	B-GeneOrGeneProduct
/	O
A1	I-GeneOrGeneProduct
gene	O
mutation	O
associated	O
with	O
suture	O
-	O
sparing	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
congenital	I-DiseaseOrPhenotypicFeature
nuclear	I-DiseaseOrPhenotypicFeature
cataract	I-DiseaseOrPhenotypicFeature
:	O
a	O
novel	O
phenotype	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	B-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
leading	O
to	O
the	O
congenital	B-DiseaseOrPhenotypicFeature
nuclear	I-DiseaseOrPhenotypicFeature
cataract	I-DiseaseOrPhenotypicFeature
affecting	O
a	O
large	O
five	O
-	O
generation	O
Swiss	O
family	O
.	O

METHODS	O
:	O
Family	O
history	O
and	O
clinical	O
data	O
were	O
recorded	O
.	O

The	O
phenotype	O
was	O
documented	O
by	O
both	O
slit	O
lamp	O
and	O
Scheimpflug	O
photography	O
.	O

One	O
cortical	O
lens	O
was	O
evaluated	O
by	O
electron	O
microscopy	O
after	O
cataract	B-DiseaseOrPhenotypicFeature
extraction	O
.	O

Lenticular	O
phenotyping	O
and	O
genotyping	O
were	O
performed	O
independently	O
with	O
short	O
tandem	O
repeat	O
polymorphism	O
.	O

Linkage	O
analysis	O
was	O
performed	O
,	O
and	O
candidate	O
genes	O
were	O
PCR	O
amplified	O
and	O
screened	O
for	O
mutations	O
on	O
both	O
strands	O
using	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Affected	O
individuals	O
had	O
a	O
congenital	B-DiseaseOrPhenotypicFeature
nuclear	I-DiseaseOrPhenotypicFeature
lactescent	I-DiseaseOrPhenotypicFeature
cataract	I-DiseaseOrPhenotypicFeature
in	O
both	O
eyes	O
.	O

Linkage	O
was	O
observed	O
on	O
chromosome	O
17	O
for	O
DNA	O
marker	O
D17S1857	O
(	O
lod	O
score	O
:	O
3	O
.	O
44	O
at	O
theta	O
=	O
0	O
)	O
.	O

Direct	O
sequencing	O
of	O
CRYBA3	B-GeneOrGeneProduct
/	O
A1	I-GeneOrGeneProduct
,	O
which	O
maps	O
to	O
the	O
vicinity	O
,	O
revealed	O
an	O
in	O
-	O
frame	O
3	B-SequenceVariant
-	O
bp	I-SequenceVariant
deletion	I-SequenceVariant
in	O
exon	O
4	O
(	O
279delGAG	B-SequenceVariant
)	O
.	O

This	O
mutation	O
involved	O
a	O
deletion	B-SequenceVariant
of	I-SequenceVariant
glycine	I-SequenceVariant
-	O
91	I-SequenceVariant
,	O
cosegregated	O
in	O
all	O
affected	O
individuals	O
,	O
and	O
was	O
not	O
observed	O
in	O
unaffected	O
individuals	O
or	O
in	O
250	O
normal	O
control	O
subjects	O
from	O
the	O
same	O
ethnic	O
background	O
.	O

Electron	O
microscopy	O
showed	O
that	O
cortical	O
lens	O
fiber	O
morphology	O
was	O
normal	O
.	O

CONCLUSIONS	O
:	O
The	O
DeltaG91	B-SequenceVariant
mutation	O
in	O
CRYBA3	B-GeneOrGeneProduct
/	O
A1	I-GeneOrGeneProduct
is	O
associated	O
with	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
congenital	I-DiseaseOrPhenotypicFeature
nuclear	I-DiseaseOrPhenotypicFeature
lactescent	I-DiseaseOrPhenotypicFeature
cataract	I-DiseaseOrPhenotypicFeature
.	O

A	O
splice	O
mutation	O
(	O
IVS3	B-SequenceVariant
+	O
1G	I-SequenceVariant
/	O
A	I-SequenceVariant
)	O
in	O
this	O
gene	O
has	O
been	O
reported	O
in	O
a	O
zonular	B-DiseaseOrPhenotypicFeature
cataract	I-DiseaseOrPhenotypicFeature
with	O
sutural	O
opacities	O
.	O

These	O
results	O
indicate	O
phenotypic	O
heterogeneity	O
related	O
to	O
mutations	O
in	O
this	O
gene	O
.	O
Mutations	O
associated	O
with	O
lamivudine	B-ChemicalEntity
-	O
resistance	O
in	O
therapy	O
-	O
na	O
ve	O
hepatitis	B-DiseaseOrPhenotypicFeature
B	I-DiseaseOrPhenotypicFeature
virus	I-DiseaseOrPhenotypicFeature
(	O
HBV	I-DiseaseOrPhenotypicFeature
)	O
infected	I-DiseaseOrPhenotypicFeature
patients	O
with	O
and	O
without	O
HIV	B-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infection	I-DiseaseOrPhenotypicFeature
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
HIV	I-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
South	O
African	O
patients	O
.	O

This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	B-ChemicalEntity
-	O
resistant	O
hepatitis	B-OrganismTaxon
B	I-OrganismTaxon
virus	I-OrganismTaxon
(	O
HBV	B-OrganismTaxon
)	O
strains	O
in	O
selected	O
lamivudine	B-ChemicalEntity
-	O
na	O
ve	O
HBV	B-OrganismTaxon
carriers	O
with	O
and	O
without	O
human	B-DiseaseOrPhenotypicFeature
immunodeficiency	I-DiseaseOrPhenotypicFeature
virus	I-DiseaseOrPhenotypicFeature
(	O
HIV	I-DiseaseOrPhenotypicFeature
)	O
co	I-DiseaseOrPhenotypicFeature
-	O
infection	I-DiseaseOrPhenotypicFeature
in	O
South	O
African	O
patients	O
.	O

Thirty	O
-	O
five	O
lamivudine	B-ChemicalEntity
-	O
na	O
ve	O
HBV	B-DiseaseOrPhenotypicFeature
infected	I-DiseaseOrPhenotypicFeature
patients	O
with	O
or	O
without	O
HIV	B-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infection	I-DiseaseOrPhenotypicFeature
were	O
studied	O
:	O
15	O
chronic	O
HBV	B-DiseaseOrPhenotypicFeature
mono	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
patients	O
and	O
20	O
HBV	B-DiseaseOrPhenotypicFeature
-	O
HIV	I-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
patients	O
.	O

The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	B-OrganismTaxon
(	O
HBsAg	B-ChemicalEntity
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	B-OrganismTaxon
(	O
HBsAg	B-ChemicalEntity
-	O
positive	O
)	O
patients	O
.	O

HBsAg	B-ChemicalEntity
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	B-OrganismTaxon
1	I-OrganismTaxon
/	O
2	I-OrganismTaxon
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	B-OrganismTaxon
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	O
-	O
methionine	O
-	O
aspartate	O
-	O
aspartate	O
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	B-OrganismTaxon
RT	O
enzyme	O
.	O

HBV	B-OrganismTaxon
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	B-OrganismTaxon
Monitor	O
test	O
v2	O
.	O
0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O

HBV	B-OrganismTaxon
lamivudine	B-ChemicalEntity
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B-DiseaseOrPhenotypicFeature
B	I-DiseaseOrPhenotypicFeature
patients	O
and	O
10	O
of	O
20	O
HBV	B-DiseaseOrPhenotypicFeature
-	O
HIV	I-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
patients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	B-OrganismTaxon
lamivudine	B-ChemicalEntity
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	O
ve	O
HBV	B-DiseaseOrPhenotypicFeature
-	O
HIV	I-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
patients	O
.	O

The	O
HBV	B-OrganismTaxon
viral	O
loads	O
for	O
mono	O
-	O
infected	O
and	O
co	O
-	O
infected	O
patients	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
copies	O
/	O
ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	B-OrganismTaxon
resistant	O
strains	O
when	O
lamivudine	B-ChemicalEntity
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B-DiseaseOrPhenotypicFeature
-	O
HIV	I-DiseaseOrPhenotypicFeature
co	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
patients	O
.	O
Compound	O
heterozygosity	O
for	O
a	O
novel	O
nine	O
-	O
nucleotide	O
deletion	O
and	O
the	O
Asn45Ser	B-SequenceVariant
missense	O
mutation	O
in	O
the	O
glycoprotein	B-GeneOrGeneProduct
IX	I-GeneOrGeneProduct
gene	O
in	O
a	O
patient	B-OrganismTaxon
with	O
Bernard	B-DiseaseOrPhenotypicFeature
-	O
Soulier	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Bernard	B-DiseaseOrPhenotypicFeature
-	O
Soulier	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
BSS	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
inherited	B-DiseaseOrPhenotypicFeature
bleeding	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
due	O
to	O
quantitative	O
or	O
qualitative	O
abnormalities	O
in	O
the	O
platelet	O
glycoprotein	B-GeneOrGeneProduct
(	O
GP	I-GeneOrGeneProduct
)	O
Ib	I-GeneOrGeneProduct
/	O
IX	I-GeneOrGeneProduct
/	O
V	I-GeneOrGeneProduct
complex	O
,	O
the	O
major	O
von	B-GeneOrGeneProduct
Willebrand	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
receptor	O
.	O

The	O
complex	O
comprises	O
four	O
subunits	O
,	O
each	O
encoded	O
by	O
a	O
separate	O
gene	O
.	O

Several	O
mutations	O
have	O
been	O
described	O
for	O
each	O
of	O
the	O
subunits	O
,	O
except	O
for	O
GPV	B-GeneOrGeneProduct
,	O
as	O
a	O
cause	O
of	O
BSS	B-DiseaseOrPhenotypicFeature
.	O

We	O
describe	O
here	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
a	O
child	O
with	O
BSS	B-DiseaseOrPhenotypicFeature
.	O

Flow	O
-	O
cytometric	O
analysis	O
of	O
the	O
patient	B-OrganismTaxon
'	O
s	O
platelets	O
showed	O
a	O
markedly	O
reduced	O
surface	O
expression	O
of	O
all	O
three	O
glycoproteins	B-GeneOrGeneProduct
of	O
the	O
GPIb	B-GeneOrGeneProduct
/	O
IX	I-GeneOrGeneProduct
/	O
V	I-GeneOrGeneProduct
complex	O
.	O

DNA	O
sequencing	O
analysis	O
showed	O
the	O
patient	B-OrganismTaxon
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
the	O
GPIX	B-GeneOrGeneProduct
gene	O
,	O
a	O
novel	O
nine	B-SequenceVariant
-	O
nucleotide	I-SequenceVariant
deletion	I-SequenceVariant
starting	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
1952	I-SequenceVariant
of	O
the	O
gene	O
that	O
changes	B-SequenceVariant
asparagine	I-SequenceVariant
86	I-SequenceVariant
for	I-SequenceVariant
alanine	I-SequenceVariant
and	I-SequenceVariant
eliminates	I-SequenceVariant
amino	I-SequenceVariant
acids	I-SequenceVariant
87	I-SequenceVariant
,	O
88	I-SequenceVariant
,	O
and	I-SequenceVariant
89	I-SequenceVariant
(	O
arginine	I-SequenceVariant
,	O
threonine	I-SequenceVariant
,	O
and	I-SequenceVariant
proline	I-SequenceVariant
)	O
and	O
a	O
previously	O
reported	O
point	O
mutation	O
that	O
changes	O
the	O
codon	O
asparagine	B-SequenceVariant
(	O
AAC	I-SequenceVariant
)	O
for	I-SequenceVariant
serine	I-SequenceVariant
(	O
AGC	I-SequenceVariant
)	O
at	I-SequenceVariant
residue	I-SequenceVariant
45	I-SequenceVariant
.	O

Her	O
mother	O
was	O
heterozygous	O
for	O
the	O
Asn45Ser	B-SequenceVariant
mutation	O
,	O
and	O
her	O
father	O
,	O
for	O
the	O
nine	O
-	O
nucleotide	O
deletion	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
additive	O
effects	O
of	O
both	O
mutations	O
in	O
the	O
GPIX	B-GeneOrGeneProduct
gene	O
are	O
responsible	O
for	O
the	O
BSS	B-DiseaseOrPhenotypicFeature
phenotype	O
of	O
the	O
patient	B-OrganismTaxon
.	O
Antipsychotic	B-ChemicalEntity
-	O
like	O
profile	O
of	O
thioperamide	B-ChemicalEntity
,	O
a	O
selective	O
H3	B-GeneOrGeneProduct
-	O
receptor	I-GeneOrGeneProduct
antagonist	O
in	O
mice	B-OrganismTaxon
.	O

Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	B-GeneOrGeneProduct
H	I-GeneOrGeneProduct
(	O
3	I-GeneOrGeneProduct
)	O
-	O
receptor	I-GeneOrGeneProduct
ligands	O
on	O
neuroleptic	B-ChemicalEntity
-	O
induced	O
catalepsy	B-DiseaseOrPhenotypicFeature
,	O
apomorphine	B-ChemicalEntity
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	B-ChemicalEntity
-	O
induced	O
locomotor	O
activities	O
in	O
mice	B-OrganismTaxon
.	O

Catalepsy	B-DiseaseOrPhenotypicFeature
was	O
induced	O
by	O
haloperidol	B-ChemicalEntity
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
apomorphine	B-ChemicalEntity
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
amphetamine	B-ChemicalEntity
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O

(	O
R	I-ChemicalEntity
)	O
-	O
alpha	I-ChemicalEntity
-	O
methylhistamine	I-ChemicalEntity
(	O
RAMH	B-ChemicalEntity
)	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thioperamide	B-ChemicalEntity
(	O
THP	B-ChemicalEntity
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-DiseaseOrPhenotypicFeature
.	O

Administration	O
of	O
THP	B-ChemicalEntity
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
haloperidol	B-ChemicalEntity
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B-DiseaseOrPhenotypicFeature
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
pretreatment	O
with	O
RAMH	B-ChemicalEntity
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	B-ChemicalEntity
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RAMH	B-ChemicalEntity
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	B-ChemicalEntity
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O

On	O
amphetamine	B-ChemicalEntity
-	O
induced	O
hyperactivity	B-DiseaseOrPhenotypicFeature
,	O
THP	B-ChemicalEntity
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pretreatment	O
with	O
RAMH	B-ChemicalEntity
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	B-ChemicalEntity
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Climbing	O
behavior	O
induced	O
by	O
apomorphine	B-ChemicalEntity
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	B-ChemicalEntity
.	O

Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	B-ChemicalEntity
.	O

THP	B-ChemicalEntity
exhibited	O
an	O
antipsychotic	B-ChemicalEntity
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-ChemicalEntity
-	O
induced	O
catalepsy	B-DiseaseOrPhenotypicFeature
,	O
reducing	O
amphetamine	B-ChemicalEntity
-	O
induced	O
hyperactivity	B-DiseaseOrPhenotypicFeature
and	O
reducing	O
apomorphine	B-ChemicalEntity
-	O
induced	O
climbing	O
in	O
mice	B-OrganismTaxon
.	O

Such	O
effects	O
of	O
THP	B-ChemicalEntity
were	O
reversed	O
by	O
RAMH	B-ChemicalEntity
indicating	O
the	O
involvement	O
of	O
histamine	B-GeneOrGeneProduct
H	I-GeneOrGeneProduct
(	O
3	I-GeneOrGeneProduct
)	O
-	O
receptors	I-GeneOrGeneProduct
.	O

Findings	O
suggest	O
a	O
potential	O
for	O
H	B-ChemicalEntity
(	O
3	I-ChemicalEntity
)	O
-	O
receptor	I-ChemicalEntity
antagonists	I-ChemicalEntity
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O
Insulin	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
mediated	O
cell	O
survival	O
in	O
hypoxia	B-DiseaseOrPhenotypicFeature
depends	O
on	O
the	O
promotion	O
of	O
autophagy	O
via	O
suppression	O
of	O
the	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
/	O
mTOR	B-GeneOrGeneProduct
signaling	O
pathway	O
.	O

Hypoxia	B-DiseaseOrPhenotypicFeature
is	O
widely	O
accepted	O
as	O
a	O
fundamental	O
biological	O
phenomenon	O
,	O
which	O
is	O
strongly	O
associated	O
with	O
tissue	O
damage	O
and	O
cell	O
viability	O
under	O
stress	O
conditions	O
.	O

Insulin	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
is	O
known	O
to	O
protect	O
tissues	O
from	O
multiple	O
types	O
of	O
damage	O
,	O
and	O
protect	O
cells	O
from	O
apoptosis	O
.	O

Hypoxia	B-DiseaseOrPhenotypicFeature
is	O
a	O
regulatory	O
factor	O
of	O
the	O
IGF	B-GeneOrGeneProduct
system	O
,	O
however	O
the	O
role	O
of	O
the	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
IGF	B-GeneOrGeneProduct
-	O
1R	I-GeneOrGeneProduct
)	O
in	O
hypoxia	B-DiseaseOrPhenotypicFeature
-	O
induced	O
apoptosis	O
remains	O
unclear	O
.	O

The	O
present	O
study	O
investigated	O
the	O
potential	O
mechanisms	O
associated	O
with	O
IGF	B-GeneOrGeneProduct
-	O
1R	I-GeneOrGeneProduct
-	O
associated	O
apoptosis	O
under	O
hypoxic	B-DiseaseOrPhenotypicFeature
conditions	O
.	O

Mouse	B-OrganismTaxon
embryonic	O
fibroblasts	O
exhibiting	O
disruption	O
or	O
overexpression	O
of	O
IGF	B-GeneOrGeneProduct
-	O
1R	I-GeneOrGeneProduct
(	O
R	O
-	O
cells	O
and	O
R	O
+	O
cells	O
)	O
were	O
used	O
to	O
examine	O
the	O
level	O
of	O
apoptosis	O
,	O
autophagy	O
,	O
and	O
production	O
of	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
(	O
ROS	B-ChemicalEntity
)	O
.	O

The	O
autophagy	O
inhibitor	O
3	B-ChemicalEntity
-	O
methyladenine	I-ChemicalEntity
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
autophagy	O
on	O
ROS	B-ChemicalEntity
production	O
and	O
apoptosis	O
under	O
hypoxic	B-DiseaseOrPhenotypicFeature
conditions	O
.	O

A	O
potential	O
downstream	O
signaling	O
pathway	O
involving	O
phosphatidylinositol	B-GeneOrGeneProduct
3	I-GeneOrGeneProduct
-	O
kinase	I-GeneOrGeneProduct
(	O
PI3K	B-GeneOrGeneProduct
)	O
/	O
threonine	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
B	I-GeneOrGeneProduct
(	O
Akt	B-GeneOrGeneProduct
)	O
/	O
mammalian	B-GeneOrGeneProduct
target	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
rapamycin	I-GeneOrGeneProduct
(	O
mTOR	B-GeneOrGeneProduct
)	O
was	O
identifiedby	O
western	O
blot	O
analysis	O
.	O

The	O
results	O
demonstrated	O
that	O
hypoxia	B-DiseaseOrPhenotypicFeature
induced	O
apoptosis	O
,	O
increased	O
ROS	B-ChemicalEntity
production	O
,	O
and	O
promoted	O
autophagy	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
relative	O
to	O
that	O
observed	O
under	O
normoxia	O
.	O

R	O
+	O
cells	O
exhibited	O
a	O
lower	O
percentage	O
of	O
apoptotic	O
cells	O
,	O
lower	O
ROS	B-ChemicalEntity
production	O
,	O
and	O
higher	O
levels	O
of	O
autophagy	O
when	O
compared	O
to	O
that	O
of	O
R	O
-	O
cells	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
autophagy	O
led	O
to	O
increased	O
ROS	B-ChemicalEntity
production	O
and	O
a	O
higher	O
percentage	O
of	O
apoptotic	O
cells	O
in	O
the	O
two	O
cell	O
types	O
.	O

Furthermore	O
,	O
IGF	B-GeneOrGeneProduct
-	O
1R	I-GeneOrGeneProduct
is	O
related	O
with	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
/	O
mTOR	B-GeneOrGeneProduct
signaling	O
pathway	O
and	O
enhanced	O
autophagy	O
-	O
associated	O
protein	O
expression	O
,	O
which	O
was	O
verified	O
following	O
treatment	O
with	O
the	O
PI3K	B-GeneOrGeneProduct
inhibitor	O
LY294002	B-ChemicalEntity
.	O

These	O
results	O
indicated	O
that	O
IGF	B-GeneOrGeneProduct
-	O
1R	I-GeneOrGeneProduct
may	O
increase	O
cell	O
viability	O
under	O
hypoxic	B-DiseaseOrPhenotypicFeature
conditions	O
by	O
promoting	O
autophagy	O
and	O
scavenging	O
ROS	B-ChemicalEntity
production	O
,	O
which	O
is	O
closed	O
with	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
/	O
mTOR	B-GeneOrGeneProduct
signaling	O
pathway	O
.	O
Serum	B-GeneOrGeneProduct
Amyloid	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
Induces	O
Inflammation	O
,	O
Proliferation	O
and	O
Cell	O
Death	O
in	O
Activated	O
Hepatic	O
Stellate	O
Cells	O
.	O

Serum	B-GeneOrGeneProduct
amyloid	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
SAA	B-GeneOrGeneProduct
)	O
is	O
an	O
evolutionary	O
highly	O
conserved	O
acute	O
phase	O
protein	O
that	O
is	O
predominantly	O
secreted	O
by	O
hepatocytes	O
.	O

However	O
,	O
its	O
role	O
in	O
liver	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
fibrogenesis	I-DiseaseOrPhenotypicFeature
has	O
not	O
been	O
elucidated	O
so	O
far	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effects	O
of	O
SAA	B-GeneOrGeneProduct
on	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
,	O
the	O
main	O
fibrogenic	O
cell	O
type	O
of	O
the	O
liver	O
.	O

Serum	B-GeneOrGeneProduct
amyloid	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
potently	O
activated	O
IkappaB	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
,	O
c	B-GeneOrGeneProduct
-	O
Jun	I-GeneOrGeneProduct
N	I-GeneOrGeneProduct
-	O
terminal	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
JNK	B-GeneOrGeneProduct
)	O
,	O
Erk	B-GeneOrGeneProduct
and	O
Akt	B-GeneOrGeneProduct
and	O
enhanced	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
-	O
dependent	O
luciferase	O
activity	O
in	O
primary	O
human	B-OrganismTaxon
and	O
rat	B-OrganismTaxon
HSCs	O
.	O

Serum	B-GeneOrGeneProduct
amyloid	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
induced	O
the	O
transcription	O
of	O
MCP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
RANTES	B-GeneOrGeneProduct
and	O
MMP9	B-GeneOrGeneProduct
in	O
an	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
-	O
and	O
JNK	B-GeneOrGeneProduct
-	O
dependent	O
manner	O
.	O

Blockade	O
of	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
revealed	O
cytotoxic	B-DiseaseOrPhenotypicFeature
effects	O
of	O
SAA	B-GeneOrGeneProduct
in	O
primary	O
HSCs	O
with	O
signs	O
of	O
apoptosis	O
such	O
as	O
caspase	B-GeneOrGeneProduct
3	I-GeneOrGeneProduct
and	O
PARP	B-GeneOrGeneProduct
cleavage	O
and	O
Annexin	B-GeneOrGeneProduct
V	I-GeneOrGeneProduct
staining	O
.	O

Serum	B-GeneOrGeneProduct
amyloid	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
induced	O
HSC	O
proliferation	O
,	O
which	O
depended	O
on	O
JNK	B-GeneOrGeneProduct
,	O
Erk	B-GeneOrGeneProduct
and	O
Akt	B-GeneOrGeneProduct
activity	O
.	O

In	O
primary	O
hepatocytes	O
,	O
SAA	B-GeneOrGeneProduct
also	O
activated	O
MAP	B-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
,	O
but	O
did	O
not	O
induce	O
relevant	O
cell	O
death	O
after	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
inhibition	O
.	O

In	O
two	O
models	O
of	O
hepatic	B-DiseaseOrPhenotypicFeature
fibrogenesis	I-DiseaseOrPhenotypicFeature
,	O
CCl4	B-GeneOrGeneProduct
treatment	O
and	O
bile	O
duct	O
ligation	O
,	O
hepatic	O
mRNA	O
levels	O
of	O
SAA1	B-GeneOrGeneProduct
and	O
SAA3	B-GeneOrGeneProduct
were	O
strongly	O
increased	O
.	O

In	O
conclusion	O
,	O
SAA	B-GeneOrGeneProduct
may	O
modulate	O
fibrogenic	O
responses	O
in	O
the	O
liver	O
in	O
a	O
positive	O
and	O
negative	O
fashion	O
by	O
inducing	O
inflammation	O
,	O
proliferation	O
and	O
cell	O
death	O
in	O
HSCs	O
.	O

Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	B-OrganismTaxon
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
Duchenne	B-GeneOrGeneProduct
muscular	I-GeneOrGeneProduct
dystrophy	I-GeneOrGeneProduct
(	O
DMD	I-GeneOrGeneProduct
)	O
gene	I-GeneOrGeneProduct
.	O

Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B-DiseaseOrPhenotypicFeature
muscular	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
DMD	B-DiseaseOrPhenotypicFeature
)	O
or	O
Becker	B-DiseaseOrPhenotypicFeature
muscular	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
BMD	B-DiseaseOrPhenotypicFeature
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
DMD	B-GeneOrGeneProduct
locus	O
.	O

This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b	O
-	O
7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O

These	O
80	O
individuals	O
account	O
for	O
approximately	O
75%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	B-OrganismTaxon
analyzed	O
with	O
the	O
entire	O
dystrophin	B-GeneOrGeneProduct
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al	O
.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
)	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	B-OrganismTaxon
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O

Thirty	O
-	O
eight	O
independent	O
patients	B-OrganismTaxon
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B-DiseaseOrPhenotypicFeature
,	O
BMD	B-DiseaseOrPhenotypicFeature
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
one	O
intermediate	O
patient	B-OrganismTaxon
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
7	O
intermediate	O
patients	B-OrganismTaxon
,	O
and	O
1	O
BMD	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in	O
-	O
frame	O
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al	O
.	O

and	O
Koenig	O
et	O
al	O
.	O

but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al	O
.	O

at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O
Cardioprotective	O
effect	O
of	O
salvianolic	B-ChemicalEntity
acid	I-ChemicalEntity
A	I-ChemicalEntity
on	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-ChemicalEntity
acid	I-ChemicalEntity
A	I-ChemicalEntity
on	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O

Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O

Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O

Isoproterenol	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	B-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
,	O
aspartate	B-GeneOrGeneProduct
transaminase	I-GeneOrGeneProduct
,	O
creatine	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
and	O
malondialdehyde	B-ChemicalEntity
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	B-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
,	O
catalase	B-GeneOrGeneProduct
and	O
glutathione	B-GeneOrGeneProduct
peroxidase	I-GeneOrGeneProduct
in	O
serum	O
and	O
heart	O
.	O

These	O
rats	B-OrganismTaxon
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
ST	O
-	O
segment	O
.	O

In	O
addition	O
,	O
mitochondrial	B-DiseaseOrPhenotypicFeature
respiratory	I-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	B-ChemicalEntity
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
.	O

Administration	O
of	O
salvianolic	B-ChemicalEntity
acid	I-ChemicalEntity
A	I-ChemicalEntity
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
cardiac	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
and	O
myocardial	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O

The	O
protective	O
role	O
of	O
salvianolic	B-ChemicalEntity
acid	I-ChemicalEntity
A	I-ChemicalEntity
against	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-ChemicalEntity
acid	I-ChemicalEntity
A	I-ChemicalEntity
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
.	O
A	O
genetic	O
analysis	O
of	O
serotonergic	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
in	O
migraine	B-DiseaseOrPhenotypicFeature
using	O
a	O
DNA	O
pooling	O
approach	O
.	O

Migraine	B-DiseaseOrPhenotypicFeature
is	O
a	O
common	O
debilitating	O
primary	O
headache	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
with	O
significant	O
mental	O
,	O
physical	O
and	O
social	O
health	O
implications	O
.	O

The	O
brain	O
neurotransmitter	B-ChemicalEntity
5	B-ChemicalEntity
-	O
hydroxytryptamine	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
;	O
serotonin	B-ChemicalEntity
)	O
is	O
involved	O
in	O
nociceptive	O
pathways	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
migraine	B-DiseaseOrPhenotypicFeature
.	O

With	O
few	O
genetic	O
studies	O
investigating	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
governing	O
the	O
rate	O
of	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
activity	O
and	O
their	O
relationship	O
to	O
migraine	B-DiseaseOrPhenotypicFeature
,	O
it	O
was	O
the	O
objective	O
of	O
this	O
study	O
to	O
assess	O
genetic	O
variants	O
within	O
the	O
human	B-OrganismTaxon
tryptophan	B-GeneOrGeneProduct
hydroxylase	I-GeneOrGeneProduct
(	O
TPH	B-GeneOrGeneProduct
)	O
,	O
amino	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
decarboxylase	I-GeneOrGeneProduct
(	O
AADC	B-GeneOrGeneProduct
)	O
and	O
monoamine	B-GeneOrGeneProduct
oxidase	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
MAOA	B-GeneOrGeneProduct
)	O
genes	O
in	O
migraine	B-DiseaseOrPhenotypicFeature
susceptibility	O
.	O

This	O
objective	O
was	O
undertaken	O
using	O
a	O
high	O
-	O
throughput	O
DNA	O
pooling	O
experimental	O
design	O
,	O
which	O
proved	O
to	O
be	O
a	O
very	O
accurate	O
,	O
sensitive	O
and	O
specific	O
method	O
of	O
estimating	O
allele	O
frequencies	O
for	O
single	O
nucleotide	O
polymorphism	O
,	O
insertion	O
deletion	O
and	O
variable	O
number	O
tandem	O
repeat	O
loci	O
.	O

Application	O
of	O
DNA	O
pooling	O
to	O
a	O
wide	O
array	O
of	O
genetic	O
loci	O
provides	O
greater	O
scope	O
in	O
the	O
assessment	O
of	O
population	O
-	O
based	O
genetic	O
association	O
study	O
designs	O
.	O

Despite	O
the	O
application	O
of	O
this	O
high	O
-	O
throughput	O
genotyping	O
method	O
,	O
negative	O
results	O
from	O
the	O
two	O
-	O
stage	O
DNA	O
pooling	O
design	O
used	O
to	O
screen	O
loci	O
within	O
the	O
TPH	B-GeneOrGeneProduct
,	O
AADC	B-GeneOrGeneProduct
and	O
MAOA	B-GeneOrGeneProduct
genes	O
did	O
not	O
support	O
their	O
role	O
in	O
migraine	B-DiseaseOrPhenotypicFeature
susceptibility	O
.	O
Inappropriate	O
use	O
of	O
carbamazepine	B-ChemicalEntity
and	O
vigabatrin	B-ChemicalEntity
in	O
typical	O
absence	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
.	O

Carbamazepine	B-ChemicalEntity
and	O
vigabatrin	B-ChemicalEntity
are	O
contraindicated	O
in	O
typical	O
absence	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
.	O

Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-ChemicalEntity
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabatrin	B-ChemicalEntity
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-ChemicalEntity
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-DiseaseOrPhenotypicFeature
jerks	I-DiseaseOrPhenotypicFeature
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-ChemicalEntity
.	O

Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-ChemicalEntity
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O

Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-ChemicalEntity
valproate	I-ChemicalEntity
,	O
lamotrigine	B-ChemicalEntity
,	O
or	O
ethosuximide	B-ChemicalEntity
alone	O
or	O
in	O
combination	O
.	O
Safety	O
of	O
celecoxib	B-ChemicalEntity
in	O
patients	O
with	O
adverse	O
skin	B-DiseaseOrPhenotypicFeature
reactions	I-DiseaseOrPhenotypicFeature
to	O
acetaminophen	B-ChemicalEntity
(	O
paracetamol	B-ChemicalEntity
)	O
and	O
nimesulide	B-ChemicalEntity
associated	O
or	O
not	O
with	O
common	O
non	B-ChemicalEntity
-	O
steroidal	I-ChemicalEntity
anti	I-ChemicalEntity
-	O
inflammatory	I-ChemicalEntity
drugs	I-ChemicalEntity
.	O

BACKGROUND	O
:	O
Acetaminophen	B-ChemicalEntity
(	O
paracetamol	B-ChemicalEntity
-	O
-	O
P	B-ChemicalEntity
)	O
and	O
Nimesulide	B-ChemicalEntity
(	O
N	B-ChemicalEntity
)	O
are	O
widely	O
used	O
analgesic	O
-	O
antipyretic	B-ChemicalEntity
/	O
anti	B-ChemicalEntity
-	O
inflammatory	I-ChemicalEntity
drugs	I-ChemicalEntity
.	O

The	O
rate	O
of	O
adverse	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O

On	O
the	O
contrary	O
non	B-ChemicalEntity
-	O
steroidal	I-ChemicalEntity
anti	I-ChemicalEntity
-	O
inflammatory	I-ChemicalEntity
drugs	I-ChemicalEntity
(	O
NSAIDs	B-ChemicalEntity
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions	O
.	O

Celecoxib	B-ChemicalEntity
(	O
CE	B-ChemicalEntity
)	O
is	O
a	O
novel	O
drug	O
,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
enzyme	O
.	O

OBJECTIVE	O
:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	B-ChemicalEntity
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B-DiseaseOrPhenotypicFeature
reactions	I-DiseaseOrPhenotypicFeature
to	O
P	B-ChemicalEntity
and	O
N	B-ChemicalEntity
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	B-ChemicalEntity
.	O

METHODS	O
:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
to	O
P	B-ChemicalEntity
and	O
N	B-ChemicalEntity
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	B-ChemicalEntity
.	O

The	O
diagnosis	O
of	O
P	B-ChemicalEntity
and	O
N	B-ChemicalEntity
-	O
induced	O
skin	B-DiseaseOrPhenotypicFeature
reactions	I-DiseaseOrPhenotypicFeature
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
days	O
,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	B-ChemicalEntity
in	O
refracted	O
doses	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
days	O
,	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered	O
.	O

All	O
patients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions	O
.	O

The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B-DiseaseOrPhenotypicFeature
,	O
rush	O
or	O
urticaria	B-DiseaseOrPhenotypicFeature
-	O
angioedema	B-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(	O
88	O
.	O
8%	O
)	O
tolerated	O
CE	B-ChemicalEntity
.	O

Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	B-DiseaseOrPhenotypicFeature
of	O
the	O
lips	O
.	O

CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
reaction	O
to	O
CE	B-ChemicalEntity
was	O
documented	O
among	O
9	O
P	B-ChemicalEntity
and	O
N	B-ChemicalEntity
-	O
highly	O
NSAIDs	B-ChemicalEntity
intolerant	O
patients	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	B-ChemicalEntity
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	B-ChemicalEntity
and	O
N	B-ChemicalEntity
.	O
Genetic	O
Variation	O
at	O
the	O
Sulfonylurea	B-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
,	O
Type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
Diabetes	I-DiseaseOrPhenotypicFeature
,	O
and	O
Coronary	B-DiseaseOrPhenotypicFeature
Heart	I-DiseaseOrPhenotypicFeature
Disease	I-DiseaseOrPhenotypicFeature
.	O

Despite	O
widespread	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
,	O
the	O
impact	O
of	O
sulfonylurea	B-ChemicalEntity
therapy	O
on	O
cardiovascular	O
outcomes	O
remains	O
uncertain	O
.	O

Studies	O
of	O
naturally	O
occurring	O
genetic	O
variation	O
can	O
be	O
used	O
to	O
anticipate	O
the	O
expected	O
clinical	O
consequences	O
of	O
a	O
pharmacological	O
therapy	O
.	O

A	O
common	O
missense	O
variant	O
in	O
the	O
gene	O
encoding	O
a	O
component	O
of	O
the	O
sulfonylurea	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
ABCC8	B-GeneOrGeneProduct
p	B-SequenceVariant
.	O
A1369S	I-SequenceVariant
)	O
promotes	O
closure	O
of	O
the	O
target	O
channel	O
of	O
sulfonylurea	B-ChemicalEntity
therapy	O
and	O
is	O
associated	O
with	O
increased	O
insulin	B-GeneOrGeneProduct
secretion	O
,	O
thus	O
mimicking	O
the	O
effects	O
of	O
sulfonylurea	B-ChemicalEntity
therapy	O
.	O

Using	O
individual	O
-	O
level	O
data	O
from	O
120	O
,	O
286	O
participants	O
in	O
the	O
UK	O
Biobank	O
and	O
summary	O
association	O
results	O
from	O
four	O
large	O
-	O
scale	O
genome	O
-	O
wide	O
association	O
studies	O
,	O
we	O
examined	O
the	O
impact	O
of	O
this	O
variant	O
on	O
cardiometabolic	O
traits	O
,	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
,	O
and	O
coronary	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

The	O
p	B-SequenceVariant
.	O
A1369S	I-SequenceVariant
variant	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
risk	O
of	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0	O
.	O
93	O
;	O
95%	O
CI	O
0	O
.	O
91	O
,	O
0	O
.	O
95	O
;	O
P	O
=	O
1	O
.	O
2	O
x	O
10	O
(	O
-	O
11	O
)	O
)	O
.	O

The	O
variant	O
was	O
associated	O
with	O
increased	O
BMI	O
(	O
+	O
0	O
.	O
062	O
kg	O
/	O
m	O
(	O
2	O
)	O
;	O
95%	O
CI	O
0	O
.	O
037	O
,	O
0	O
.	O
086	O
;	O
P	O
=	O
8	O
.	O
1	O
x	O
10	O
(	O
-	O
7	O
)	O
)	O
but	O
lower	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
adjusted	O
for	O
BMI	O
,	O
a	O
marker	O
of	O
abdominal	O
fat	O
distribution	O
.	O

Furthermore	O
,	O
p	B-SequenceVariant
.	O
A1369S	I-SequenceVariant
was	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
coronary	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
OR	O
0	O
.	O
98	O
;	O
95%	O
CI	O
0	O
.	O
96	O
,	O
0	O
.	O
99	O
;	O
P	O
=	O
5	O
.	O
9	O
x	O
10	O
(	O
-	O
4	O
)	O
)	O
.	O

These	O
results	O
suggest	O
that	O
,	O
despite	O
a	O
known	O
association	O
with	O
increased	O
weight	O
,	O
long	O
-	O
term	O
sulfonylurea	B-ChemicalEntity
therapy	O
may	O
reduce	O
the	O
risk	O
of	O
coronary	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O
Brat	B-GeneOrGeneProduct
promotes	O
stem	O
cell	O
differentiation	O
via	O
control	O
of	O
a	O
bistable	O
switch	O
that	O
restricts	O
BMP	B-GeneOrGeneProduct
signaling	O
.	O

Drosophila	B-OrganismTaxon
ovarian	O
germline	O
stem	O
cells	O
(	O
GSCs	O
)	O
are	O
maintained	O
by	O
Dpp	B-GeneOrGeneProduct
signaling	O
and	O
the	O
Pumilio	B-GeneOrGeneProduct
(	O
Pum	B-GeneOrGeneProduct
)	O
and	O
Nanos	B-GeneOrGeneProduct
(	O
Nos	B-GeneOrGeneProduct
)	O
translational	O
repressors	O
.	O

Upon	O
division	O
,	O
Dpp	B-GeneOrGeneProduct
signaling	O
is	O
extinguished	O
,	O
and	O
Nos	B-GeneOrGeneProduct
is	O
downregulated	O
in	O
one	O
daughter	O
cell	O
,	O
causing	O
it	O
to	O
switch	O
to	O
a	O
differentiating	O
cystoblast	O
(	O
CB	O
)	O
.	O

However	O
,	O
downstream	O
effectors	O
of	O
Pum	B-GeneOrGeneProduct
-	O
Nos	B-GeneOrGeneProduct
remain	O
unknown	O
,	O
and	O
how	O
CBs	O
lose	O
their	O
responsiveness	O
to	O
Dpp	B-GeneOrGeneProduct
is	O
unclear	O
.	O

Here	O
,	O
we	O
identify	O
Brain	B-GeneOrGeneProduct
Tumor	I-GeneOrGeneProduct
(	O
Brat	B-GeneOrGeneProduct
)	O
as	O
a	O
potent	O
differentiation	O
factor	O
and	O
target	O
of	O
Pum	B-GeneOrGeneProduct
-	O
Nos	B-GeneOrGeneProduct
regulation	O
.	O

Brat	B-GeneOrGeneProduct
is	O
excluded	O
from	O
GSCs	O
by	O
Pum	B-GeneOrGeneProduct
-	O
Nos	B-GeneOrGeneProduct
but	O
functions	O
with	O
Pum	B-GeneOrGeneProduct
in	O
CBs	O
to	O
translationally	O
repress	O
distinct	O
targets	O
,	O
including	O
the	O
Mad	B-GeneOrGeneProduct
and	O
dMyc	B-GeneOrGeneProduct
mRNAs	O
.	O

Regulation	O
of	O
both	O
targets	O
simultaneously	O
lowers	O
cellular	O
responsiveness	O
to	O
Dpp	B-GeneOrGeneProduct
signaling	O
,	O
forcing	O
the	O
cell	O
to	O
become	O
refractory	O
to	O
the	O
self	O
-	O
renewal	O
signal	O
.	O

Mathematical	O
modeling	O
elucidates	O
bistability	O
of	O
cell	O
fate	O
in	O
the	O
Brat	B-GeneOrGeneProduct
-	O
mediated	O
system	O
,	O
revealing	O
how	O
autoregulation	O
of	O
GSC	O
number	O
can	O
arise	O
from	O
Brat	B-GeneOrGeneProduct
coupling	O
extracellular	O
Dpp	B-GeneOrGeneProduct
regulation	O
to	O
intracellular	O
interpretation	O
.	O
Inhibitory	O
effect	O
of	O
emodin	B-ChemicalEntity
on	O
fatty	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
,	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
proliferation	O
and	O
apoptosis	O
.	O

Fatty	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
(	O
FASN	B-GeneOrGeneProduct
)	O
is	O
a	O
key	O
anabolic	O
enzyme	O
for	O
de	O
novo	O
fatty	B-ChemicalEntity
acid	I-ChemicalEntity
synthesis	O
,	O
which	O
is	O
important	O
in	O
the	O
development	O
of	O
colon	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
.	O

The	O
high	O
expression	O
of	O
FASN	B-GeneOrGeneProduct
is	O
considered	O
a	O
promising	O
molecular	O
target	O
for	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
therapy	O
.	O

Emodin	B-ChemicalEntity
,	O
a	O
naturally	O
occurring	O
anthraquinone	B-ChemicalEntity
,	O
exhibits	O
an	O
anticancer	O
effect	O
in	O
various	O
types	O
of	O
human	B-OrganismTaxon
cancer	B-DiseaseOrPhenotypicFeature
,	O
including	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
;	O
however	O
,	O
the	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

Cell	O
viability	O
was	O
evaluated	O
using	O
a	O
Cell	O
Counting	O
Kit	O
-	O
8	O
assay	O
.	O

The	O
apoptosis	O
rate	O
of	O
cells	O
was	O
quantified	O
via	O
flow	O
cytometry	O
following	O
Annexin	B-GeneOrGeneProduct
V	I-GeneOrGeneProduct
/	O
propidium	B-ChemicalEntity
iodide	I-ChemicalEntity
staining	O
.	O

FASN	B-GeneOrGeneProduct
activity	O
was	O
measured	O
by	O
monitoring	O
oxidation	O
of	O
nicotinamide	B-ChemicalEntity
adenine	I-ChemicalEntity
dinucleotide	I-ChemicalEntity
phosphate	I-ChemicalEntity
at	O
a	O
wavelength	O
of	O
340	O
nm	O
,	O
and	O
intracellular	O
free	B-ChemicalEntity
fatty	I-ChemicalEntity
acid	I-ChemicalEntity
levels	O
were	O
detected	O
using	O
a	O
Free	B-ChemicalEntity
Fatty	I-ChemicalEntity
Acid	I-ChemicalEntity
Quantification	O
kit	O
.	O

Western	O
blot	O
analysis	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
were	O
used	O
to	O
detect	O
target	O
gene	O
and	O
protein	O
expression	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
whether	O
the	O
gene	O
expression	O
of	O
FASN	B-GeneOrGeneProduct
and	O
its	O
enzymatic	O
activity	O
are	O
regulated	O
by	O
emodin	B-ChemicalEntity
in	O
a	O
human	B-OrganismTaxon
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
line	O
.	O

Emodin	B-ChemicalEntity
markedly	O
inhibited	O
the	O
proliferation	O
of	O
HCT116	B-CellLine
cells	O
and	O
a	O
higher	O
protein	O
level	O
of	O
FASN	B-GeneOrGeneProduct
was	O
expressed	O
,	O
compared	O
with	O
that	O
in	O
SW480	B-CellLine
,	O
SNU	B-CellLine
-	O
C2A	I-CellLine
or	O
SNU	B-CellLine
-	O
C5	I-CellLine
cells	O
.	O

Emodin	B-ChemicalEntity
significantly	O
downregulated	O
the	O
protein	O
expression	O
of	O
FASN	B-GeneOrGeneProduct
in	O
HCT116	B-CellLine
cells	O
,	O
which	O
was	O
caused	O
by	O
protein	O
degradation	O
due	O
to	O
elevated	O
protein	O
ubiquitination	O
.	O

Emodin	B-ChemicalEntity
also	O
inhibited	O
intracellular	O
FASN	B-GeneOrGeneProduct
enzymatic	O
activity	O
and	O
reduced	O
the	O
levels	O
of	O
intracellular	O
free	B-ChemicalEntity
fatty	I-ChemicalEntity
acids	I-ChemicalEntity
.	O

Emodin	B-ChemicalEntity
enhanced	O
antiproliferation	O
and	O
apoptosis	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
combined	O
treatment	O
of	O
emodin	B-ChemicalEntity
and	O
cerulenin	B-ChemicalEntity
,	O
a	O
commercial	O
FASN	B-GeneOrGeneProduct
inhibitor	O
,	O
had	O
an	O
additive	O
effect	O
on	O
these	O
activities	O
.	O

Palmitate	B-ChemicalEntity
,	O
the	O
final	O
product	O
of	O
the	O
FASN	B-GeneOrGeneProduct
reaction	O
,	O
rescued	O
emodin	B-ChemicalEntity
-	O
induced	O
viability	O
and	O
apoptosis	O
.	O

In	O
addition	O
,	O
emodin	B-ChemicalEntity
altered	O
FASN	B-GeneOrGeneProduct
-	O
involved	O
signaling	O
pathways	O
,	O
including	O
phosphatidylinositol	B-GeneOrGeneProduct
3	I-GeneOrGeneProduct
-	O
kinase	I-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
and	O
mitogen	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
/	O
extracellular	I-GeneOrGeneProduct
signal	I-GeneOrGeneProduct
-	O
regulated	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
.	O

These	O
results	O
suggested	O
that	O
emodin	B-ChemicalEntity
-	O
regulated	O
cell	O
growth	O
and	O
apoptosis	O
were	O
mediated	O
by	O
inhibiting	O
FASN	B-GeneOrGeneProduct
and	O
provide	O
a	O
molecular	O
basis	O
for	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
therapy	O
.	O
Circulating	O
Fatty	B-GeneOrGeneProduct
Acid	I-GeneOrGeneProduct
Synthase	I-GeneOrGeneProduct
in	O
pregnant	O
women	B-OrganismTaxon
:	O
Relationship	O
to	O
blood	O
pressure	O
,	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
.	O

The	O
enzyme	O
FASN	B-GeneOrGeneProduct
(	O
fatty	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
)	O
is	O
potentially	O
related	O
with	O
hypertension	B-DiseaseOrPhenotypicFeature
and	O
metabolic	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
.	O

FASN	B-GeneOrGeneProduct
is	O
highly	O
expressed	O
in	O
the	O
human	B-OrganismTaxon
placenta	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
relationship	O
circulating	O
FASN	B-GeneOrGeneProduct
has	O
with	O
blood	O
pressure	O
,	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
in	O
healthy	O
pregnant	O
women	B-OrganismTaxon
.	O

Circulating	O
FASN	B-GeneOrGeneProduct
was	O
assessed	O
in	O
115	O
asymptomatic	O
pregnant	O
women	B-OrganismTaxon
in	O
the	O
second	O
trimester	O
of	O
gestation	O
along	O
with	O
C	B-ChemicalEntity
-	O
peptide	I-ChemicalEntity
,	O
fasting	O
glucose	B-ChemicalEntity
and	O
insulin	B-GeneOrGeneProduct
,	O
post	O
-	O
load	O
glucose	B-ChemicalEntity
lipids	B-ChemicalEntity
,	O
HMW	B-GeneOrGeneProduct
-	O
adiponectin	B-GeneOrGeneProduct
and	O
blood	O
pressure	O
(	O
the	O
latter	O
was	O
assessed	O
in	O
each	O
trimester	O
of	O
gestation	O
)	O
.	O

At	O
birth	O
,	O
newborns	O
and	O
placentas	O
were	O
weighed	O
.	O

FASN	B-GeneOrGeneProduct
expression	O
was	O
also	O
able	O
to	O
be	O
assessed	O
in	O
80	O
placentas	O
.	O

Higher	O
circulating	O
FASN	B-GeneOrGeneProduct
was	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
with	O
a	O
more	O
favourable	O
metabolic	O
phenotype	O
(	O
lower	O
fasting	O
glucose	B-ChemicalEntity
and	O
insulin	B-GeneOrGeneProduct
,	O
post	O
load	O
glucose	B-ChemicalEntity
,	O
HbAc1	B-GeneOrGeneProduct
,	O
HOMA	O
-	O
IR	O
and	O
C	B-ChemicalEntity
-	O
peptide	I-ChemicalEntity
)	O
,	O
and	O
with	O
lower	O
placental	O
and	O
birth	O
weight	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
to	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Placental	O
FASN	B-GeneOrGeneProduct
expression	O
related	O
positively	O
to	O
circulating	O
FASN	B-GeneOrGeneProduct
(	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
negatively	O
to	O
placental	O
weight	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
observations	O
suggest	O
a	O
physiological	O
role	O
of	O
placental	O
FASN	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
pregnancy	O
.	O

Future	O
studies	O
will	O
clarify	O
whether	O
circulating	O
FASN	B-GeneOrGeneProduct
of	O
placental	O
origin	O
does	O
actually	O
regulate	O
placental	O
and	O
fetal	O
growth	O
,	O
and	O
(	O
thereby	O
)	O
has	O
a	O
favourable	O
influence	O
on	O
the	O
pregnant	O
mother	O
'	O
s	O
insulin	B-GeneOrGeneProduct
sensitivity	O
and	O
blood	O
pressure	O
.	O
Syncope	B-DiseaseOrPhenotypicFeature
caused	O
by	O
hyperkalemia	B-DiseaseOrPhenotypicFeature
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	B-ChemicalEntity
-	O
converting	I-ChemicalEntity
enzyme	I-ChemicalEntity
inhibitor	I-ChemicalEntity
and	O
spironolactone	B-ChemicalEntity
.	O

A	O
76	O
year	O
-	O
old	O
woman	B-OrganismTaxon
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
consciousness	I-DiseaseOrPhenotypicFeature
due	O
to	O
marked	O
bradycardia	B-DiseaseOrPhenotypicFeature
caused	O
by	O
hyperkalemia	B-DiseaseOrPhenotypicFeature
.	O

The	O
concentration	O
of	O
serum	O
potassium	B-ChemicalEntity
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	B-ChemicalEntity
level	O
.	O

The	O
cause	O
of	O
hyperkalemia	B-DiseaseOrPhenotypicFeature
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	B-ChemicalEntity
,	O
an	O
aldosterone	B-ChemicalEntity
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	B-ChemicalEntity
,	O
an	O
ACE	B-GeneOrGeneProduct
inhibitor	O
.	O

This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life	O
-	O
threatening	O
cardiac	O
events	O
.	O

Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B-DiseaseOrPhenotypicFeature
,	O
especially	O
in	O
elderly	O
patients	B-OrganismTaxon
using	O
ACE	B-GeneOrGeneProduct
/	O
ARB	B-ChemicalEntity
in	O
combination	O
with	O
potassium	B-ChemicalEntity
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B-DiseaseOrPhenotypicFeature
disturbance	I-DiseaseOrPhenotypicFeature
.	O
The	O
dopamine	B-GeneOrGeneProduct
b	I-GeneOrGeneProduct
-	O
hydroxylase	I-GeneOrGeneProduct
-	O
1021C	I-SequenceVariant
/	O
T	I-SequenceVariant
polymorphism	O
is	O
associated	O
with	O
the	O
risk	O
of	O
Alzheimer	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
in	O
the	O
Epistasis	O
Project	O
.	O

BACKGROUND	O
:	O
The	O
loss	O
of	O
noradrenergic	O
neurones	O
of	O
the	O
locus	O
coeruleus	O
is	O
a	O
major	O
feature	O
of	O
Alzheimer	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
AD	B-DiseaseOrPhenotypicFeature
)	O
.	O

Dopamine	B-GeneOrGeneProduct
b	I-GeneOrGeneProduct
-	O
hydroxylase	I-GeneOrGeneProduct
(	O
DBH	B-GeneOrGeneProduct
)	O
catalyses	O
the	O
conversion	O
of	O
dopamine	B-ChemicalEntity
to	O
noradrenaline	B-ChemicalEntity
.	O

Interactions	O
have	O
been	O
reported	O
between	O
the	O
low	O
-	O
activity	O
-	O
1021T	I-SequenceVariant
allele	O
(	O
rs1611115	B-SequenceVariant
)	O
of	O
DBH	B-GeneOrGeneProduct
and	O
polymorphisms	O
of	O
the	O
pro	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
cytokine	O
genes	O
,	O
IL1A	B-GeneOrGeneProduct
and	O
IL6	B-GeneOrGeneProduct
,	O
contributing	O
to	O
the	O
risk	O
of	O
AD	B-DiseaseOrPhenotypicFeature
.	O

We	O
therefore	O
examined	O
the	O
associations	O
with	O
AD	B-DiseaseOrPhenotypicFeature
of	O
the	O
DBH	B-GeneOrGeneProduct
-	O
1021T	I-SequenceVariant
allele	O
and	O
of	O
the	O
above	O
interactions	O
in	O
the	O
Epistasis	O
Project	O
,	O
with	O
1757	O
cases	O
of	O
AD	B-DiseaseOrPhenotypicFeature
and	O
6294	O
elderly	O
controls	O
.	O

METHODS	O
:	O
We	O
genotyped	O
eight	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
three	O
genes	O
,	O
DBH	B-GeneOrGeneProduct
,	O
IL1A	B-GeneOrGeneProduct
and	O
IL6	B-GeneOrGeneProduct
.	O

We	O
used	O
logistic	O
regression	O
models	O
and	O
synergy	O
factor	O
analysis	O
to	O
examine	O
potential	O
interactions	O
and	O
associations	O
with	O
AD	B-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
We	O
found	O
that	O
the	O
presence	O
of	O
the	O
-	O
1021T	I-SequenceVariant
allele	O
was	O
associated	O
with	O
AD	B-DiseaseOrPhenotypicFeature
:	O
odds	O
ratio	O
=	O
1	O
.	O
2	O
(	O
95%	O
confidence	O
interval	O
:	O
1	O
.	O
06	O
-	O
1	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

This	O
association	O
was	O
nearly	O
restricted	O
to	O
men	B-OrganismTaxon
<	O
75	O
years	O
old	O
:	O
odds	O
ratio	O
=	O
2	O
.	O
2	O
(	O
1	O
.	O
4	O
-	O
3	O
.	O
3	O
,	O
0	O
.	O
0004	O
)	O
.	O

We	O
also	O
found	O
an	O
interaction	O
between	O
the	O
presence	O
of	O
DBH	B-GeneOrGeneProduct
-	O
1021T	I-SequenceVariant
and	O
the	O
-	O
889TT	I-SequenceVariant
genotype	O
(	O
rs1800587	B-SequenceVariant
)	O
of	O
IL1A	B-GeneOrGeneProduct
:	O
synergy	O
factor	O
=	O
1	O
.	O
9	O
(	O
1	O
.	O
2	O
-	O
3	O
.	O
1	O
,	O
0	O
.	O
005	O
)	O
.	O

All	O
these	O
results	O
were	O
consistent	O
between	O
North	O
Europe	O
and	O
North	O
Spain	O
.	O

CONCLUSIONS	O
:	O
Extensive	O
,	O
previous	O
evidence	O
(	O
reviewed	O
here	O
)	O
indicates	O
an	O
important	O
role	O
for	O
noradrenaline	B-ChemicalEntity
in	O
the	O
control	O
of	O
inflammation	B-DiseaseOrPhenotypicFeature
in	O
the	O
brain	O
.	O

Thus	O
,	O
the	O
-	O
1021T	I-SequenceVariant
allele	O
with	O
presumed	O
low	O
activity	O
may	O
be	O
associated	O
with	O
misregulation	O
of	O
inflammation	B-DiseaseOrPhenotypicFeature
,	O
which	O
could	O
contribute	O
to	O
the	O
onset	O
of	O
AD	B-DiseaseOrPhenotypicFeature
.	O

We	O
suggest	O
that	O
such	O
misregulation	O
is	O
the	O
predominant	O
mechanism	O
of	O
the	O
association	O
we	O
report	O
here	O
.	O
Association	O
between	O
promoter	O
-	O
1607	O
polymorphism	O
of	O
MMP1	B-GeneOrGeneProduct
and	O
lumbar	B-DiseaseOrPhenotypicFeature
disc	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
in	O
Southern	O
Chinese	O
.	O

BACKGROUND	O
:	O
Matrix	B-GeneOrGeneProduct
metalloproteinases	I-GeneOrGeneProduct
(	O
MMPs	B-GeneOrGeneProduct
)	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
of	O
the	O
intervertebral	O
disc	O
.	O

A	O
SNP	O
for	O
guanine	B-SequenceVariant
insertion	I-SequenceVariant
/	O
deletion	I-SequenceVariant
(	O
G	I-SequenceVariant
/	O
D	I-SequenceVariant
)	O
,	O
the	I-SequenceVariant
-	O
1607	I-SequenceVariant
promoter	I-SequenceVariant
polymorphism	I-SequenceVariant
,	O
of	O
the	O
MMP1	B-GeneOrGeneProduct
gene	O
was	O
found	O
significantly	O
affecting	O
promoter	O
activity	O
and	O
corresponding	O
transcription	O
level	O
.	O

Hence	O
it	O
is	O
a	O
good	O
candidate	O
for	O
genetic	O
studies	O
in	O
DDD	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Southern	O
Chinese	O
volunteers	O
between	O
18	O
and	O
55	O
years	O
were	O
recruited	O
from	O
the	O
population	O
.	O

DDD	B-DiseaseOrPhenotypicFeature
in	O
the	O
lumbar	O
spine	O
was	O
defined	O
by	O
MRI	O
using	O
Schneiderman	O
'	O
s	O
classification	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
leukocytes	O
and	O
genotyping	O
was	O
performed	O
using	O
the	O
Sequenom	O
platform	O
.	O

Association	O
and	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
checking	O
were	O
assessed	O
by	O
Chi	O
-	O
square	O
test	O
and	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

RESULTS	O
:	O
Our	O
results	O
showed	O
substantial	O
evidence	O
of	O
association	O
between	O
-	O
1607	O
promoter	O
polymorphism	O
of	O
MMP1	B-GeneOrGeneProduct
and	O
DDD	B-DiseaseOrPhenotypicFeature
in	O
the	O
Southern	O
Chinese	O
subjects	O
.	O

D	O
allelic	O
was	O
significantly	O
associated	O
with	O
DDD	B-DiseaseOrPhenotypicFeature
(	O
p	O
value	O
=	O
0	O
.	O
027	O
,	O
odds	O
ratio	O
=	O
1	O
.	O
41	O
with	O
95%	O
CI	O
=	O
1	O
.	O
04	O
-	O
1	O
.	O
90	O
)	O
while	O
Genotypic	O
association	O
on	O
the	O
presence	O
of	O
D	O
allele	O
was	O
also	O
significantly	O
associated	O
with	O
DDD	B-DiseaseOrPhenotypicFeature
(	O
p	O
value	O
=	O
0	O
.	O
046	O
,	O
odds	O
ratio	O
=	O
1	O
.	O
50	O
with	O
95%	O
CI	O
=	O
1	O
.	O
01	O
-	O
2	O
.	O
24	O
)	O
.	O

Further	O
age	O
stratification	O
showed	O
significant	O
genotypic	O
as	O
well	O
as	O
allelic	O
association	O
in	O
the	O
group	O
of	O
over	O
40	O
years	O
(	O
genotypic	O
:	O
p	O
value	O
=	O
0	O
.	O
035	O
,	O
odds	O
ratio	O
=	O
1	O
.	O
617	O
with	O
95%	O
CI	O
=	O
1	O
.	O
033	O
-	O
2	O
.	O
529	O
;	O
allelic	O
:	O
p	O
value	O
=	O
0	O
.	O
033	O
,	O
odds	O
ratio	O
=	O
1	O
.	O
445	O
with	O
95%	O
CI	O
=	O
1	O
.	O
029	O
-	O
2	O
.	O
029	O
)	O
.	O

Disc	O
bulge	O
,	O
annular	O
tears	O
and	O
the	O
Schmorl	O
'	O
s	O
nodes	O
were	O
not	O
associated	O
with	O
the	O
D	O
allele	O
.	O

CONCLUSION	O
:	O
We	O
demonstrated	O
that	O
individuals	O
with	O
the	O
presence	O
of	O
D	B-SequenceVariant
allele	I-SequenceVariant
for	I-SequenceVariant
the	I-SequenceVariant
-	O
1607	I-SequenceVariant
promoter	O
polymorphism	O
of	O
MMP1	B-GeneOrGeneProduct
are	O
about	O
1	O
.	O
5	O
times	O
more	O
susceptible	O
to	O
develop	O
DDD	B-DiseaseOrPhenotypicFeature
when	O
compared	O
with	O
those	O
having	O
G	O
allele	O
only	O
.	O

Further	O
association	O
was	O
identified	O
in	O
individuals	O
over	O
40	O
years	O
of	O
age	O
.	O

Disc	O
bulge	O
,	O
annular	O
tear	O
as	O
well	O
as	O
Schmorl	O
'	O
s	O
nodes	O
were	O
not	O
associated	O
with	O
this	O
polymorphism	O
.	O
Recurrent	O
acute	O
interstitial	B-DiseaseOrPhenotypicFeature
nephritis	I-DiseaseOrPhenotypicFeature
induced	O
by	O
azithromycin	B-ChemicalEntity
.	O

A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	B-ChemicalEntity
-	O
induced	O
,	O
acute	O
interstitial	B-DiseaseOrPhenotypicFeature
nephritis	I-DiseaseOrPhenotypicFeature
.	O

The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	B-ChemicalEntity
therapy	O
,	O
renal	O
function	O
remained	O
impaired	O
.	O

Although	O
most	O
cases	O
of	O
antibiotic	B-ChemicalEntity
induced	O
acute	O
interstitial	B-DiseaseOrPhenotypicFeature
nephritis	I-DiseaseOrPhenotypicFeature
are	O
benign	O
and	O
self	O
-	O
limited	O
,	O
some	O
patients	B-OrganismTaxon
are	O
at	O
risk	O
for	O
permanent	O
renal	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O
CFI	B-GeneOrGeneProduct
-	O
rs7356506	B-SequenceVariant
polymorphisms	O
associated	O
with	O
Vogt	B-DiseaseOrPhenotypicFeature
-	O
Koyanagi	I-DiseaseOrPhenotypicFeature
-	O
Harada	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

PURPOSE	O
:	O
Complement	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
(	O
CFI	B-GeneOrGeneProduct
)	O
plays	O
an	O
important	O
role	O
in	O
complement	O
activation	O
pathways	O
and	O
is	O
known	O
to	O
affect	O
the	O
development	O
of	O
uveitis	B-DiseaseOrPhenotypicFeature
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
existence	O
of	O
an	O
association	O
between	O
CFI	B-GeneOrGeneProduct
genetic	O
polymorphisms	O
and	O
Vogt	B-DiseaseOrPhenotypicFeature
-	O
Koyanagi	I-DiseaseOrPhenotypicFeature
-	O
Harada	I-DiseaseOrPhenotypicFeature
(	O
VKH	I-DiseaseOrPhenotypicFeature
)	O
syndrome	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
A	O
total	O
of	O
100	O
patients	B-OrganismTaxon
diagnosed	O
with	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
and	O
300	O
healthy	O
controls	O
were	O
recruited	O
for	O
the	O
study	O
.	O

Two	O
milliliters	O
of	O
peripheral	O
blood	O
were	O
collected	O
in	O
a	O
sterile	O
anticoagulative	O
tube	O
.	O

CFI	B-GeneOrGeneProduct
-	O
rs7356506	B-SequenceVariant
polymorphisms	O
were	O
genotyped	O
using	O
Sequenom	O
MassARRAY	O
technology	O
.	O

Allele	O
and	O
genotype	O
frequencies	O
were	O
compared	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
using	O
a	O
X	O
(	O
2	O
)	O
test	O
.	O

The	O
analyses	O
were	O
stratified	O
for	O
recurrent	O
status	O
,	O
complicated	O
cataract	B-DiseaseOrPhenotypicFeature
status	O
,	O
and	O
steroid	B-ChemicalEntity
-	O
sensitive	O
status	O
.	O

RESULTS	O
:	O
No	O
significant	O
association	O
was	O
found	O
between	O
CFI	B-GeneOrGeneProduct
-	O
rs7356506	B-SequenceVariant
polymorphisms	O
and	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
patients	B-OrganismTaxon
with	O
recurrent	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
had	O
lower	O
frequencies	O
of	O
the	O
G	O
allele	O
and	O
GG	O
homozygosity	O
in	O
CFI	B-GeneOrGeneProduct
-	O
rs7356506	B-SequenceVariant
when	O
compared	O
to	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
016	O
,	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
0	O
.	O
429	O
,	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0	O
.	O
212	O
-	O
0	O
.	O
871	O
;	O
p	O
=	O
0	O
.	O
014	O
,	O
OR	O
=	O
0	O
.	O
364	O
,	O
95%	O
CI	O
=	O
0	O
.	O
158	O
-	O
0	O
.	O
837	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
there	O
were	O
significant	O
decreases	O
in	O
the	O
frequencies	O
of	O
the	O
G	O
allele	O
and	O
GG	O
homozygosity	O
in	O
CFI	B-GeneOrGeneProduct
-	O
rs7356506	B-SequenceVariant
in	O
patients	B-OrganismTaxon
with	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
with	O
complicated	O
cataract	B-DiseaseOrPhenotypicFeature
compared	O
to	O
the	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
OR	O
=	O
0	O
.	O
357	O
,	O
95%	O
CI	O
=	O
0	O
.	O
197	O
-	O
0	O
.	O
648	O
;	O
p	O
<	O
0	O
.	O
001	O
,	O
OR	O
=	O
0	O
.	O
273	O
,	O
95%	O
CI	O
=	O
0	O
.	O
135	O
-	O
0	O
.	O
551	O
,	O
respectively	O
)	O
.	O

Nevertheless	O
,	O
no	O
significant	O
association	O
with	O
patients	B-OrganismTaxon
with	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
in	O
steroid	B-ChemicalEntity
-	O
sensitive	O
statuses	O
was	O
detected	O
for	O
CFI	B-GeneOrGeneProduct
-	O
rs7356506	B-SequenceVariant
polymorphisms	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
CFI	B-GeneOrGeneProduct
polymorphisms	O
are	O
not	O
significantly	O
associated	O
with	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
;	O
nevertheless	O
,	O
we	O
identified	O
a	O
trend	O
for	O
the	O
association	O
of	O
CFI	B-GeneOrGeneProduct
-	O
7356506	B-SequenceVariant
with	O
VKH	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
that	O
depends	O
on	O
the	O
recurrent	O
status	O
and	O
the	O
complicated	O
cataract	B-DiseaseOrPhenotypicFeature
status	O
but	O
not	O
on	O
the	O
steroid	B-ChemicalEntity
-	O
sensitive	O
status	O
.	O
The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	B-ChemicalEntity
and	O
their	O
effects	O
on	O
cardiac	B-DiseaseOrPhenotypicFeature
arrhythmias	I-DiseaseOrPhenotypicFeature
.	O

1	O
.	O

The	O
optical	O
isomers	O
of	O
propranolol	B-ChemicalEntity
have	O
been	O
compared	O
for	O
their	O
beta	O
-	O
blocking	O
and	O
antiarrhythmic	O
activities	O
.	O
2	O
.	O

In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	B-ChemicalEntity
,	O
(	O
+	O
)	O
-	O
propranolol	B-ChemicalEntity
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-ChemicalEntity
.	O

At	O
dose	O
levels	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-ChemicalEntity
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	B-ChemicalEntity
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O
3	O
.	O

The	O
metabolic	O
responses	O
to	O
isoprenaline	B-ChemicalEntity
in	O
dogs	B-OrganismTaxon
(	O
an	O
increase	O
in	O
circulating	O
glucose	B-ChemicalEntity
,	O
lactate	B-ChemicalEntity
and	O
free	O
fatty	B-ChemicalEntity
acids	I-ChemicalEntity
)	O
were	O
all	O
blocked	O
by	O
(	O
-	O
)	O
-	O
propranolol	B-ChemicalEntity
.	O

(	O
+	O
)	O
-	O
Propranolol	B-ChemicalEntity
had	O
no	O
effect	O
on	O
fatty	B-ChemicalEntity
acid	I-ChemicalEntity
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B-ChemicalEntity
and	O
glucose	B-ChemicalEntity
.	O
4	O
.	O

Both	O
isomers	O
of	O
propranolol	B-ChemicalEntity
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea	B-OrganismTaxon
-	O
pigs	I-OrganismTaxon
.	O
5	O
.	O

The	O
isomers	O
of	O
propranolol	B-ChemicalEntity
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	B-ChemicalEntity
.	O

The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer	O
.	O
6	O
.	O

Both	O
isomers	O
of	O
propranolol	B-ChemicalEntity
were	O
capable	O
of	O
preventing	O
adrenaline	B-ChemicalEntity
-	O
induced	O
cardiac	B-DiseaseOrPhenotypicFeature
arrhythmias	I-DiseaseOrPhenotypicFeature
in	O
cats	B-OrganismTaxon
anaesthetized	O
with	O
halothane	B-ChemicalEntity
,	O
but	O
the	O
mean	O
dose	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-ChemicalEntity
was	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-ChemicalEntity
was	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O

At	O
the	O
effective	O
dose	O
level	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-ChemicalEntity
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O

Blockade	O
of	O
arrhythmias	B-DiseaseOrPhenotypicFeature
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline	B-ChemicalEntity
.	O
7	O
.	O

Both	O
isomers	O
of	O
propranolol	B-ChemicalEntity
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B-DiseaseOrPhenotypicFeature
tachycardia	I-DiseaseOrPhenotypicFeature
caused	O
by	O
ouabain	B-ChemicalEntity
in	O
anaesthetized	O
cats	B-OrganismTaxon
and	O
dogs	B-OrganismTaxon
.	O

The	O
dose	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-ChemicalEntity
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-ChemicalEntity
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta	O
-	O
blockade	O
.	O
8	O
.	O

The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O
Combination	O
of	O
polymorphisms	O
within	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
thymidylate	B-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
gene	O
modulates	O
survival	O
in	O
5	B-ChemicalEntity
fluorouracil	I-ChemicalEntity
-	O
treated	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

In	O
the	O
present	O
study	O
we	O
explored	O
the	O
effect	O
of	O
three	O
polymorphisms	O
of	O
the	O
TS	B-GeneOrGeneProduct
gene	O
on	O
overall	O
and	O
progression	O
-	O
free	O
survival	O
of	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
CRC	B-DiseaseOrPhenotypicFeature
)	O
patients	B-OrganismTaxon
subjected	O
to	O
5FU	B-ChemicalEntity
chemotherapy	O
.	O

A	O
28	B-SequenceVariant
bp	I-SequenceVariant
variable	I-SequenceVariant
number	I-SequenceVariant
of	I-SequenceVariant
tandem	I-SequenceVariant
repeats	I-SequenceVariant
(	O
VNTR	O
)	O
,	O
a	O
G	B-SequenceVariant
/	O
C	I-SequenceVariant
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
and	O
a	O
deletion	B-SequenceVariant
of	I-SequenceVariant
6	I-SequenceVariant
bp	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
1494	I-SequenceVariant
were	O
studied	O
.	O

The	O
possible	O
combined	O
effect	O
of	O
these	O
DNA	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
patients	B-OrganismTaxon
was	O
also	O
evaluated	O
.	O

A	O
retrospective	O
study	O
was	O
carried	O
out	O
on	O
paraffin	B-ChemicalEntity
-	O
embedded	O
sections	O
from	O
113	O
patients	B-OrganismTaxon
diagnosed	O
of	O
advanced	O
CRC	B-DiseaseOrPhenotypicFeature
.	O

TS	B-GeneOrGeneProduct
genotyping	O
methods	O
were	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
VNTR	O
and	O
PCR	O
,	O
followed	O
by	O
restriction	O
length	O
fragment	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
SNP	O
and	O
ins	B-SequenceVariant
/	O
del	I-SequenceVariant
6	I-SequenceVariant
bp	I-SequenceVariant
.	O

To	O
study	O
the	O
combined	O
effect	O
of	O
TS	B-GeneOrGeneProduct
polymorphisms	O
,	O
four	O
categories	O
were	O
defined	O
accordingly	O
to	O
the	O
level	O
of	O
expression	O
attributed	O
to	O
SNP	O
and	O
ins	B-SequenceVariant
/	O
del	I-SequenceVariant
6	I-SequenceVariant
bp	I-SequenceVariant
genotypes	O
:	O
C_allele	O
6	O
-	O
,	O
C_6	O
+	O
/	O
6	O
+	O
,	O
G_allele6	O
-	O
and	O
G_6	O
+	O
/	O
6	O
+	O
.	O

VNTR	O
and	O
ins	B-SequenceVariant
/	O
del	I-SequenceVariant
6	I-SequenceVariant
bp	I-SequenceVariant
genotypes	O
varied	O
with	O
tumour	B-DiseaseOrPhenotypicFeature
anatomical	O
site	O
:	O
2R	O
/	O
2R	O
genotype	O
was	O
rare	O
in	O
left	O
-	O
sided	O
tumours	B-DiseaseOrPhenotypicFeature
(	O
7	O
.	O
0%	O
vs	O
.	O

26	O
.	O
3%	O
of	O
right	O
-	O
sided	O
and	O
24	O
.	O
1%	O
of	O
rectal	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
;	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
where	O
the	O
variant	O
allele	O
6	O
-	O
was	O
very	O
frequent	O
(	O
69	O
.	O
0%	O
)	O
.	O

Instead	O
,	O
most	O
patients	B-OrganismTaxon
with	O
right	O
-	O
sided	O
tumours	B-DiseaseOrPhenotypicFeature
were	O
wild	O
-	O
type	O
homozygous	O
6	O
+	O
/	O
6	O
+	O
(	O
63	O
.	O
9%	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Heterozygous	O
6	O
+	O
/	O
6	O
-	O
genotype	O
was	O
more	O
frequent	O
among	O
tumours	B-DiseaseOrPhenotypicFeature
classified	O
as	O
C	O
(	O
50	O
.	O
0%	O
)	O
and	O
D	O
(	O
76	O
.	O
5%	O
)	O
Dukes	O
stages	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

None	O
of	O
the	O
studied	O
polymorphisms	O
alone	O
affected	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
.	O

C_6	O
+	O
/	O
6	O
+	O
and	O
G_6	O
+	O
/	O
6	O
+	O
combined	O
genotypes	O
were	O
respectively	O
associated	O
to	O
the	O
best	O
and	O
worst	O
PFS	O
(	O
P	O
=	O
0	O
.	O
03	O
when	O
compared	O
with	O
each	O
other	O
)	O
,	O
while	O
combinations	O
carrying	O
the	O
allele	O
6	O
-	O
determined	O
an	O
intermediate	O
evolution	O
that	O
might	O
be	O
indicative	O
of	O
a	O
variable	O
response	O
to	O
chemotherapy	O
.	O

The	O
rate	O
of	O
Dukes	O
B	O
stage	O
tumours	B-DiseaseOrPhenotypicFeature
was	O
unexpectedly	O
high	O
(	O
59	O
.	O
1%	O
)	O
among	O
patients	B-OrganismTaxon
with	O
the	O
unfavourable	O
G_6	O
+	O
/	O
6	O
+	O
combination	O
.	O

In	O
our	O
study	O
the	O
combination	O
of	O
high	O
TS	B-GeneOrGeneProduct
expression	O
genotypes	O
G_6	O
+	O
/	O
6	O
+	O
identifies	O
a	O
group	O
of	O
high	O
risk	O
within	O
CRC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
treated	O
with	O
5FU	B-ChemicalEntity
.	O
Polymorphisms	O
in	O
the	O
FOXP3	B-GeneOrGeneProduct
gene	O
in	O
Han	O
Chinese	O
psoriasis	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

BACKGROUND	O
:	O
Psoriasis	B-DiseaseOrPhenotypicFeature
is	O
a	O
common	O
dermatological	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
,	O
in	O
which	O
autoimmunity	O
plays	O
an	O
important	O
role	O
.	O

CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
CD25	B-GeneOrGeneProduct
(	O
+	O
)	O
regulatory	O
T	O
cells	O
(	O
T	O
-	O
regs	O
)	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
some	O
autoimmune	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

T	O
-	O
regs	O
express	O
the	O
fork	O
head	O
/	O
winged	O
helix	O
transcription	O
factor	O
,	O
FOXP3	B-GeneOrGeneProduct
,	O
which	O
appears	O
to	O
be	O
of	O
key	O
importance	O
in	O
the	O
development	O
and	O
function	O
of	O
T	O
-	O
regs	O
.	O

Studies	O
have	O
found	O
that	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
FOXP3	B-GeneOrGeneProduct
gene	O
contribute	O
to	O
susceptibility	O
to	O
some	O
autoimmune	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
information	O
about	O
FOXP3	B-GeneOrGeneProduct
gene	O
in	O
psoriasis	B-DiseaseOrPhenotypicFeature
is	O
limited	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
evaluated	O
the	O
association	O
between	O
FOXP3	B-GeneOrGeneProduct
gene	O
SNPs	O
and	O
susceptibility	O
to	O
psoriasis	B-DiseaseOrPhenotypicFeature
in	O
a	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
In	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
524	O
patients	B-OrganismTaxon
with	O
psoriasis	B-DiseaseOrPhenotypicFeature
and	O
549	O
psoriasis	B-DiseaseOrPhenotypicFeature
-	O
free	O
controls	O
were	O
recruited	O
according	O
to	O
age	O
and	O
gender	O
.	O

We	O
investigated	O
four	O
SNPs	O
in	O
the	O
FOXP3	B-GeneOrGeneProduct
gene	O
(	O
-	O
6054	I-SequenceVariant
,	O
deletion	I-SequenceVariant
/	O
ATT	I-SequenceVariant
;	O
-	O
3279	I-SequenceVariant
,	O
A	I-SequenceVariant
/	O
C	I-SequenceVariant
;	O
-	O
924	I-SequenceVariant
,	O
A	I-SequenceVariant
/	O
G	I-SequenceVariant
;	O
IVS9	B-SequenceVariant
+	O
459	I-SequenceVariant
,	O
A	I-SequenceVariant
/	O
G	I-SequenceVariant
)	O
in	O
psoriatic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
and	O
assessed	O
allele	O
and	O
genotype	O
frequencies	O
in	O
psoriatic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
237	O
females	O
,	O
287	O
males	O
)	O
and	O
normal	O
controls	O
(	O
272	O
females	O
,	O
277	O
males	O
)	O
.	O

The	O
polymorphisms	O
were	O
genotyped	O
using	O
the	O
PCR	O
sequence	O
-	O
specific	O
primer	O
(	O
PCR	O
-	O
SSP	O
)	O
technique	O
and	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
increased	O
risk	O
of	O
psoriasis	B-DiseaseOrPhenotypicFeature
was	O
associated	O
with	O
the	O
FOXP3	B-GeneOrGeneProduct
-	O
3279	I-SequenceVariant
AC	I-SequenceVariant
genotype	O
(	O
adjusted	O
OR	O
,	O
1	O
.	O
32	O
;	O
95%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
74	O
)	O
and	O
the	O
combined	O
AC	O
+	O
AA	O
genotype	O
(	O
adjusted	O
OR	O
,	O
1	O
.	O
38	O
;	O
95%	O
CI	O
,	O
1	O
.	O
07	O
-	O
1	O
.	O
78	O
)	O
,	O
compared	O
with	O
the	O
-	O
3279	I-SequenceVariant
CC	I-SequenceVariant
genotype	O
.	O

We	O
also	O
found	O
that	O
an	O
increased	O
risk	O
of	O
psoriasis	B-DiseaseOrPhenotypicFeature
was	O
associated	O
with	O
the	O
FOXP3	B-GeneOrGeneProduct
IVS9	B-SequenceVariant
+	O
459	I-SequenceVariant
GG	I-SequenceVariant
genotype	O
(	O
adjusted	O
OR	O
,	O
2	O
.	O
24	O
;	O
95%	O
CI	O
,	O
1	O
.	O
41	O
-	O
3	O
.	O
58	O
)	O
.	O

However	O
,	O
the	O
combined	O
GA	O
+	O
GG	O
genotype	O
showed	O
no	O
such	O
tendency	O
(	O
adjusted	O
OR	O
=	O
1	O
.	O
28	O
;	O
95%	O
CI	O
,	O
1	O
.	O
00	O
-	O
1	O
.	O
64	O
)	O
,	O
compared	O
with	O
the	O
IVS9	B-SequenceVariant
+	O
459	I-SequenceVariant
AA	I-SequenceVariant
genotype	O
.	O

There	O
was	O
no	O
evidence	O
of	O
an	O
increased	O
risk	O
associated	O
with	O
the	O
FOXP3	B-GeneOrGeneProduct
-	O
6054	I-SequenceVariant
deletion	I-SequenceVariant
/	O
ATT	I-SequenceVariant
or	O
FOXP3	B-GeneOrGeneProduct
-	O
924	I-SequenceVariant
A	I-SequenceVariant
/	O
G	I-SequenceVariant
genotype	O
.	O

In	O
combined	O
genotype	O
analyses	O
,	O
the	O
FOXP3	B-GeneOrGeneProduct
-	O
3279	I-SequenceVariant
AC	I-SequenceVariant
+	O
AA	I-SequenceVariant
genotype	O
was	O
more	O
obviously	O
associated	O
in	O
males	O
(	O
adjusted	O
OR	O
=	O
1	O
.	O
60	O
,	O
95%	O
CI	O
=	O
1	O
.	O
11	O
-	O
2	O
.	O
31	O
)	O
and	O
severe	O
psoriasis	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
PASI	O
score	O
>	O
20	O
;	O
adjusted	O
OR	O
=	O
1	O
.	O
97	O
,	O
95%	O
CI	O
=	O
1	O
.	O
41	O
-	O
2	O
.	O
75	O
)	O
.	O

Meanwhile	O
,	O
the	O
FOXP3	B-GeneOrGeneProduct
IVS9	B-SequenceVariant
+	O
459	I-SequenceVariant
GA	I-SequenceVariant
+	O
GG	I-SequenceVariant
genotype	O
was	O
also	O
associated	O
with	O
severe	O
psoriasis	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
adjusted	O
OR	O
=	O
1	O
.	O
69	O
,	O
95%	O
CI	O
=	O
1	O
.	O
21	O
-	O
2	O
.	O
36	O
)	O
.	O

CONCLUSIONS	O
:	O
FOXP3	B-GeneOrGeneProduct
polymorphisms	O
appear	O
to	O
contribute	O
to	O
the	O
risk	O
of	O
psoriasis	B-DiseaseOrPhenotypicFeature
in	O
a	O
Han	O
Chinese	O
population	O
.	O

Larger	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
findings	O
.	O
Late	O
-	O
onset	O
scleroderma	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
crisis	I-DiseaseOrPhenotypicFeature
induced	O
by	O
tacrolimus	B-ChemicalEntity
and	O
prednisolone	B-ChemicalEntity
:	O
a	O
case	O
report	O
.	O

Scleroderma	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
crisis	I-DiseaseOrPhenotypicFeature
(	O
SRC	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
(	O
SSc	B-DiseaseOrPhenotypicFeature
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O

Moderate	O
to	O
high	O
dose	O
corticosteroid	B-ChemicalEntity
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	B-DiseaseOrPhenotypicFeature
.	O

Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B-DiseaseOrPhenotypicFeature
microangiopathy	I-DiseaseOrPhenotypicFeature
precipitated	O
by	O
cyclosporine	B-ChemicalEntity
in	O
patients	B-OrganismTaxon
with	O
SSc	B-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	B-OrganismTaxon
with	O
SRC	B-DiseaseOrPhenotypicFeature
induced	O
by	O
tacrolimus	B-ChemicalEntity
and	O
corticosteroids	B-ChemicalEntity
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B-ChemicalEntity
use	O
in	O
patients	B-OrganismTaxon
with	O
SSc	B-DiseaseOrPhenotypicFeature
.	O
A	O
novel	O
mutation	O
in	O
the	O
connexin	B-GeneOrGeneProduct
26	I-GeneOrGeneProduct
gene	O
(	O
GJB2	B-GeneOrGeneProduct
)	O
in	O
a	O
child	O
with	O
clinical	O
and	O
histological	O
features	O
of	O
keratitis	B-DiseaseOrPhenotypicFeature
-	O
ichthyosis	I-DiseaseOrPhenotypicFeature
-	O
deafness	I-DiseaseOrPhenotypicFeature
(	O
KID	I-DiseaseOrPhenotypicFeature
)	O
syndrome	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Keratitis	B-DiseaseOrPhenotypicFeature
-	O
ichthyosis	I-DiseaseOrPhenotypicFeature
-	O
deafness	I-DiseaseOrPhenotypicFeature
(	O
KID	I-DiseaseOrPhenotypicFeature
)	O
syndrome	I-DiseaseOrPhenotypicFeature
is	O
a	O
rare	O
congenital	B-DiseaseOrPhenotypicFeature
ectodermal	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
,	O
caused	O
by	O
heterozygous	O
missense	O
mutation	O
in	O
GJB2	B-GeneOrGeneProduct
,	O
encoding	O
the	O
gap	O
junction	O
protein	O
connexin	B-GeneOrGeneProduct
26	I-GeneOrGeneProduct
.	O

The	O
commonest	O
mutation	O
is	O
the	O
p	B-SequenceVariant
.	O
Asp50Asn	I-SequenceVariant
mutation	O
,	O
and	O
only	O
a	O
few	O
other	O
mutations	O
have	O
been	O
described	O
to	O
date	O
.	O

AIM	O
:	O
To	O
report	O
the	O
fatal	O
clinical	O
course	O
and	O
characterize	O
the	O
genetic	O
background	O
of	O
a	O
premature	O
male	O
neonate	O
with	O
the	O
clinical	O
and	O
histological	O
features	O
of	O
KID	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
GJB2	B-GeneOrGeneProduct
gene	O
.	O

Direct	O
sequencing	O
was	O
used	O
for	O
mutation	O
analysis	O
.	O

RESULTS	O
:	O
The	O
clinical	O
features	O
included	O
hearing	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
,	O
ichthyosiform	B-DiseaseOrPhenotypicFeature
erythroderma	I-DiseaseOrPhenotypicFeature
with	O
hyperkeratotic	O
plaques	O
,	O
palmoplantar	B-DiseaseOrPhenotypicFeature
keratoderma	I-DiseaseOrPhenotypicFeature
,	O
alopecia	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
scalp	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
eyelashes	I-DiseaseOrPhenotypicFeature
,	O
and	O
a	O
thick	O
vernix	O
caseosa	O
-	O
like	O
covering	O
of	O
the	O
scalp	O
.	O

On	O
histological	O
analysis	O
,	O
features	O
characteristic	O
of	O
KID	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
such	O
as	O
acanthosis	B-DiseaseOrPhenotypicFeature
and	O
papillomatosis	B-DiseaseOrPhenotypicFeature
of	O
the	O
epidermis	O
with	O
basket	O
-	O
weave	O
hyperkeratosis	B-DiseaseOrPhenotypicFeature
,	O
were	O
seen	O
.	O

The	O
skin	O
symptoms	O
were	O
treated	O
successfully	O
with	O
acitretin	B-ChemicalEntity
0	O
.	O
5	O
mg	O
/	O
kg	O
.	O

The	O
boy	O
developed	O
intraventricular	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
intracerebral	I-DiseaseOrPhenotypicFeature
haemorrhage	I-DiseaseOrPhenotypicFeature
,	O
leading	O
to	O
hydrocephalus	B-DiseaseOrPhenotypicFeature
.	O

His	O
condition	O
was	O
further	O
complicated	O
by	O
septicaemia	B-DiseaseOrPhenotypicFeature
and	O
meningitis	B-DiseaseOrPhenotypicFeature
caused	O
by	O
infection	B-DiseaseOrPhenotypicFeature
with	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
-	O
producing	O
Klebsiella	B-DiseaseOrPhenotypicFeature
pneumoniae	I-DiseaseOrPhenotypicFeature
.	O

Severe	O
respiratory	B-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
followed	O
,	O
and	O
the	O
child	O
died	O
at	O
46	O
weeks	O
of	O
gestational	O
age	O
(	O
13	O
weeks	O
postnatally	O
)	O
.	O

Sequencing	O
of	O
the	O
GJB2	B-GeneOrGeneProduct
gene	O
showed	O
that	O
the	O
child	O
was	O
heterozygous	O
for	O
a	O
novel	O
nucleotide	O
change	O
,	O
c	B-SequenceVariant
.	O
263C	I-SequenceVariant
>	O
T	I-SequenceVariant
,	O
in	O
exon	O
2	O
,	O
leading	O
to	O
a	O
substitution	O
of	O
alanine	B-SequenceVariant
for	I-SequenceVariant
valine	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
88	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Ala88Val	I-SequenceVariant
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
has	O
identified	O
a	O
new	O
heterozygous	O
de	O
novo	O
mutation	O
in	O
the	O
Cx26	B-GeneOrGeneProduct
gene	O
(	O
c	B-SequenceVariant
.	O
263C	I-SequenceVariant
>	O
T	I-SequenceVariant
;	O
p	B-SequenceVariant
.	O
Ala88Val	I-SequenceVariant
)	O
leading	O
to	O
KID	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O
Mono	O
-	O
allelic	O
POLG	B-GeneOrGeneProduct
expression	O
resulting	O
from	O
nonsense	O
-	O
mediated	O
decay	O
and	O
alternative	O
splicing	O
in	O
a	O
patient	B-OrganismTaxon
with	O
Alpers	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Alpers	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
is	O
an	O
autosomal	O
recessive	O
mitochondrial	B-DiseaseOrPhenotypicFeature
DNA	I-DiseaseOrPhenotypicFeature
depletion	I-DiseaseOrPhenotypicFeature
disorder	O
that	O
affects	O
children	O
and	O
young	O
adults	O
.	O

It	O
is	O
characterized	O
by	O
a	O
progressive	O
,	O
fatal	O
brain	O
and	O
liver	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

This	O
syndrome	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
POLG	B-GeneOrGeneProduct
,	O
the	O
gene	O
encoding	O
the	O
mitochondrial	O
DNA	O
polymerase	O
(	O
pol	B-GeneOrGeneProduct
gamma	I-GeneOrGeneProduct
)	O
.	O

Most	O
patients	B-OrganismTaxon
with	O
Alpers	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
have	O
been	O
found	O
to	O
be	O
compound	O
heterozygotes	O
,	O
carrying	O
two	O
pathogenic	O
mutations	O
in	O
trans	O
at	O
the	O
POLG	B-GeneOrGeneProduct
locus	O
.	O

POLG	B-GeneOrGeneProduct
is	O
a	O
nuclear	O
-	O
encoded	O
gene	O
whose	O
protein	O
product	O
is	O
imported	O
into	O
mitochondria	O
,	O
where	O
it	O
is	O
essential	O
for	O
mtDNA	O
replication	O
and	O
repair	O
.	O

We	O
studied	O
the	O
skin	O
fibroblasts	O
of	O
a	O
patient	B-OrganismTaxon
with	O
Alpers	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
having	O
the	O
genotype	O
E873stop	B-SequenceVariant
/	O
A467T	B-SequenceVariant
.	O

The	O
E873stop	B-SequenceVariant
mutation	O
produces	O
a	O
premature	O
termination	O
codon	O
(	O
TAG	O
)	O
in	O
exon	O
17	O
.	O

The	O
A467T	B-SequenceVariant
mutation	O
produces	O
a	O
threonine	B-SequenceVariant
to	I-SequenceVariant
alanine	I-SequenceVariant
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
exon	O
7	O
.	O

The	O
allele	O
bearing	O
the	O
stop	O
codon	O
(	O
E873	B-SequenceVariant
-	O
TAG	I-SequenceVariant
)	O
is	O
predicted	O
to	O
produce	O
a	O
truncated	O
,	O
catalytically	O
inactive	O
polymerase	O
.	O

However	O
,	O
only	O
full	O
-	O
length	O
pol	B-GeneOrGeneProduct
gamma	I-GeneOrGeneProduct
protein	O
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O

Here	O
,	O
we	O
show	O
that	O
transcripts	O
containing	O
this	O
stop	O
codon	O
undergo	O
nonsense	O
-	O
associated	O
alternative	O
splicing	O
and	O
nonsense	O
-	O
mediated	O
decay	O
.	O

More	O
than	O
95%	O
of	O
the	O
functional	O
POLG	B-GeneOrGeneProduct
mRNA	O
was	O
derived	O
from	O
the	O
allele	O
bearing	O
the	O
A467T	B-SequenceVariant
mutation	O
and	O
less	O
than	O
5%	O
contained	O
the	O
E873stop	B-SequenceVariant
mutation	O
.	O

These	O
events	O
ensured	O
that	O
virtually	O
all	O
POLG	B-GeneOrGeneProduct
protein	O
in	O
the	O
cell	O
was	O
expressed	O
from	O
the	O
A467T	B-SequenceVariant
allele	O
.	O

Therefore	O
,	O
the	O
Alpers	O
phenotype	O
in	O
this	O
patient	B-OrganismTaxon
was	O
a	O
consequence	O
of	O
a	O
single	O
-	O
copy	O
gene	O
dose	O
of	O
the	O
A467T	B-SequenceVariant
allele	O
,	O
and	O
selective	O
elimination	O
of	O
transcripts	O
bearing	O
the	O
E873stop	B-SequenceVariant
mutation	O
.	O
Metallothionein	B-ChemicalEntity
induction	O
reduces	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
activity	O
and	O
TNFalpha	B-GeneOrGeneProduct
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
.	O

Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions	O
.	O

On	O
the	O
other	O
hand	O
,	O
induction	O
of	O
metallothionein	B-ChemicalEntity
(	O
MT	B-ChemicalEntity
)	O
by	O
ZnSO	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	B-ChemicalEntity
induction	O
on	O
carmustine	B-ChemicalEntity
(	O
BCNU	B-ChemicalEntity
)	O
-	O
induced	O
hippocampal	O
cognitive	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	B-OrganismTaxon
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15	O
/	O
group	O
)	O
:	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	B-ChemicalEntity
solvent	O
(	O
i	O
.	O
v	O
)	O
.	O

The	O
second	O
group	O
administered	O
ZnSO	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BCNU	B-ChemicalEntity
solvent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O

Third	O
group	O
received	O
BCNU	B-ChemicalEntity
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O

Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BCNU	B-ChemicalEntity
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	O
.	O

The	O
obtained	O
data	O
revealed	O
that	O
BCNU	B-ChemicalEntity
administration	O
resulted	O
in	O
deterioration	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
learning	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
short	I-DiseaseOrPhenotypicFeature
-	O
term	I-DiseaseOrPhenotypicFeature
memory	I-DiseaseOrPhenotypicFeature
(	O
STM	O
)	O
,	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	B-GeneOrGeneProduct
reductase	I-GeneOrGeneProduct
(	O
GR	B-GeneOrGeneProduct
)	O
activity	O
and	O
reduced	O
glutathione	B-ChemicalEntity
(	O
GSH	B-ChemicalEntity
)	O
content	O
.	O

Also	O
,	O
BCNU	B-ChemicalEntity
administration	O
increased	O
serum	O
tumor	B-GeneOrGeneProduct
necrosis	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
(	O
TNFalpha	B-GeneOrGeneProduct
)	O
,	O
hippocampal	O
MT	B-ChemicalEntity
and	O
malondialdehyde	B-ChemicalEntity
(	O
MDA	B-ChemicalEntity
)	O
contents	O
as	O
well	O
as	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O

ZnSO	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
pretreatment	O
counteracted	O
BCNU	B-ChemicalEntity
-	O
induced	O
inhibition	O
of	O
GR	B-GeneOrGeneProduct
and	O
depletion	O
of	O
GSH	B-ChemicalEntity
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	B-ChemicalEntity
and	O
TNFalpha	B-GeneOrGeneProduct
as	O
well	O
as	O
the	O
activity	O
of	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
.	O

The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	B-OrganismTaxon
treated	O
with	O
ZnSO	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
+	O
BCNU	B-ChemicalEntity
compared	O
to	O
only	O
BCNU	B-ChemicalEntity
-	O
treated	O
animals	O
.	O

In	O
conclusion	O
,	O
MT	B-ChemicalEntity
induction	O
halts	O
BCNU	B-ChemicalEntity
-	O
induced	O
hippocampal	O
toxicity	B-DiseaseOrPhenotypicFeature
as	O
it	O
prevented	O
GR	B-GeneOrGeneProduct
inhibition	O
and	O
GSH	B-ChemicalEntity
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	B-GeneOrGeneProduct
,	O
MDA	B-ChemicalEntity
and	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O
Identification	O
and	O
molecular	O
characterization	O
of	O
six	O
novel	O
mutations	O
in	O
the	O
UDP	B-GeneOrGeneProduct
-	O
N	I-GeneOrGeneProduct
-	O
acetylglucosamine	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
phosphotransferase	I-GeneOrGeneProduct
gamma	I-GeneOrGeneProduct
subunit	I-GeneOrGeneProduct
(	O
GNPTG	B-GeneOrGeneProduct
)	O
gene	O
in	O
patients	B-OrganismTaxon
with	O
mucolipidosis	B-DiseaseOrPhenotypicFeature
III	I-DiseaseOrPhenotypicFeature
gamma	I-DiseaseOrPhenotypicFeature
.	O

Mucolipidosis	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
III	I-DiseaseOrPhenotypicFeature
(	O
MLIII	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
affecting	O
lysosomal	O
hydrolase	O
trafficking	O
.	O

In	O
a	O
study	O
of	O
10	O
patients	B-OrganismTaxon
from	O
seven	O
families	O
with	O
a	O
clinical	O
phenotype	O
and	O
enzymatic	O
diagnosis	O
of	O
MLIII	B-DiseaseOrPhenotypicFeature
,	O
six	O
novel	O
GNPTG	B-GeneOrGeneProduct
gene	O
mutations	O
were	O
identified	O
.	O

These	O
included	O
missense	O
(	O
p	B-SequenceVariant
.	O
T286M	I-SequenceVariant
)	O
and	O
nonsense	O
(	O
p	B-SequenceVariant
.	O
W111X	I-SequenceVariant
)	O
mutations	O
and	O
a	O
transition	O
in	O
the	O
obligate	O
AG	B-SequenceVariant
-	O
dinucleotide	I-SequenceVariant
of	O
the	O
intron	O
8	O
acceptor	O
splice	O
site	O
(	O
c	B-SequenceVariant
.	O
610	I-SequenceVariant
-	O
2A	I-SequenceVariant
>	O
G	I-SequenceVariant
)	O
.	O

Three	O
microdeletions	O
were	O
also	O
identified	O
,	O
two	O
of	O
which	O
(	O
c	B-SequenceVariant
.	O
611delG	I-SequenceVariant
and	O
c	B-SequenceVariant
.	O
640_667del28	I-SequenceVariant
)	O
were	O
located	O
within	O
the	O
coding	O
region	O
whereas	O
one	O
(	O
c	B-SequenceVariant
.	O
609	I-SequenceVariant
+	O
28_610	I-SequenceVariant
-	O
16del	I-SequenceVariant
)	O
was	O
located	O
entirely	O
within	O
intron	O
8	O
.	O

RT	O
-	O
PCR	O
analysis	O
of	O
the	O
c	B-SequenceVariant
.	O
610	I-SequenceVariant
-	O
2A	I-SequenceVariant
>	O
G	I-SequenceVariant
transition	O
demonstrated	O
that	O
the	O
change	O
altered	O
splicing	O
,	O
leading	O
to	O
the	O
production	O
of	O
two	O
distinct	O
aberrantly	O
spliced	O
forms	O
,	O
viz	O
.	O

the	O
skipping	O
of	O
exon	O
9	O
(	O
p	B-SequenceVariant
.	O
G204_K247del	I-SequenceVariant
)	O
or	O
the	O
retention	O
of	O
introns	O
8	O
and	O
9	O
(	O
p	B-SequenceVariant
.	O
G204VfsX28	I-SequenceVariant
)	O
.	O

RT	O
-	O
PCR	O
analysis	O
,	O
performed	O
on	O
a	O
patient	B-OrganismTaxon
homozygous	O
for	O
the	O
intronic	O
deletion	O
(	O
c	B-SequenceVariant
.	O
609	I-SequenceVariant
+	O
28_610	I-SequenceVariant
-	O
16del	I-SequenceVariant
)	O
,	O
failed	O
to	O
detect	O
any	O
GNPTG	B-GeneOrGeneProduct
RNA	O
transcripts	O
.	O

To	O
determine	O
whether	O
c	B-SequenceVariant
.	O
609	I-SequenceVariant
+	O
28_610	I-SequenceVariant
-	O
16del	I-SequenceVariant
allele	O
-	O
derived	O
transcripts	O
were	O
subject	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
,	O
patient	B-OrganismTaxon
fibroblasts	O
were	O
incubated	O
with	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	B-ChemicalEntity
.	O

An	O
RT	O
-	O
PCR	O
fragment	O
retaining	O
43	O
bp	O
of	O
intron	O
8	O
was	O
consistently	O
detected	O
suggesting	O
that	O
the	O
33	B-SequenceVariant
-	O
bp	I-SequenceVariant
genomic	I-SequenceVariant
deletion	I-SequenceVariant
had	O
elicited	O
NMD	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
and	O
GNPTG	B-GeneOrGeneProduct
western	O
blot	O
analysis	O
confirmed	O
that	O
the	O
homozygous	O
microdeletion	O
p	B-SequenceVariant
.	O
G204VfsX17	I-SequenceVariant
had	O
elicited	O
NMD	O
resulting	O
in	O
failure	O
to	O
synthesize	O
GNPTG	B-GeneOrGeneProduct
protein	O
.	O

Analysis	O
of	O
the	O
sequences	O
surrounding	O
the	O
microdeletion	O
breakpoints	O
revealed	O
either	O
intrinsic	O
repetitivity	O
of	O
the	O
deleted	O
region	O
or	O
short	O
direct	O
repeats	O
adjacent	O
to	O
the	O
breakpoint	O
junctions	O
.	O

This	O
is	O
consistent	O
with	O
these	O
repeats	O
having	O
mediated	O
the	O
microdeletions	O
via	O
replication	O
slippage	O
and	O
supports	O
the	O
view	O
that	O
the	O
mutational	O
spectrum	O
of	O
the	O
GNPTG	B-GeneOrGeneProduct
gene	O
is	O
strongly	O
influenced	O
by	O
the	O
properties	O
of	O
the	O
local	O
DNA	O
sequence	O
environment	O
.	O
Curcumin	B-ChemicalEntity
prevents	O
maleate	B-ChemicalEntity
-	O
induced	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	B-ChemicalEntity
consumption	O
and	O
activity	O
of	O
respiratory	B-ChemicalEntity
complex	I-ChemicalEntity
I	I-ChemicalEntity
.	O

The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	B-ChemicalEntity
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
induced	O
by	O
maleate	B-ChemicalEntity
was	O
evaluated	O
.	O

Tubular	O
proteinuria	B-DiseaseOrPhenotypicFeature
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	B-ChemicalEntity
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rats	B-OrganismTaxon
.	O

Maleate	B-ChemicalEntity
-	O
induced	O
renal	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	B-ChemicalEntity
,	O
sodium	B-ChemicalEntity
,	O
neutrophil	B-GeneOrGeneProduct
gelatinase	I-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
lipocalin	I-GeneOrGeneProduct
(	O
NGAL	B-GeneOrGeneProduct
)	O
and	O
N	B-GeneOrGeneProduct
-	O
acetyl	I-GeneOrGeneProduct
b	I-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
-	O
glucosaminidase	I-GeneOrGeneProduct
(	O
NAG	B-GeneOrGeneProduct
)	O
,	O
upregulation	O
of	O
kidney	B-GeneOrGeneProduct
injury	I-GeneOrGeneProduct
molecule	I-GeneOrGeneProduct
(	O
KIM	I-GeneOrGeneProduct
)	O
-	O
1	I-GeneOrGeneProduct
,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
expression	O
besides	O
of	O
necrosis	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
apoptosis	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
tubular	I-DiseaseOrPhenotypicFeature
cells	I-DiseaseOrPhenotypicFeature
on	O
24	O
h	O
.	O

Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	B-ChemicalEntity
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	B-GeneOrGeneProduct
levels	O
.	O

Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC	B-CellLine
-	O
PK1	I-CellLine
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O

Maleate	B-ChemicalEntity
induced	O
cell	O
damage	O
and	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
(	O
ROS	B-ChemicalEntity
)	O
production	O
in	O
LLC	B-CellLine
-	O
PK1	I-CellLine
cells	O
in	O
culture	O
.	O

In	O
addition	O
,	O
maleate	B-ChemicalEntity
treatment	O
reduced	O
oxygen	B-ChemicalEntity
consumption	O
in	O
ADP	B-ChemicalEntity
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	B-ChemicalEntity
/	O
glutamate	B-ChemicalEntity
as	O
substrate	O
.	O

The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	B-GeneOrGeneProduct
were	O
also	O
diminished	O
.	O

All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	B-ChemicalEntity
.	O

It	O
is	O
concluded	O
that	O
curcumin	B-ChemicalEntity
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	B-ChemicalEntity
-	O
induced	O
nephropathy	B-DiseaseOrPhenotypicFeature
and	O
in	O
vitro	O
cell	O
damage	O
.	O

The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	B-ChemicalEntity
consumption	O
and	O
activity	O
of	O
respiratory	B-ChemicalEntity
complex	I-ChemicalEntity
I	I-ChemicalEntity
,	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	B-ChemicalEntity
production	O
.	O
A	O
novel	O
SCN5A	B-GeneOrGeneProduct
mutation	O
manifests	O
as	O
a	O
malignant	O
form	O
of	O
long	B-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
with	O
perinatal	O
onset	O
of	O
tachycardia	B-DiseaseOrPhenotypicFeature
/	O
bradycardia	B-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
Congenital	O
long	B-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
LQTS	B-DiseaseOrPhenotypicFeature
)	O
with	O
in	O
utero	O
onset	O
of	O
the	O
rhythm	O
disturbances	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

In	O
this	O
study	O
we	O
investigated	O
a	O
newborn	O
patient	B-OrganismTaxon
with	O
fetal	O
bradycardia	B-DiseaseOrPhenotypicFeature
,	O
2	O
:	O
1	O
atrioventricular	B-DiseaseOrPhenotypicFeature
block	I-DiseaseOrPhenotypicFeature
and	O
ventricular	B-DiseaseOrPhenotypicFeature
tachycardia	I-DiseaseOrPhenotypicFeature
soon	O
after	O
birth	O
.	O

METHODS	O
:	O
Mutational	O
analysis	O
and	O
DNA	O
sequencing	O
were	O
conducted	O
in	O
a	O
newborn	O
.	O

The	O
2	O
:	O
1	O
atrioventricular	B-DiseaseOrPhenotypicFeature
block	I-DiseaseOrPhenotypicFeature
improved	O
to	O
1	O
:	O
1	O
conduction	O
only	O
after	O
intravenous	O
lidocaine	B-ChemicalEntity
infusion	O
or	O
a	O
high	O
dose	O
of	O
mexiletine	B-ChemicalEntity
,	O
which	O
also	O
controlled	O
the	O
ventricular	B-DiseaseOrPhenotypicFeature
tachycardia	I-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
A	O
novel	O
,	O
spontaneous	O
LQTS	B-DiseaseOrPhenotypicFeature
-	O
3	O
mutation	O
was	O
identified	O
in	O
the	O
transmembrane	O
segment	O
6	O
of	O
domain	O
IV	O
of	O
the	O
Na	B-GeneOrGeneProduct
(	O
v	I-GeneOrGeneProduct
)	O
1	I-GeneOrGeneProduct
.	O
5	I-GeneOrGeneProduct
cardiac	O
sodium	B-ChemicalEntity
channel	O
,	O
with	O
a	O
G	B-SequenceVariant
-	O
-	O
>	O
A	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
1763	I-SequenceVariant
,	O
which	O
changed	O
a	O
valine	B-SequenceVariant
(	O
GTG	I-SequenceVariant
)	O
to	I-SequenceVariant
a	I-SequenceVariant
methionine	I-SequenceVariant
(	O
ATG	I-SequenceVariant
)	O
.	O

The	O
proband	O
was	O
heterozygous	O
but	O
the	O
mutation	O
was	O
absent	O
in	O
the	O
parents	O
and	O
the	O
sister	O
.	O

Expression	O
of	O
this	O
mutant	O
channel	O
in	O
tsA201	B-CellLine
mammalian	O
cells	O
by	O
site	O
-	O
directed	O
mutagenesis	O
revealed	O
a	O
persistent	O
tetrodotoxin	B-ChemicalEntity
-	O
sensitive	O
but	O
lidocaine	B-ChemicalEntity
-	O
resistant	O
current	O
that	O
was	O
associated	O
with	O
a	O
positive	O
shift	O
of	O
the	O
steady	O
-	O
state	O
inactivation	O
curve	O
,	O
steeper	O
activation	O
curve	O
and	O
faster	O
recovery	O
from	O
inactivation	O
.	O

We	O
also	O
found	O
a	O
similar	O
electrophysiological	O
profile	O
for	O
the	O
neighboring	O
V1764M	B-SequenceVariant
mutant	O
.	O

But	O
,	O
the	O
other	O
neighboring	O
I1762A	B-SequenceVariant
mutant	O
had	O
no	O
persistent	O
current	O
and	O
was	O
still	O
associated	O
with	O
a	O
positive	O
shift	O
of	O
inactivation	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
Na	B-GeneOrGeneProduct
(	O
v	I-GeneOrGeneProduct
)	O
1	I-GeneOrGeneProduct
.	O
5	I-GeneOrGeneProduct
/	O
V1763M	B-SequenceVariant
channel	O
dysfunction	O
and	O
possible	O
neighboring	O
mutants	O
contribute	O
to	O
a	O
persistent	O
inward	O
current	O
due	O
to	O
altered	O
inactivation	O
kinetics	O
and	O
clinically	O
congenital	O
LQTS	B-DiseaseOrPhenotypicFeature
with	O
perinatal	O
onset	O
of	O
arrhythmias	B-DiseaseOrPhenotypicFeature
that	O
responded	O
to	O
lidocaine	B-ChemicalEntity
and	O
mexiletine	B-ChemicalEntity
.	O
Photochemoprevention	O
of	O
ultraviolet	O
B	O
signaling	O
and	O
photocarcinogenesis	O
.	O

Exposure	O
to	O
solar	O
radiation	O
,	O
particularly	O
its	O
ultraviolet	O
(	O
UV	O
)	O
B	O
component	O
,	O
has	O
a	O
variety	O
of	O
harmful	O
effects	O
on	O
human	B-OrganismTaxon
health	O
.	O

Some	O
of	O
these	O
effects	O
include	O
sunburn	O
cell	O
formation	O
,	O
basal	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
squamous	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
,	O
melanoma	B-DiseaseOrPhenotypicFeature
,	O
cataracts	B-DiseaseOrPhenotypicFeature
,	O
photoaging	O
of	O
the	O
skin	O
,	O
and	O
immune	O
suppression	O
.	O

Amongst	O
these	O
various	O
adverse	O
effects	O
of	O
UV	O
radiation	O
,	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
is	O
of	O
the	O
greatest	O
concern	O
.	O

Over	O
the	O
years	O
,	O
changes	O
in	O
lifestyle	O
has	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
amount	O
of	O
UV	O
radiation	O
that	O
people	O
receive	O
,	O
and	O
this	O
consequently	O
has	O
led	O
to	O
a	O
surge	O
in	O
the	O
incidence	O
of	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

The	O
development	O
of	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
is	O
a	O
complex	O
multistage	O
phenomenon	O
involving	O
three	O
distinct	O
stages	O
exemplified	O
by	O
initiation	O
,	O
promotion	O
and	O
progression	O
stages	O
.	O

Each	O
of	O
these	O
stages	O
is	O
mediated	O
via	O
alterations	O
in	O
various	O
cellular	O
,	O
biochemical	O
,	O
and	O
molecular	O
changes	O
.	O

Initiation	O
,	O
the	O
first	O
step	O
in	O
the	O
carcinogenesis	B-DiseaseOrPhenotypicFeature
process	O
is	O
essentially	O
an	O
irreversible	O
step	O
in	O
which	O
genetic	O
alterations	O
occur	O
in	O
genes	O
that	O
ultimately	O
leads	O
to	O
DNA	O
modification	O
and	O
fixation	O
of	O
mutation	O
.	O

Tumor	B-DiseaseOrPhenotypicFeature
promotion	O
is	O
the	O
essential	O
process	O
in	O
cancer	B-DiseaseOrPhenotypicFeature
development	O
involving	O
clonal	O
expansion	O
of	O
initiated	O
cells	O
giving	O
rise	O
to	O
pre	O
-	O
malignant	O
and	O
then	O
to	O
malignant	O
lesions	O
,	O
essentially	O
by	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

Tumor	B-DiseaseOrPhenotypicFeature
progression	O
involves	O
the	O
conversion	O
of	O
pre	O
-	O
malignant	O
and	O
malignant	O
lesions	O
into	O
an	O
invasive	O
and	O
potentially	O
metastatic	O
malignant	O
tumor	B-DiseaseOrPhenotypicFeature
.	O

All	O
these	O
processes	O
for	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
development	O
involve	O
stimulation	O
of	O
DNA	O
synthesis	O
,	O
DNA	O
damage	O
and	O
proliferation	O
,	O
inflammation	B-DiseaseOrPhenotypicFeature
,	O
immunosuppression	O
,	O
epidermal	B-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
,	O
cell	O
cycle	O
dysregulation	O
,	O
depletion	O
of	O
antioxidant	B-ChemicalEntity
defenses	O
,	O
impairment	O
of	O
signal	O
transduction	O
pathways	O
,	O
induction	O
of	O
cyclooxygenase	B-GeneOrGeneProduct
,	O
increase	O
in	O
prostaglandin	B-ChemicalEntity
synthesis	O
,	O
and	O
induction	O
of	O
ornithine	B-GeneOrGeneProduct
decarboxylase	I-GeneOrGeneProduct
.	O

Photochemoprevention	O
has	O
been	O
appreciated	O
as	O
a	O
viable	O
approach	O
to	O
reduce	O
the	O
occurrence	O
of	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
and	O
in	O
recent	O
years	O
,	O
the	O
use	O
of	O
agents	O
,	O
especially	O
botanical	O
antioxidants	B-ChemicalEntity
,	O
present	O
in	O
the	O
common	O
diet	O
and	O
beverages	O
consumed	O
by	O
human	B-OrganismTaxon
population	O
have	O
gained	O
considerable	O
attention	O
as	O
photochemopreventive	O
agents	O
for	O
human	B-OrganismTaxon
use	O
.	O

Many	O
such	O
agents	O
have	O
also	O
found	O
a	O
place	O
in	O
skin	O
care	O
products	O
.	O

Although	O
this	O
is	O
more	O
common	O
in	O
oriental	O
countries	O
,	O
its	O
popularity	O
is	O
significantly	O
growing	O
in	O
western	O
countries	O
.	O

In	O
this	O
article	O
,	O
we	O
have	O
summarized	O
the	O
available	O
information	O
of	O
laboratory	O
studies	O
on	O
UVB	O
-	O
mediated	O
signaling	O
that	O
can	O
be	O
exploited	O
as	O
targets	O
for	O
photochemoprevention	O
.	O

We	O
suggest	O
that	O
the	O
use	O
of	O
skin	O
care	O
products	O
supplemented	O
with	O
proven	O
chemopreventive	O
agents	O
in	O
conjunction	O
with	O
the	O
use	O
of	O
sunscreens	O
along	O
with	O
educational	O
efforts	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
reducing	O
UV	O
-	O
induced	O
photodamage	O
and	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
in	O
humans	B-OrganismTaxon
.	O

The	O
mechanistic	O
basis	O
for	O
the	O
use	O
of	O
such	O
products	O
is	O
discussed	O
.	O
Association	O
of	O
obesity	B-DiseaseOrPhenotypicFeature
risk	O
SNPs	O
in	O
PCSK1	B-GeneOrGeneProduct
with	O
insulin	B-GeneOrGeneProduct
sensitivity	O
and	O
proinsulin	B-ChemicalEntity
conversion	O
.	O

BACKGROUND	O
:	O
Prohormone	B-GeneOrGeneProduct
convertase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
is	O
involved	O
in	O
maturation	O
of	O
peptides	O
.	O

Rare	O
mutations	O
in	O
gene	O
PCSK1	B-GeneOrGeneProduct
,	O
encoding	O
this	O
enzyme	O
,	O
cause	O
childhood	O
obesity	B-DiseaseOrPhenotypicFeature
and	O
abnormal	B-DiseaseOrPhenotypicFeature
glucose	I-DiseaseOrPhenotypicFeature
homeostasis	I-DiseaseOrPhenotypicFeature
with	O
elevated	O
proinsulin	B-ChemicalEntity
concentrations	O
.	O

Common	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
this	O
gene	O
,	O
rs6232	B-SequenceVariant
and	O
rs6235	B-SequenceVariant
,	O
are	O
associated	O
with	O
obesity	B-DiseaseOrPhenotypicFeature
.	O

We	O
studied	O
whether	O
these	O
SNPs	O
influence	O
the	O
prediabetic	O
traits	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
,	O
beta	B-DiseaseOrPhenotypicFeature
-	O
cell	I-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
,	O
or	O
glucose	B-DiseaseOrPhenotypicFeature
intolerance	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
We	O
genotyped	O
1498	O
German	O
subjects	O
for	O
SNPs	O
rs6232	B-SequenceVariant
and	O
rs6235	B-SequenceVariant
within	O
PCSK1	B-GeneOrGeneProduct
.	O

The	O
subjects	O
were	O
metabolically	O
characterized	O
by	O
oral	O
glucose	B-ChemicalEntity
tolerance	O
test	O
with	O
glucose	B-ChemicalEntity
,	O
insulin	B-GeneOrGeneProduct
,	O
proinsulin	B-ChemicalEntity
,	O
and	O
C	B-ChemicalEntity
-	O
peptide	I-ChemicalEntity
measurements	O
.	O

A	O
subgroup	O
of	O
512	O
subjects	O
underwent	O
a	O
hyperinsulinemic	B-DiseaseOrPhenotypicFeature
-	O
euglycemic	I-DiseaseOrPhenotypicFeature
clamp	O
.	O

RESULTS	O
:	O
The	O
minor	O
allele	O
frequencies	O
were	O
25	O
.	O
8%	O
for	O
SNP	O
rs6235	B-SequenceVariant
and	O
6	O
.	O
0%	O
for	O
rs6232	B-SequenceVariant
.	O

After	O
adjustment	O
for	O
sex	O
and	O
age	O
,	O
we	O
found	O
no	O
association	O
of	O
SNPs	O
rs6235	B-SequenceVariant
and	O
rs6232	B-SequenceVariant
with	O
BMI	O
or	O
other	O
weight	O
-	O
related	O
traits	O
(	O
all	O
p	O
>	O
or	O
=	O
0	O
.	O
07	O
)	O
.	O

Both	O
minor	O
alleles	O
,	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
BMI	O
and	O
insulin	B-GeneOrGeneProduct
sensitivity	O
were	O
associated	O
with	O
elevated	O
AUCproinsulin	O
and	O
AUCproinsulin	O
/	O
AUCinsulin	O
(	O
rs6235	B-SequenceVariant
:	O
p	O
(	O
additive	O
)	O
model	O
<	O
or	O
=	O
0	O
.	O
009	O
,	O
effect	O
sizes	O
8	O
/	O
8%	O
,	O
rs6232	B-SequenceVariant
:	O
pdominant	O
model	O
<	O
or	O
=	O
0	O
.	O
01	O
,	O
effect	O
sizes	O
10	O
/	O
21%	O
)	O
.	O

Insulin	B-GeneOrGeneProduct
secretion	O
was	O
not	O
affected	O
by	O
the	O
variants	O
(	O
different	O
secretion	O
parameters	O
,	O
all	O
p	O
>	O
or	O
=	O
0	O
.	O
08	O
)	O
.	O

The	O
minor	O
allele	O
of	O
SNP	O
rs6232	B-SequenceVariant
was	O
additionally	O
associated	O
with	O
15%	O
higher	O
OGTT	O
-	O
derived	O
and	O
19%	O
higher	O
clamp	O
-	O
derived	O
insulin	B-GeneOrGeneProduct
sensitivity	O
(	O
pdom	O
<	O
or	O
=	O
0	O
.	O
0047	O
)	O
,	O
4	O
.	O
5%	O
lower	O
HOMAIR	O
(	O
pdom	O
=	O
0	O
.	O
02	O
)	O
and	O
3	O
.	O
5%	O
lower	O
120	O
-	O
min	O
glucose	B-ChemicalEntity
(	O
pdom	O
=	O
0	O
.	O
0003	O
)	O
independently	O
of	O
BMI	O
and	O
proinsulin	B-ChemicalEntity
conversion	O
.	O

SNP	O
rs6235	B-SequenceVariant
was	O
not	O
associated	O
with	O
parameters	O
of	O
glucose	O
metabolism	O
.	O

CONCLUSIONS	O
:	O
Like	O
rare	O
mutations	O
in	O
PCSK1	B-GeneOrGeneProduct
,	O
the	O
more	O
common	O
variants	O
tested	O
determine	O
glucose	B-ChemicalEntity
-	O
stimulated	O
proinsulin	B-ChemicalEntity
conversion	O
,	O
but	O
not	O
insulin	B-GeneOrGeneProduct
secretion	O
.	O

In	O
addition	O
,	O
rs6232	B-SequenceVariant
,	O
encoding	O
the	O
amino	O
acid	O
exchange	O
N221D	B-SequenceVariant
,	O
influences	O
insulin	B-GeneOrGeneProduct
sensitivity	O
and	O
glucose	B-ChemicalEntity
homeostasis	O
.	O
Metalloprotease	B-GeneOrGeneProduct
-	O
disintegrin	I-GeneOrGeneProduct
ADAM12	B-GeneOrGeneProduct
actively	O
promotes	O
the	O
stem	O
cell	O
-	O
like	O
phenotype	O
in	O
claudin	B-GeneOrGeneProduct
-	O
low	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
ADAM12	B-GeneOrGeneProduct
is	O
upregulated	O
in	O
human	B-OrganismTaxon
breast	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
and	O
is	O
a	O
predictor	O
of	O
chemoresistance	O
in	O
estrogen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
negative	O
tumors	B-DiseaseOrPhenotypicFeature
.	O

ADAM12	B-GeneOrGeneProduct
is	O
induced	O
during	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
,	O
a	O
feature	O
associated	O
with	O
claudin	B-GeneOrGeneProduct
-	O
low	O
breast	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
,	O
which	O
are	O
enriched	O
in	O
cancer	B-DiseaseOrPhenotypicFeature
stem	O
cell	O
(	O
CSC	O
)	O
markers	O
.	O

It	O
is	O
currently	O
unknown	O
whether	O
ADAM12	B-GeneOrGeneProduct
plays	O
an	O
active	O
role	O
in	O
promoting	O
the	O
CSC	O
phenotype	O
in	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O

METHODS	O
:	O
ADAM12	B-GeneOrGeneProduct
expression	O
was	O
downregulated	O
in	O
representative	O
claudin	B-GeneOrGeneProduct
-	O
low	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
lines	O
,	O
SUM159PT	B-CellLine
and	O
Hs578T	B-CellLine
,	O
using	O
siRNA	O
transfection	O
or	O
inducible	O
shRNA	O
expression	O
.	O

Cell	O
characteristics	O
commonly	O
associated	O
with	O
the	O
CSC	O
phenotype	O
in	O
vitro	O
(	O
cell	O
migration	O
,	O
invasion	O
,	O
anoikis	O
resistance	O
,	O
mammosphere	O
formation	O
,	O
ALDH	B-GeneOrGeneProduct
activity	O
,	O
and	O
expression	O
of	O
the	O
CD44	B-GeneOrGeneProduct
and	O
CD24	B-GeneOrGeneProduct
cell	O
surface	O
markers	O
)	O
and	O
in	O
vivo	O
(	O
tumor	B-DiseaseOrPhenotypicFeature
formation	O
in	O
mice	B-OrganismTaxon
using	O
limiting	O
dilution	O
transplantation	O
assays	O
)	O
were	O
evaluated	O
.	O

RNA	O
sequencing	O
was	O
performed	O
to	O
identify	O
global	O
gene	O
expression	O
changes	O
after	O
ADAM12	B-GeneOrGeneProduct
knockdown	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
sorted	O
SUM159PT	B-CellLine
cell	O
populations	O
with	O
high	O
ADAM12	B-GeneOrGeneProduct
levels	O
had	O
elevated	O
expression	O
of	O
CSC	O
markers	O
and	O
an	O
increased	O
ability	O
to	O
form	O
mammospheres	O
.	O

ADAM12	B-GeneOrGeneProduct
knockdown	O
reduced	O
cell	O
migration	O
and	O
invasion	O
,	O
decreased	O
anoikis	O
resistance	O
,	O
and	O
compromised	O
mammosphere	O
formation	O
.	O

ADAM12	B-GeneOrGeneProduct
knockdown	O
also	O
diminished	O
ALDEFLUOR	O
(	O
+	O
)	O
and	O
CD44	B-GeneOrGeneProduct
(	O
hi	O
)	O
/	O
CD24	B-GeneOrGeneProduct
(	O
-	O
/	O
lo	O
)	O
CSC	O
-	O
enriched	O
populations	O
in	O
vitro	O
and	O
reduced	O
tumorigenesis	B-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
in	O
vivo	O
.	O

RNA	O
sequencing	O
identified	O
a	O
significant	O
overlap	O
between	O
ADAM12	B-GeneOrGeneProduct
-	O
and	O
Epidermal	B-GeneOrGeneProduct
Growth	I-GeneOrGeneProduct
Factor	I-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
(	O
EGFR	B-GeneOrGeneProduct
)	O
-	O
regulated	O
genes	O
.	O

Consequently	O
,	O
ADAM12	B-GeneOrGeneProduct
knockdown	O
lowered	O
the	O
basal	O
activation	O
level	O
of	O
EGFR	B-GeneOrGeneProduct
,	O
and	O
this	O
effect	O
was	O
abolished	O
by	O
batimastat	B-ChemicalEntity
,	O
a	O
metalloproteinase	B-GeneOrGeneProduct
inhibitor	O
.	O

Furthermore	O
,	O
incubation	O
of	O
cells	O
with	O
exogenously	O
added	O
EGF	B-GeneOrGeneProduct
prevented	O
the	O
downregulation	O
of	O
CD44	B-GeneOrGeneProduct
(	O
hi	O
)	O
/	O
CD24	B-GeneOrGeneProduct
(	O
-	O
/	O
lo	O
)	O
cell	O
population	O
by	O
ADAM12	B-GeneOrGeneProduct
knockdown	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
ADAM12	B-GeneOrGeneProduct
actively	O
supports	O
the	O
CSC	O
phenotype	O
in	O
claudin	B-GeneOrGeneProduct
-	O
low	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
via	O
modulation	O
of	O
the	O
EGFR	B-GeneOrGeneProduct
pathway	O
.	O
An	O
evaluation	O
of	O
amikacin	B-ChemicalEntity
nephrotoxicity	B-DiseaseOrPhenotypicFeature
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O

Amikacin	B-ChemicalEntity
is	O
an	O
aminoglycoside	B-ChemicalEntity
commonly	O
used	O
to	O
provide	O
empirical	O
double	O
gram	O
-	O
negative	O
treatment	O
for	O
febrile	B-DiseaseOrPhenotypicFeature
neutropenia	I-DiseaseOrPhenotypicFeature
and	O
other	O
suspected	O
infections	B-DiseaseOrPhenotypicFeature
.	O

Strategies	O
of	O
extended	O
-	O
interval	O
and	O
conventional	O
dosing	O
have	O
been	O
utilized	O
extensively	O
in	O
the	O
general	O
medical	O
population	O
;	O
however	O
,	O
data	O
are	O
lacking	O
to	O
support	O
a	O
dosing	O
strategy	O
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O

To	O
evaluate	O
amikacin	B-ChemicalEntity
-	O
associated	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
in	O
an	O
adult	O
hematology	O
/	O
oncology	O
population	O
,	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
trial	O
was	O
conducted	O
at	O
a	O
university	O
-	O
affiliated	O
medical	O
center	O
.	O

Forty	O
patients	B-OrganismTaxon
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic	B-DiseaseOrPhenotypicFeature
/	O
oncologic	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	B-ChemicalEntity
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended	O
-	O
interval	O
amikacin	B-ChemicalEntity
.	O

The	O
occurrence	O
of	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
by	O
means	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	B-ChemicalEntity
and	O
evaluation	O
of	O
efficacy	O
via	O
amikacin	B-ChemicalEntity
serum	O
concentrations	O
with	O
respective	O
pathogens	O
were	O
assessed	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
was	O
similar	O
between	O
the	O
conventional	O
and	O
extended	O
-	O
interval	O
groups	O
,	O
at	O
10%	O
and	O
5%	O
,	O
respectively	O
(	O
P	O
=	O
1	O
.	O
00	O
)	O
.	O

Six	O
patients	B-OrganismTaxon
in	O
the	O
conventional	O
group	O
had	O
a	O
positive	O
culture	O
,	O
compared	O
with	O
none	O
in	O
the	O
extended	O
-	O
interval	O
group	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
was	O
similar	O
between	O
the	O
two	O
dosing	O
regimens	O
,	O
but	O
the	O
distribution	O
of	O
risk	O
factors	O
was	O
variable	O
between	O
the	O
two	O
groups	O
.	O

Efficacy	O
could	O
not	O
be	O
assessed	O
.	O
Homozygous	O
deletion	O
and	O
reduced	O
expression	O
of	O
the	O
DOCK8	B-GeneOrGeneProduct
gene	O
in	O
human	B-OrganismTaxon
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

A	O
homozygous	O
deletion	O
of	O
the	O
DOCK8	B-GeneOrGeneProduct
(	O
dedicator	B-GeneOrGeneProduct
of	I-GeneOrGeneProduct
cytokinesis	I-GeneOrGeneProduct
8	I-GeneOrGeneProduct
)	O
locus	O
at	O
chromosome	O
9p24	O
was	O
found	O
in	O
a	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
line	O
by	O
array	O
-	O
CGH	O
analysis	O
.	O

Cloning	O
of	O
the	O
full	O
-	O
length	O
DOCK8	B-GeneOrGeneProduct
cDNA	O
led	O
us	O
to	O
define	O
that	O
the	O
DOCK8	B-GeneOrGeneProduct
gene	O
encodes	O
a	O
protein	O
consisting	O
of	O
2	O
,	O
099	O
amino	O
acids	O
.	O

DOCK8	B-GeneOrGeneProduct
was	O
expressed	O
in	O
a	O
variety	O
of	O
human	B-OrganismTaxon
organs	O
,	O
including	O
the	O
lungs	O
,	O
and	O
was	O
also	O
expressed	O
in	O
type	O
II	O
alveolar	O
,	O
bronchiolar	O
epithelial	O
and	O
bronchial	O
epithelial	O
cells	O
,	O
which	O
are	O
considered	O
as	O
being	O
progenitors	O
for	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O

DOCK8	B-GeneOrGeneProduct
expression	O
was	O
reduced	O
in	O
62	O
/	O
71	O
(	O
87%	O
)	O
primary	O
lung	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
compared	O
with	O
normal	O
lung	O
tissue	O
,	O
and	O
the	O
reduction	O
occurred	O
irrespective	O
of	O
the	O
histological	O
type	O
of	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

5	B-ChemicalEntity
-	O
Aza	I-ChemicalEntity
-	O
2	I-ChemicalEntity
'	O
-	O
deoxy	I-ChemicalEntity
-	O
cytidine	I-ChemicalEntity
and	O
/	O
or	O
Trichostatin	B-ChemicalEntity
A	I-ChemicalEntity
treatments	O
induced	O
DOCK8	B-GeneOrGeneProduct
expression	O
in	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
lines	O
with	O
reduced	O
DOCK8	B-GeneOrGeneProduct
expression	O
.	O

Therefore	O
,	O
epigenetic	O
mechanisms	O
,	O
including	O
DNA	O
methylation	O
and	O
histone	O
deacetylation	O
,	O
were	O
indicated	O
to	O
be	O
involved	O
in	O
DOCK8	B-GeneOrGeneProduct
down	O
-	O
regulation	O
in	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O

Further	O
screening	O
revealed	O
homozygous	O
deletions	O
of	O
the	O
DOCK8	B-GeneOrGeneProduct
gene	O
in	O
a	O
gastric	O
and	O
a	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
line	O
.	O

DOCK	B-GeneOrGeneProduct
family	O
proteins	O
have	O
been	O
shown	O
to	O
play	O
roles	O
in	O
regulation	O
of	O
migration	O
,	O
morphology	O
,	O
adhesion	O
and	O
growth	O
of	O
cells	O
.	O

Thus	O
,	O
the	O
present	O
results	O
suggest	O
that	O
genetic	O
and	O
epigenetic	O
inactivation	O
of	O
DOCK8	B-GeneOrGeneProduct
is	O
involved	O
in	O
the	O
development	O
and	O
/	O
or	O
progression	O
of	O
lung	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
other	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
by	O
disturbing	O
such	O
regulations	O
.	O
Ectodermal	B-DiseaseOrPhenotypicFeature
dysplasia	I-DiseaseOrPhenotypicFeature
-	O
skin	I-DiseaseOrPhenotypicFeature
fragility	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
resulting	O
from	O
a	O
new	O
homozygous	O
mutation	O
,	O
888delC	B-SequenceVariant
,	O
in	O
the	O
desmosomal	O
protein	O
plakophilin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
an	O
inherited	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
of	O
the	O
desmosomal	O
protein	O
plakophilin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
,	O
resulting	O
in	O
ectodermal	B-DiseaseOrPhenotypicFeature
dysplasia	I-DiseaseOrPhenotypicFeature
-	O
skin	I-DiseaseOrPhenotypicFeature
fragility	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

The	O
affected	O
6	O
-	O
year	O
-	O
old	O
boy	O
had	O
red	O
skin	O
at	O
birth	O
and	O
subsequently	O
developed	O
skin	B-DiseaseOrPhenotypicFeature
fragility	I-DiseaseOrPhenotypicFeature
,	O
progressive	O
plantar	B-DiseaseOrPhenotypicFeature
keratoderma	I-DiseaseOrPhenotypicFeature
,	O
nail	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
,	O
and	O
alopecia	B-DiseaseOrPhenotypicFeature
.	O

Skin	O
biopsy	O
revealed	O
widening	O
of	O
intercellular	O
spaces	O
in	O
the	O
epidermis	O
and	O
a	O
reduced	O
number	O
of	O
small	O
,	O
poorly	O
formed	O
desmosomes	O
.	O

Mutation	O
analysis	O
of	O
the	O
plakophilin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
gene	O
PKP1	B-GeneOrGeneProduct
revealed	O
a	O
homozygous	O
deletion	B-SequenceVariant
of	I-SequenceVariant
C	I-SequenceVariant
at	I-SequenceVariant
nucleotide	I-SequenceVariant
888	I-SequenceVariant
within	O
exon	O
5	O
.	O

This	O
mutation	O
differs	O
from	O
the	O
PKP1	B-GeneOrGeneProduct
gene	O
pathology	O
reported	O
in	O
8	O
previously	O
published	O
individuals	O
with	O
this	O
rare	O
genodermatosis	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
all	O
cases	O
show	O
similar	O
clinical	O
features	O
,	O
highlighting	O
the	O
importance	O
of	O
functional	O
plakophilin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
in	O
maintaining	O
desmosomal	O
adhesion	O
in	O
skin	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
this	O
protein	O
in	O
aspects	O
of	O
ectodermal	O
development	O
.	O
Disruption	O
of	O
the	O
temporally	O
regulated	O
cloaca	O
endodermal	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
signaling	O
causes	O
anorectal	B-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
.	O

The	O
cloaca	O
is	O
temporally	O
formed	O
and	O
eventually	O
divided	O
by	O
the	O
urorectal	O
septum	O
(	O
URS	O
)	O
during	O
urogenital	O
and	O
anorectal	O
organ	O
development	O
.	O

Although	O
congenital	B-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
,	O
such	O
as	O
anorectal	B-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
(	O
ARMs	B-DiseaseOrPhenotypicFeature
)	O
,	O
are	O
frequently	O
observed	O
during	O
this	O
process	O
,	O
the	O
underlying	O
pathogenic	O
mechanisms	O
remain	O
unclear	O
.	O

b	B-GeneOrGeneProduct
-	O
Catenin	I-GeneOrGeneProduct
is	O
a	O
critical	O
component	O
of	O
canonical	O
Wnt	B-GeneOrGeneProduct
signaling	O
and	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
differentiation	O
and	O
morphogenesis	O
during	O
embryogenesis	O
.	O

The	O
expression	O
of	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
is	O
observed	O
in	O
endodermal	O
epithelia	O
,	O
including	O
URS	O
epithelia	O
.	O

We	O
modulated	O
the	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
gene	O
conditionally	O
in	O
endodermal	O
epithelia	O
by	O
utilizing	O
tamoxifen	B-ChemicalEntity
-	O
inducible	O
Cre	O
driver	O
line	O
(	O
Shh	B-GeneOrGeneProduct
(	O
CreERT2	O
)	O
)	O
.	O

Both	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
loss	O
-	O
and	O
gain	O
-	O
of	O
-	O
function	O
(	O
LOF	O
and	O
GOF	O
)	O
mutants	O
displayed	O
abnormal	O
clefts	O
in	O
the	O
perineal	O
region	O
and	O
hypoplastic	B-DiseaseOrPhenotypicFeature
elongation	O
of	O
the	O
URS	O
.	O

The	O
mutants	O
also	O
displayed	O
reduced	O
cell	O
proliferation	O
in	O
the	O
URS	O
mesenchyme	O
.	O

In	O
addition	O
,	O
the	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
GOF	O
mutants	O
displayed	O
reduced	O
apoptosis	O
and	O
subsequently	O
increased	O
apoptosis	O
in	O
the	O
URS	O
epithelium	O
.	O

This	O
instability	O
possibly	O
resulted	O
in	O
reduced	O
expression	O
levels	O
of	O
differentiation	O
markers	O
,	O
such	O
as	O
keratin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
and	O
filaggrin	B-GeneOrGeneProduct
,	O
in	O
the	O
perineal	O
epithelia	O
.	O

The	O
expression	O
of	O
bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
Bmp	B-GeneOrGeneProduct
)	O
genes	O
,	O
such	O
as	O
Bmp4	B-GeneOrGeneProduct
and	O
Bmp7	B-GeneOrGeneProduct
,	O
was	O
also	O
ectopically	O
induced	O
in	O
the	O
epithelia	O
of	O
the	O
URS	O
in	O
the	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
GOF	O
mutants	O
.	O

The	O
expression	O
of	O
the	O
Msx2	B-GeneOrGeneProduct
gene	O
and	O
phosphorylated	O
-	O
Smad1	B-GeneOrGeneProduct
/	O
5	I-GeneOrGeneProduct
/	O
8	I-GeneOrGeneProduct
,	O
possible	O
readouts	O
of	O
Bmp	B-GeneOrGeneProduct
signaling	O
,	O
was	O
also	O
increased	O
in	O
the	O
mutants	O
.	O

Moreover	O
,	O
we	O
introduced	O
an	O
additional	O
mutation	O
for	O
a	O
Bmp	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
:	O
BmprIA	B-GeneOrGeneProduct
.	O

The	O
Shh	B-GeneOrGeneProduct
(	O
CreERT2	O
/	O
+	O
)	O
;	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
(	O
flox	O
(	O
ex3	O
)	O
/	O
+	O
)	O
;	O
BmprIA	B-GeneOrGeneProduct
(	O
flox	O
/	O
-	O
)	O
mutants	O
displayed	O
partial	O
restoration	O
of	O
URS	O
elongation	O
compared	O
with	O
the	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
GOF	O
mutants	O
.	O

These	O
results	O
indicate	O
that	O
some	O
ARM	B-DiseaseOrPhenotypicFeature
phenotypes	O
in	O
the	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
GOF	O
mutants	O
were	O
caused	O
by	O
abnormal	O
Bmp	B-GeneOrGeneProduct
signaling	O
.	O

The	O
current	O
analysis	O
revealed	O
the	O
close	O
relation	O
of	O
endodermal	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
signaling	O
to	O
the	O
ARM	B-DiseaseOrPhenotypicFeature
phenotypes	O
.	O

These	O
results	O
are	O
considered	O
to	O
shed	O
light	O
on	O
the	O
pathogenic	O
mechanisms	O
of	O
human	B-OrganismTaxon
ARMs	B-DiseaseOrPhenotypicFeature
.	O
An	O
inducible	O
mouse	B-OrganismTaxon
model	O
of	O
podocin	B-GeneOrGeneProduct
-	O
mutation	O
-	O
related	O
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Mutations	O
in	O
the	O
NPHS2	B-GeneOrGeneProduct
gene	O
,	O
encoding	O
podocin	B-GeneOrGeneProduct
,	O
cause	O
hereditary	O
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

The	O
most	O
common	O
podocin	B-GeneOrGeneProduct
mutation	O
,	O
R138Q	B-SequenceVariant
,	O
is	O
associated	O
with	O
early	O
disease	O
onset	O
and	O
rapid	O
progression	O
to	O
end	O
-	O
stage	O
renal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

Knock	O
-	O
in	O
mice	B-OrganismTaxon
carrying	O
a	O
R140Q	B-SequenceVariant
mutation	O
,	O
the	O
mouse	B-OrganismTaxon
analogue	O
of	O
human	B-OrganismTaxon
R138Q	B-SequenceVariant
,	O
show	O
developmental	O
arrest	O
of	O
podocytes	O
and	O
lethal	O
renal	B-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
at	O
neonatal	O
age	O
.	O

Here	O
we	O
created	O
a	O
conditional	O
podocin	B-GeneOrGeneProduct
knock	O
-	O
in	O
model	O
named	O
NPHS2	B-GeneOrGeneProduct
R140Q	B-SequenceVariant
/	O
-	O
,	O
using	O
a	O
tamoxifen	B-ChemicalEntity
-	O
inducible	O
Cre	O
recombinase	O
,	O
which	O
permits	O
to	O
study	O
the	O
effects	O
of	O
the	O
mutation	O
in	O
postnatal	O
life	O
.	O

Within	O
the	O
first	O
week	O
of	O
R140Q	B-SequenceVariant
hemizygosity	O
induction	O
the	O
animals	O
developed	O
proteinuria	B-DiseaseOrPhenotypicFeature
,	O
which	O
peaked	O
after	O
4	O
-	O
5	O
weeks	O
.	O

Subsequently	O
the	O
animals	O
developed	O
progressive	O
renal	B-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
12	O
(	O
95%	O
CI	O
:	O
11	O
-	O
13	O
)	O
weeks	O
.	O

Foot	O
process	O
fusion	O
was	O
observed	O
within	O
one	O
week	O
,	O
progressing	O
to	O
severe	O
and	O
global	O
effacement	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

The	O
number	O
of	O
podocytes	O
per	O
glomerulus	O
gradually	O
diminished	O
to	O
18%	O
compared	O
to	O
healthy	O
controls	O
12	O
-	O
16	O
weeks	O
after	O
induction	O
.	O

The	O
fraction	O
of	O
segmentally	O
sclerosed	O
glomeruli	O
was	O
25%	O
,	O
85%	O
and	O
97%	O
at	O
2	O
,	O
4	O
and	O
8	O
weeks	O
,	O
respectively	O
.	O

Severe	O
tubulointerstitial	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
was	O
present	O
at	O
later	O
disease	O
stage	O
and	O
was	O
correlated	O
quantitatively	O
with	O
the	O
level	O
of	O
proteinuria	B-DiseaseOrPhenotypicFeature
at	O
early	O
disease	O
stages	O
.	O

While	O
R140Q	B-SequenceVariant
podocin	B-GeneOrGeneProduct
mRNA	O
expression	O
was	O
elevated	O
,	O
protein	O
abundance	O
was	O
reduced	O
by	O
more	O
than	O
50%	O
within	O
one	O
week	O
following	O
induction	O
.	O

Whereas	O
miRNA21	B-GeneOrGeneProduct
expression	O
persistently	O
increased	O
during	O
the	O
first	O
4	O
weeks	O
,	O
miRNA	B-GeneOrGeneProduct
-	O
193a	I-GeneOrGeneProduct
expression	O
peaked	O
2	O
weeks	O
after	O
induction	O
.	O

In	O
conclusion	O
,	O
the	O
inducible	O
R140Q	B-SequenceVariant
-	O
podocin	B-GeneOrGeneProduct
mouse	B-OrganismTaxon
model	O
is	O
an	O
auspicious	O
model	O
of	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
human	B-OrganismTaxon
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
with	O
a	O
spontaneous	O
disease	O
course	O
strongly	O
reminiscent	O
of	O
the	O
human	B-OrganismTaxon
disorder	O
.	O

This	O
model	O
constitutes	O
a	O
valuable	O
tool	O
to	O
test	O
the	O
efficacy	O
of	O
novel	O
pharmacological	O
interventions	O
aimed	O
to	O
improve	O
podocyte	O
function	O
and	O
viability	O
and	O
attenuate	O
proteinuria	B-DiseaseOrPhenotypicFeature
,	O
glomerulosclerosis	B-DiseaseOrPhenotypicFeature
and	O
progressive	O
renal	B-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
.	O
Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	B-ChemicalEntity
in	O
suspected	O
Staphylococcus	B-OrganismTaxon
aureus	I-OrganismTaxon
meningitis	B-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	B-ChemicalEntity
-	O
sensitive	O
Staphylococcus	B-OrganismTaxon
aureus	I-OrganismTaxon
(	O
MSSA	O
)	O
bacteremia	B-DiseaseOrPhenotypicFeature
with	O
suspected	O
MSSA	O
meningitis	B-DiseaseOrPhenotypicFeature
treated	O
with	O
high	O
-	O
dose	O
daptomycin	B-ChemicalEntity
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B-DiseaseOrPhenotypicFeature
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	B-DiseaseOrPhenotypicFeature
shown	O
on	O
chest	O
radiograph	O
.	O

Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	B-ChemicalEntity
,	O
levofloxacin	B-ChemicalEntity
,	O
and	O
piperacillin	B-ChemicalEntity
/	O
tazobactam	I-ChemicalEntity
.	O

Blood	O
cultures	O
revealed	O
S	B-OrganismTaxon
.	O

aureus	I-OrganismTaxon
susceptible	O
to	O
oxacillin	B-ChemicalEntity
.	O

Empiric	O
antibiotic	B-ChemicalEntity
treatment	O
was	O
narrowed	O
to	O
nafcillin	B-ChemicalEntity
on	O
day	O
4	O
.	O

On	O
day	O
8	O
,	O
the	O
patient	B-OrganismTaxon
developed	O
acute	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
(	O
serum	O
creatinine	B-ChemicalEntity
1	O
.	O
9	O
mg	O
/	O
dL	O
,	O
increased	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
admission	O
)	O
.	O

The	O
patient	B-OrganismTaxon
'	O
s	O
Glasgow	O
Coma	B-DiseaseOrPhenotypicFeature
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B-DiseaseOrPhenotypicFeature
arrest	I-DiseaseOrPhenotypicFeature
on	O
day	O
10	O
.	O

The	O
patient	B-OrganismTaxon
experienced	O
relapsing	O
MSSA	O
bacteremia	B-DiseaseOrPhenotypicFeature
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	B-DiseaseOrPhenotypicFeature
nervous	I-DiseaseOrPhenotypicFeature
system	I-DiseaseOrPhenotypicFeature
(	O
CNS	I-DiseaseOrPhenotypicFeature
)	O
infection	I-DiseaseOrPhenotypicFeature
.	O

Nafcillin	B-ChemicalEntity
was	O
discontinued	O
and	O
daptomycin	B-ChemicalEntity
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B-DiseaseOrPhenotypicFeature
and	O
was	O
continued	O
until	O
the	O
patient	B-OrganismTaxon
'	O
s	O
death	B-DiseaseOrPhenotypicFeature
on	O
day	O
16	O
.	O

Daptomycin	B-ChemicalEntity
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dose	O
.	O

Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA	O
.	O

Creatine	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	B-ChemicalEntity
therapy	O
and	O
were	O
not	O
reassessed	O
.	O

DISCUSSION	O
:	O
Daptomycin	B-ChemicalEntity
was	O
initiated	O
in	O
our	O
patient	B-OrganismTaxon
secondary	O
to	O
possible	O
nafcillin	B-ChemicalEntity
-	O
induced	O
acute	O
interstitial	B-DiseaseOrPhenotypicFeature
nephritis	I-DiseaseOrPhenotypicFeature
and	O
relapsing	O
bacteremia	B-DiseaseOrPhenotypicFeature
.	O

At	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
,	O
resultant	O
penetration	O
of	O
5%	O
was	O
higher	O
than	O
in	O
previous	O
reports	O
,	O
more	O
consistent	O
with	O
inflamed	O
meninges	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
dose	O
daptomycin	B-ChemicalEntity
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B-DiseaseOrPhenotypicFeature
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	B-OrganismTaxon
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
standard	O
therapy	O
.	O

Further	O
clinical	O
evaluation	O
in	O
patients	B-OrganismTaxon
with	O
confirmed	O
meningitis	B-DiseaseOrPhenotypicFeature
is	O
warranted	O
.	O
Reversible	O
inferior	B-DiseaseOrPhenotypicFeature
colliculus	I-DiseaseOrPhenotypicFeature
lesion	I-DiseaseOrPhenotypicFeature
in	O
metronidazole	B-ChemicalEntity
-	O
induced	O
encephalopathy	B-DiseaseOrPhenotypicFeature
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-DiseaseOrPhenotypicFeature
colliculus	I-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
in	O
metronidazole	B-ChemicalEntity
-	O
induced	O
encephalopathy	B-DiseaseOrPhenotypicFeature
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	B-OrganismTaxon
(	O
5	O
men	B-OrganismTaxon
and	O
3	O
women	B-OrganismTaxon
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	B-ChemicalEntity
-	O
induced	O
encephalopathy	B-DiseaseOrPhenotypicFeature
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O

They	O
had	O
been	O
taking	O
metronidazole	B-ChemicalEntity
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-DiseaseOrPhenotypicFeature
in	O
various	O
organs	O
.	O

Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)	O
,	O
FLAIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
image	O
(	O
8	O
/	O
8	O
)	O
.	O

Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	B-OrganismTaxon
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-ChemicalEntity
administration	O
.	O

Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	O
changes	O
on	O
follow	O
-	O
up	O
images	O
.	O

RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8	O
/	O
8	O
)	O
,	O
inferior	O
colliculus	O
(	O
6	O
/	O
8	O
)	O
,	O
corpus	O
callosum	O
(	O
2	O
/	O
8	O
)	O
,	O
pons	O
(	O
2	O
/	O
8	O
)	O
,	O
medulla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O

High	O
-	O
signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
patient	B-OrganismTaxon
,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O

All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	B-OrganismTaxon
,	O
but	O
in	O
1	O
patient	B-OrganismTaxon
of	O
them	O
,	O
corpus	O
callosal	B-DiseaseOrPhenotypicFeature
lesion	I-DiseaseOrPhenotypicFeature
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversible	O
inferior	B-DiseaseOrPhenotypicFeature
colliculus	I-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	B-ChemicalEntity
-	O
induced	O
encephalopathy	B-DiseaseOrPhenotypicFeature
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O
Mutations	O
in	O
phospholipase	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
epsilon	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
are	O
not	O
sufficient	O
to	O
cause	O
diffuse	B-DiseaseOrPhenotypicFeature
mesangial	I-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
.	O

Diffuse	B-DiseaseOrPhenotypicFeature
mesangial	I-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
occurs	O
as	O
an	O
isolated	O
abnormality	O
or	O
as	O
a	O
part	O
of	O
a	O
syndrome	O
.	O

Recently	O
,	O
mutations	O
in	O
phospholipase	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
epsilon	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
PLCE1	B-GeneOrGeneProduct
)	O
were	O
found	O
to	O
cause	O
a	O
nonsyndromic	O
,	O
autosomal	O
recessive	O
form	O
of	O
this	O
disease	O
.	O

Here	O
we	O
describe	O
three	O
children	O
from	O
one	O
consanguineous	O
kindred	O
of	O
Pakistani	O
origin	O
with	O
diffuse	B-DiseaseOrPhenotypicFeature
mesangial	I-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
who	O
presented	O
with	O
congenital	B-DiseaseOrPhenotypicFeature
or	I-DiseaseOrPhenotypicFeature
infantile	I-DiseaseOrPhenotypicFeature
nephrotic	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Homozygous	O
mutations	O
in	O
PLCE1	B-GeneOrGeneProduct
(	O
also	O
known	O
as	O
KIAA1516	B-GeneOrGeneProduct
,	O
PLCE	B-GeneOrGeneProduct
,	O
or	O
NPHS3	B-GeneOrGeneProduct
)	O
were	O
identified	O
following	O
genome	O
-	O
wide	O
mapping	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
.	O

All	O
affected	O
children	O
were	O
homozygous	O
for	O
a	O
four	B-SequenceVariant
-	O
basepair	I-SequenceVariant
deletion	I-SequenceVariant
in	O
exon	O
3	O
,	O
which	O
created	O
a	O
premature	O
translational	O
stop	O
codon	O
.	O

Analysis	O
of	O
the	O
asymptomatic	O
father	O
of	O
two	O
of	O
the	O
children	O
revealed	O
that	O
he	O
was	O
also	O
homozygous	O
for	O
the	O
same	O
mutation	O
.	O

We	O
conclude	O
this	O
nonpenetrance	O
may	O
be	O
due	O
to	O
compensatory	O
mutations	O
at	O
a	O
second	O
locus	O
and	O
that	O
mutation	O
within	O
PLCE1	B-GeneOrGeneProduct
is	O
not	O
always	O
sufficient	O
to	O
cause	O
diffuse	B-DiseaseOrPhenotypicFeature
mesangial	I-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
.	O
TIPE2	B-GeneOrGeneProduct
Inhibits	O
Lung	B-DiseaseOrPhenotypicFeature
Cancer	I-DiseaseOrPhenotypicFeature
Growth	O
Attributing	O
to	O
Promotion	O
of	O
Apoptosis	O
by	O
Regulating	O
Some	O
Apoptotic	O
Molecules	O
Expression	O
.	O

Recent	O
studies	O
found	O
that	O
TIPE2	B-GeneOrGeneProduct
was	O
involved	O
in	O
cancer	B-DiseaseOrPhenotypicFeature
development	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
TIPE2	B-GeneOrGeneProduct
in	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

Our	O
study	O
aims	O
to	O
clarify	O
the	O
role	O
of	O
TIPE2	B-GeneOrGeneProduct
in	O
lung	B-DiseaseOrPhenotypicFeature
carcinogenesis	I-DiseaseOrPhenotypicFeature
.	O

We	O
examined	O
the	O
expression	O
of	O
TIPE2	B-GeneOrGeneProduct
in	O
lung	B-DiseaseOrPhenotypicFeature
squamous	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
LSC	B-DiseaseOrPhenotypicFeature
)	O
,	O
small	B-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
and	O
lung	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
(	O
AdC	B-DiseaseOrPhenotypicFeature
)	O
tissues	O
and	O
found	O
that	O
TIPE2	B-GeneOrGeneProduct
expression	O
was	O
lost	O
in	O
small	B-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
compared	O
with	O
adjacent	O
non	O
-	O
tumor	B-DiseaseOrPhenotypicFeature
tissues	O
.	O

Overexpression	O
of	O
TIPE2	B-GeneOrGeneProduct
significantly	O
inhibited	O
the	O
growth	O
of	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
H446	B-CellLine
in	O
vitro	O
and	O
even	O
suppressed	O
tumor	B-DiseaseOrPhenotypicFeature
formation	O
in	O
vivo	O
.	O

Flow	O
cytometry	O
analysis	O
found	O
TIPE2	B-GeneOrGeneProduct
overexpression	O
promoted	O
apoptosis	O
of	O
H446	B-CellLine
.	O

In	O
TIPE2	B-GeneOrGeneProduct
over	O
-	O
expression	O
cells	O
,	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
,	O
caspase	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
and	O
Bax	B-GeneOrGeneProduct
were	O
significantly	O
up	O
-	O
regulated	O
while	O
Bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
was	O
down	O
-	O
regulated	O
.	O

Moreover	O
,	O
coincident	O
results	O
were	O
shown	O
by	O
immunohistochemistry	O
in	O
tumors	B-DiseaseOrPhenotypicFeature
from	O
nude	O
mice	B-OrganismTaxon
.	O

TIPE2	B-GeneOrGeneProduct
inhibited	O
the	O
phosphorylation	O
of	O
Akt	B-GeneOrGeneProduct
,	O
while	O
promoting	O
the	O
phosphorylation	O
of	O
P38	B-GeneOrGeneProduct
,	O
but	O
had	O
no	O
effect	O
on	O
IkBa	B-GeneOrGeneProduct
and	O
ERK	B-GeneOrGeneProduct
pathway	O
.	O

Taken	O
together	O
,	O
TIPE2	B-GeneOrGeneProduct
promoted	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
apoptosis	O
through	O
affecting	O
apoptosis	O
-	O
related	O
molecules	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
,	O
caspase	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
Bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
and	O
Bax	B-GeneOrGeneProduct
,	O
possibly	O
via	O
regulating	O
P38	B-GeneOrGeneProduct
and	O
Akt	B-GeneOrGeneProduct
pathways	O
,	O
indicating	O
that	O
TIPE2	B-GeneOrGeneProduct
might	O
be	O
a	O
novel	O
marker	O
for	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
diagnosis	O
and	O
therapy	O
.	O
An	O
improved	O
tetra	O
-	O
primer	O
PCR	O
approach	O
for	O
the	O
detection	O
of	O
the	O
FGFR3	B-GeneOrGeneProduct
G380R	B-SequenceVariant
mutation	O
responsible	O
for	O
achondroplasia	B-DiseaseOrPhenotypicFeature
.	O

Achondroplasia	B-DiseaseOrPhenotypicFeature
is	O
the	O
most	O
common	O
form	O
of	O
dwarfism	B-DiseaseOrPhenotypicFeature
and	O
has	O
an	O
incidence	O
of	O
approximately	O
1	O
/	O
7500	O
.	O

In	O
more	O
than	O
98%	O
of	O
cases	O
,	O
the	O
disease	O
is	O
associated	O
with	O
a	O
G	B-SequenceVariant
to	I-SequenceVariant
A	I-SequenceVariant
or	I-SequenceVariant
G	I-SequenceVariant
to	I-SequenceVariant
C	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
nucleotide	I-SequenceVariant
position	I-SequenceVariant
1138	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
G380R	I-SequenceVariant
)	O
of	O
the	O
fibroblast	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
(	O
FGFR3	B-GeneOrGeneProduct
)	O
gene	O
.	O

We	O
have	O
developed	O
a	O
sensitive	O
single	O
tube	O
tetra	O
-	O
primer	O
PCR	O
assay	O
to	O
detect	O
both	O
the	O
c	B-SequenceVariant
.	O
1138G	I-SequenceVariant
>	O
A	I-SequenceVariant
and	O
c	B-SequenceVariant
.	O
1138G	I-SequenceVariant
>	O
C	I-SequenceVariant
mutations	O
and	O
can	O
successfully	O
distinguish	O
DNA	O
samples	O
that	O
are	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
c	B-SequenceVariant
.	O
1138G	I-SequenceVariant
>	O
A	I-SequenceVariant
mutation	O
.	O

Titration	O
studies	O
showed	O
that	O
the	O
assay	O
could	O
reliably	O
detect	O
one	O
copy	O
of	O
the	O
mutant	O
allele	O
in	O
a	O
mix	O
of	O
100	O
wild	O
-	O
type	O
alleles	O
.	O

The	O
assay	O
has	O
been	O
tested	O
in	O
50	O
healthy	O
controls	O
,	O
3	O
known	O
patients	B-OrganismTaxon
with	O
achondroplasia	B-DiseaseOrPhenotypicFeature
,	O
and	O
5	O
amniotic	O
fluids	O
suspected	O
of	O
having	O
achondroplasia	B-DiseaseOrPhenotypicFeature
and	O
for	O
whom	O
we	O
had	O
previously	O
determined	O
the	O
genotypes	O
for	O
the	O
c	B-SequenceVariant
.	O
1138G	I-SequenceVariant
>	O
A	I-SequenceVariant
mutation	O
by	O
PCR	O
-	O
RFLP	O
.	O

We	O
have	O
observed	O
complete	O
concordance	O
between	O
methods	O
.	O

Our	O
tetra	O
-	O
primer	O
PCR	O
assay	O
is	O
sensitive	O
,	O
low	O
-	O
cost	O
,	O
and	O
easy	O
to	O
use	O
method	O
for	O
FGFR3	B-GeneOrGeneProduct
p	B-SequenceVariant
.	O
G380R	I-SequenceVariant
genotyping	O
,	O
which	O
could	O
be	O
used	O
even	O
in	O
""""	O
low	O
-	O
tech	O
""""	O
laboratories	O
.	O
Gartanin	B-ChemicalEntity
induces	O
cell	O
cycle	O
arrest	O
and	O
autophagy	O
and	O
suppresses	O
migration	O
involving	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
/	O
mTOR	B-GeneOrGeneProduct
and	O
MAPK	B-GeneOrGeneProduct
signalling	O
pathway	O
in	O
human	B-OrganismTaxon
glioma	B-DiseaseOrPhenotypicFeature
cells	O
.	O

In	O
central	O
nervous	O
system	O
,	O
glioma	B-DiseaseOrPhenotypicFeature
is	O
the	O
most	O
common	O
primary	B-DiseaseOrPhenotypicFeature
brain	I-DiseaseOrPhenotypicFeature
tumour	I-DiseaseOrPhenotypicFeature
.	O

The	O
diffuse	O
migration	O
and	O
rapid	O
proliferation	O
are	O
main	O
obstacles	O
for	O
successful	O
treatment	O
.	O

Gartanin	B-ChemicalEntity
,	O
a	O
natural	O
xanthone	B-ChemicalEntity
of	O
mangosteen	B-OrganismTaxon
,	O
suppressed	O
proliferation	O
,	O
migration	O
and	O
colony	O
formation	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
in	O
T98G	B-CellLine
glioma	B-DiseaseOrPhenotypicFeature
cells	O
but	O
not	O
in	O
mouse	B-OrganismTaxon
normal	O
neuronal	O
HT22	B-CellLine
cells	O
.	O

Gartanin	B-ChemicalEntity
,	O
at	O
low	O
micromole	O
,	O
led	O
to	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
accompanied	O
by	O
inhibited	O
expression	O
level	O
of	O
G1	O
cell	O
cycle	O
regulatory	O
proteins	O
cyclin	B-GeneOrGeneProduct
D1	I-GeneOrGeneProduct
,	O
while	O
increased	O
expression	O
level	O
of	O
cyclin	B-GeneOrGeneProduct
-	O
dependent	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
inhibitor	O
p27Kip1	B-GeneOrGeneProduct
.	O

In	O
addition	O
,	O
the	O
secretion	O
and	O
activity	O
of	O
matrix	B-GeneOrGeneProduct
metalloproteinases	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
/	O
9	I-GeneOrGeneProduct
(	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
-	O
9	I-GeneOrGeneProduct
)	O
were	O
significantly	O
suppressed	O
in	O
T98G	B-CellLine
cells	O
treated	O
with	O
gartanin	B-ChemicalEntity
,	O
and	O
it	O
might	O
result	O
from	O
modulating	O
mitogen	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
(	O
MAPK	B-GeneOrGeneProduct
)	O
signalling	O
pathway	O
in	O
T98G	B-CellLine
glioma	B-DiseaseOrPhenotypicFeature
cells	O
.	O

Moreover	O
,	O
gartanin	B-ChemicalEntity
significantly	O
induced	O
autophagy	O
in	O
T98G	B-CellLine
cells	O
and	O
increased	O
GFP	O
-	O
LC3	B-GeneOrGeneProduct
punctate	O
fluorescence	O
accompanied	O
by	O
the	O
increased	O
expression	O
level	O
of	O
Beclin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
and	O
LC3	B-GeneOrGeneProduct
-	O
II	O
,	O
while	O
suppressed	O
expression	O
level	O
of	O
p62	B-GeneOrGeneProduct
.	O

Gartanin	B-ChemicalEntity
treatment	O
resulted	O
in	O
obvious	O
inhibition	O
of	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
/	O
mTOR	B-GeneOrGeneProduct
signalling	O
pathway	O
,	O
which	O
is	O
important	O
in	O
modulating	O
autophagy	O
.	O

Notably	O
,	O
gartanin	B-ChemicalEntity
-	O
mediated	O
anti	O
-	O
viability	O
was	O
significantly	O
abrogated	O
by	O
autophagy	O
inhibitors	O
including	O
3	B-ChemicalEntity
-	O
methyladenine	I-ChemicalEntity
(	O
3	B-ChemicalEntity
-	O
MA	I-ChemicalEntity
)	O
and	O
chloroquine	B-ChemicalEntity
(	O
CQ	B-ChemicalEntity
)	O
.	O

These	O
results	O
indicate	O
that	O
anti	O
-	O
proliferation	O
effect	O
of	O
gartanin	B-ChemicalEntity
in	O
T98G	B-CellLine
cells	O
is	O
most	O
likely	O
via	O
cell	O
cycle	O
arrest	O
modulated	O
by	O
autophagy	O
,	O
which	O
is	O
regulated	O
by	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
/	O
mTOR	B-GeneOrGeneProduct
signalling	O
pathway	O
,	O
while	O
anti	O
-	O
migration	O
effect	O
is	O
most	O
likely	O
via	O
suppression	O
of	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
-	O
9	I-GeneOrGeneProduct
activity	O
which	O
is	O
involved	O
in	O
MAPK	B-GeneOrGeneProduct
signalling	O
pathway	O
.	O
Angiotensin	B-GeneOrGeneProduct
converting	I-GeneOrGeneProduct
enzyme	I-GeneOrGeneProduct
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Asthma	B-DiseaseOrPhenotypicFeature
is	O
a	O
chronic	O
inflammatory	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
of	O
the	O
airways	O
.	O

Several	O
candidate	O
genes	O
have	O
been	O
identified	O
with	O
a	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	B-DiseaseOrPhenotypicFeature
,	O
including	O
the	O
angiotensin	B-GeneOrGeneProduct
converting	I-GeneOrGeneProduct
enzyme	I-GeneOrGeneProduct
(	O
ACE	B-GeneOrGeneProduct
)	O
gene	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
frequency	O
of	O
an	O
ACE	B-GeneOrGeneProduct
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
to	O
determine	O
its	O
impact	O
on	O
clinical	O
parameters	O
and	O
disease	O
severity	O
.	O

Ninety	O
-	O
seven	O
asthmatic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
M	O
/	O
F	O
25	O
/	O
72	O
,	O
mean	O
age	O
39	O
+	O
/	O
-	O
13	O
years	O
)	O
and	O
96	O
healthy	O
subjects	O
(	O
M	O
/	O
F	O
26	O
/	O
70	O
,	O
mean	O
age	O
38	O
+	O
/	O
-	O
12	O
years	O
)	O
were	O
included	O
.	O

At	O
baseline	O
,	O
all	O
participants	O
completed	O
a	O
questionnaire	O
on	O
demographics	O
,	O
symptoms	O
,	O
triggering	O
factors	O
,	O
severity	O
of	O
asthma	B-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
presence	O
of	O
atopism	B-DiseaseOrPhenotypicFeature
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
all	O
patients	B-OrganismTaxon
and	O
genomic	O
DNA	O
was	O
isolated	O
.	O

The	O
frequency	O
of	O
the	O
ACE	B-GeneOrGeneProduct
genotypes	O
(	O
I	O
=	O
insertion	O
and	O
D	O
=	O
deletion	O
)	O
among	O
asthmatics	B-DiseaseOrPhenotypicFeature
and	O
controls	O
were	O
compared	O
:	O
asthmatics	B-DiseaseOrPhenotypicFeature
showed	O
a	O
40	O
.	O
2%	O
prevalence	O
of	O
the	O
DD	O
genotype	O
(	O
n	O
=	O
39	O
)	O
,	O
ID	O
was	O
45	O
.	O
4%	O
(	O
n	O
=	O
44	O
)	O
,	O
and	O
II	O
was	O
14	O
.	O
4%	O
(	O
n	O
=	O
14	O
.	O
4	O
)	O
.	O

In	O
the	O
control	O
subjects	O
,	O
the	O
frequency	O
of	O
DD	O
was	O
18	O
.	O
8%	O
(	O
n	O
=	O
18	O
)	O
,	O
ID	O
was	O
50%	O
(	O
n	O
=	O
48	O
)	O
and	O
II	O
was	O
31	O
.	O
3%	O
(	O
n	O
=	O
30	O
)	O
.	O

The	O
DD	O
ACE	B-GeneOrGeneProduct
genotype	O
was	O
significantly	O
more	O
frequent	O
in	O
asthmatics	B-DiseaseOrPhenotypicFeature
compared	O
with	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Asthmatics	B-DiseaseOrPhenotypicFeature
with	O
the	O
ID	O
ACE	B-GeneOrGeneProduct
genotype	O
showed	O
a	O
higher	O
frequency	O
of	O
drug	B-DiseaseOrPhenotypicFeature
allergies	I-DiseaseOrPhenotypicFeature
,	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

Asthmatics	B-DiseaseOrPhenotypicFeature
with	O
the	O
DD	O
genotype	O
appeared	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
asthmatic	B-DiseaseOrPhenotypicFeature
episode	O
exacerbations	O
due	O
to	O
viral	B-DiseaseOrPhenotypicFeature
infections	I-DiseaseOrPhenotypicFeature
,	O
but	O
again	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

Patients	B-OrganismTaxon
with	O
mild	O
or	O
moderate	O
-	O
severe	O
asthma	B-DiseaseOrPhenotypicFeature
had	O
similar	O
frequencies	O
of	O
these	O
mutations	O
.	O

We	O
found	O
a	O
higher	O
frequency	O
of	O
the	O
ACE	B-GeneOrGeneProduct
DD	O
gene	O
mutation	O
in	O
Turkish	O
asthmatic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
compared	O
with	O
non	O
-	O
asthmatics	B-DiseaseOrPhenotypicFeature
,	O
suggesting	O
that	O
this	O
ACE	B-GeneOrGeneProduct
gene	O
polymorphism	O
may	O
be	O
a	O
risk	O
factor	O
for	O
asthma	B-DiseaseOrPhenotypicFeature
but	O
does	O
not	O
increase	O
the	O
severity	O
of	O
the	O
disease	O
.	O
Valproate	B-ChemicalEntity
-	O
induced	O
chorea	B-DiseaseOrPhenotypicFeature
and	O
encephalopathy	B-DiseaseOrPhenotypicFeature
in	O
atypical	O
nonketotic	B-DiseaseOrPhenotypicFeature
hyperglycinemia	I-DiseaseOrPhenotypicFeature
.	O

Nonketotic	B-DiseaseOrPhenotypicFeature
hyperglycinemia	I-DiseaseOrPhenotypicFeature
is	O
a	O
disorder	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
amino	I-DiseaseOrPhenotypicFeature
acid	I-DiseaseOrPhenotypicFeature
metabolism	I-DiseaseOrPhenotypicFeature
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	B-ChemicalEntity
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	B-ChemicalEntity
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O

In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	B-DiseaseOrPhenotypicFeature
,	O
intractable	O
seizures	B-DiseaseOrPhenotypicFeature
,	O
and	O
hypotonia	B-DiseaseOrPhenotypicFeature
,	O
followed	O
by	O
significant	O
psychomotor	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
.	O

An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	B-DiseaseOrPhenotypicFeature
hyperglycinemia	I-DiseaseOrPhenotypicFeature
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O

This	O
report	O
describes	O
a	O
patient	B-OrganismTaxon
with	O
mild	O
language	B-DiseaseOrPhenotypicFeature
delay	I-DiseaseOrPhenotypicFeature
and	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
,	O
who	O
was	O
found	O
to	O
have	O
nonketotic	B-DiseaseOrPhenotypicFeature
hyperglycinemia	I-DiseaseOrPhenotypicFeature
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	B-DiseaseOrPhenotypicFeature
and	O
chorea	B-DiseaseOrPhenotypicFeature
shortly	O
after	O
initiation	O
of	O
valproate	B-ChemicalEntity
therapy	O
.	O
Two	O
distinct	O
mutations	O
at	O
a	O
single	O
BamHI	O
site	O
in	O
phenylketonuria	B-DiseaseOrPhenotypicFeature
.	O

Classical	B-DiseaseOrPhenotypicFeature
phenylketonuria	I-DiseaseOrPhenotypicFeature
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
caused	O
by	O
a	O
deficiency	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
hepatic	I-DiseaseOrPhenotypicFeature
phenylalanine	I-DiseaseOrPhenotypicFeature
hydroxylase	I-DiseaseOrPhenotypicFeature
(	O
PAH	B-GeneOrGeneProduct
)	O
.	O

The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	O
located	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
PAH	B-GeneOrGeneProduct
gene	O
(	O
exon	O
7	O
)	O
led	O
to	O
the	O
recognition	O
of	O
two	O
new	O
point	O
mutations	O
at	O
codon	O
272	O
and	O
273	O
(	O
272gly	B-SequenceVariant
-	O
-	O
-	O
-	O
stop	I-SequenceVariant
and	O
273ser	B-SequenceVariant
-	O
-	O
-	O
-	O
phe	I-SequenceVariant
,	O
respectively	O
)	O
.	O

Both	O
mutations	O
were	O
detected	O
in	O
north	O
eastern	O
France	O
or	O
Belgium	O
and	O
occurred	O
on	O
the	O
background	O
of	O
RFLP	O
haplotype	O
7	O
alleles	O
.	O

The	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
PKU	B-DiseaseOrPhenotypicFeature
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
PAH	B-DiseaseOrPhenotypicFeature
deficiencies	I-DiseaseOrPhenotypicFeature
.	O
Fatal	O
carbamazepine	B-ChemicalEntity
induced	O
fulminant	O
eosinophilic	O
(	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
)	O
myocarditis	B-DiseaseOrPhenotypicFeature
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B-DiseaseOrPhenotypicFeature
hypersensitivity	I-DiseaseOrPhenotypicFeature
and	O
differential	O
diagnosis	O
.	O

The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	B-ChemicalEntity
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O

A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-ChemicalEntity
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
)	O
myocarditis	B-DiseaseOrPhenotypicFeature
.	O

We	O
report	O
a	O
case	O
of	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
myocarditis	B-DiseaseOrPhenotypicFeature
secondary	O
to	O
administration	O
of	O
carbamazepine	B-ChemicalEntity
.	O

Acute	O
hypersensitivity	B-DiseaseOrPhenotypicFeature
myocarditis	B-DiseaseOrPhenotypicFeature
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O

Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage	O
.	O

Clinically	O
,	O
death	B-DiseaseOrPhenotypicFeature
was	O
due	O
to	O
cardiogenic	B-DiseaseOrPhenotypicFeature
shock	I-DiseaseOrPhenotypicFeature
.	O

To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	B-ChemicalEntity
induced	O
myocarditis	B-DiseaseOrPhenotypicFeature
reported	O
in	O
English	O
literature	O
.	O
Bach1	B-GeneOrGeneProduct
siRNA	O
attenuates	O
bleomycin	B-ChemicalEntity
-	O
induced	O
pulmonary	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
by	O
modulating	O
oxidative	O
stress	O
in	O
mice	B-OrganismTaxon
.	O

Oxidative	O
stress	O
plays	O
an	O
essential	O
role	O
in	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
fibrosis	B-DiseaseOrPhenotypicFeature
.	O

Bach1	B-GeneOrGeneProduct
is	O
an	O
important	O
transcriptional	O
repressor	O
that	O
acts	O
by	O
modulating	O
oxidative	O
stress	O
and	O
represents	O
a	O
potential	O
target	O
in	O
the	O
treatment	O
of	O
pulmonary	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
(	O
PF	B-DiseaseOrPhenotypicFeature
)	O
.	O

In	O
this	O
study	O
,	O
we	O
knocked	O
down	O
Bach1	B-GeneOrGeneProduct
using	O
adenovirus	O
-	O
mediated	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
to	O
determine	O
whether	O
the	O
use	O
of	O
Bach1	B-GeneOrGeneProduct
siRNA	O
is	O
an	O
effective	O
therapeutic	O
strategy	O
in	O
mice	B-OrganismTaxon
with	O
bleomycin	B-ChemicalEntity
(	O
BLM	B-ChemicalEntity
)	O
-	O
induced	O
PF	B-DiseaseOrPhenotypicFeature
.	O

Mouse	B-OrganismTaxon
lung	O
fibroblasts	O
(	O
MLFs	O
)	O
were	O
incubated	O
with	O
transforming	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
TGF	I-GeneOrGeneProduct
)	O
-	O
b1	I-GeneOrGeneProduct
(	O
5	O
ng	O
/	O
ml	O
)	O
and	O
subsequently	O
infected	O
with	O
recombined	O
adenovirus	O
-	O
like	O
Bach1	B-GeneOrGeneProduct
siRNA1	O
and	O
Bach1	B-GeneOrGeneProduct
siRNA2	O
,	O
while	O
an	O
empty	O
adenovirus	O
vector	O
was	O
used	O
as	O
the	O
negative	O
control	O
.	O

The	O
selected	O
Bach1	B-GeneOrGeneProduct
siRNA	O
with	O
higher	O
interference	O
efficiency	O
was	O
used	O
for	O
the	O
animal	O
experiments	O
.	O

A	O
mouse	B-OrganismTaxon
model	O
of	O
BLM	B-ChemicalEntity
-	O
induced	O
PF	B-DiseaseOrPhenotypicFeature
was	O
established	O
,	O
and	O
Bach1	B-GeneOrGeneProduct
siRNA	O
(	O
1x109	O
pfu	O
)	O
was	O
administered	O
to	O
the	O
mice	B-OrganismTaxon
via	O
the	O
tail	O
vein	O
.	O

The	O
results	O
revealed	O
that	O
the	O
Bach1	B-GeneOrGeneProduct
mRNA	O
and	O
protein	O
levels	O
were	O
significantly	O
downregulated	O
by	O
Bach1	B-GeneOrGeneProduct
siRNA	O
.	O

Furthermore	O
,	O
the	O
MLFs	O
infected	O
with	O
Bach1	B-GeneOrGeneProduct
siRNA	O
exhibited	O
increased	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
heme	B-GeneOrGeneProduct
oxygenase	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	O
glutathione	B-GeneOrGeneProduct
peroxidase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
,	O
but	O
decreased	O
levels	O
of	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
and	O
interleukin	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
in	O
the	O
cell	O
supernatants	O
compared	O
with	O
the	O
cells	O
exposed	O
to	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
alone	O
.	O

Bach1	B-GeneOrGeneProduct
knockdown	O
by	O
siRNA	O
also	O
enhanced	O
the	O
expression	O
of	O
antioxidant	B-GeneOrGeneProduct
factors	I-GeneOrGeneProduct
,	O
but	O
suppressed	O
that	O
of	O
fibrosis	B-DiseaseOrPhenotypicFeature
-	O
related	O
cytokines	O
in	O
mice	B-OrganismTaxon
compared	O
with	O
the	O
BLM	B-ChemicalEntity
group	O
.	O

Finally	O
,	O
the	O
inflammatory	B-DiseaseOrPhenotypicFeature
infiltration	O
of	O
alveolar	O
and	O
interstitial	O
cells	O
and	O
the	O
destruction	O
of	O
lung	O
structure	O
were	O
significantly	O
attenuated	O
in	O
the	O
mide	O
administered	O
Bach1	B-GeneOrGeneProduct
siRNA	O
compared	O
with	O
those	O
in	O
the	O
BLM	B-ChemicalEntity
group	O
.	O

On	O
the	O
whole	O
,	O
our	O
findings	O
demonstrate	O
that	O
Bach1	B-GeneOrGeneProduct
siRNA	O
exerts	O
protective	O
effects	O
against	O
BLM	B-ChemicalEntity
-	O
induced	O
PF	B-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
.	O

Our	O
data	O
may	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
novel	O
targeted	O
therapeutic	O
strategies	O
for	O
PF	B-DiseaseOrPhenotypicFeature
.	O
Acute	O
low	B-DiseaseOrPhenotypicFeature
back	I-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
during	O
intravenous	O
administration	O
of	O
amiodarone	B-ChemicalEntity
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	B-ChemicalEntity
represents	O
an	O
effective	O
antiarrhythmic	B-ChemicalEntity
drug	I-ChemicalEntity
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
(	O
AF	B-DiseaseOrPhenotypicFeature
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	B-OrganismTaxon
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B-DiseaseOrPhenotypicFeature
back	I-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B-ChemicalEntity
loading	O
.	O

Notably	O
,	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O
Long	O
-	O
term	O
exposure	O
of	O
MCF	B-CellLine
-	O
7	I-CellLine
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
to	O
ethanol	B-ChemicalEntity
stimulates	O
oncogenic	O
features	O
.	O

Alcohol	B-ChemicalEntity
consumption	O
is	O
a	O
risk	O
factor	O
for	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

Little	O
is	O
known	O
regarding	O
the	O
mechanism	O
,	O
although	O
it	O
is	O
assumed	O
that	O
acetaldehyde	B-ChemicalEntity
or	O
estrogen	B-ChemicalEntity
mediated	O
pathways	O
play	O
a	O
role	O
.	O

We	O
previously	O
showed	O
that	O
long	O
-	O
term	O
exposure	O
to	O
2	O
.	O
5	O
mM	O
ethanol	B-ChemicalEntity
(	O
blood	O
alcohol	B-ChemicalEntity
~	O
0	O
.	O
012%	O
)	O
of	O
MCF	B-CellLine
-	O
12A	I-CellLine
,	O
a	O
human	B-OrganismTaxon
normal	O
epithelial	O
breast	O
cell	O
line	O
,	O
induced	O
epithelial	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
and	O
oncogenic	O
transformation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
in	O
the	O
human	B-OrganismTaxon
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
line	O
MCF	B-CellLine
-	O
7	I-CellLine
,	O
whether	O
a	O
similar	O
exposure	O
to	O
ethanol	B-ChemicalEntity
at	O
concentrations	O
ranging	O
up	O
to	O
peak	O
blood	O
levels	O
in	O
heavy	O
drinkers	O
would	O
increase	O
malignant	O
progression	O
.	O

Short	O
-	O
term	O
(	O
1	O
-	O
week	O
)	O
incubation	O
to	O
ethanol	B-ChemicalEntity
at	O
as	O
low	O
as	O
1	O
-	O
5	O
mM	O
(	O
corresponding	O
to	O
blood	O
alcohol	B-ChemicalEntity
concentration	O
of	O
~	O
0	O
.	O
0048	O
-	O
0	O
.	O
024%	O
)	O
upregulated	O
the	O
stem	O
cell	O
related	O
proteins	O
Oct4	B-GeneOrGeneProduct
and	O
Nanog	B-GeneOrGeneProduct
,	O
but	O
they	O
were	O
reduced	O
after	O
exposure	O
at	O
25	O
mM	O
.	O

Long	O
-	O
term	O
(	O
4	O
-	O
week	O
)	O
exposure	O
to	O
25	O
mM	O
ethanol	B-ChemicalEntity
upregulated	O
the	O
Oct4	B-GeneOrGeneProduct
and	O
Nanog	B-GeneOrGeneProduct
proteins	O
,	O
as	O
well	O
as	O
the	O
malignancy	B-DiseaseOrPhenotypicFeature
marker	O
Ceacam6	B-GeneOrGeneProduct
.	O

DNA	O
microarray	O
analysis	O
in	O
cells	O
exposed	O
for	O
1	O
week	O
showed	O
upregulated	O
expression	O
of	O
metallothionein	B-GeneOrGeneProduct
genes	O
,	O
particularly	O
MT1X	B-GeneOrGeneProduct
.	O

Long	O
-	O
term	O
exposure	O
upregulated	O
expression	O
of	O
some	O
malignancy	B-DiseaseOrPhenotypicFeature
related	O
genes	O
(	O
STEAP4	B-GeneOrGeneProduct
,	O
SERPINA3	B-GeneOrGeneProduct
,	O
SAMD9	B-GeneOrGeneProduct
,	O
GDF15	B-GeneOrGeneProduct
,	O
KRT15	B-GeneOrGeneProduct
,	O
ITGB6	B-GeneOrGeneProduct
,	O
TP63	B-GeneOrGeneProduct
,	O
and	O
PGR	B-GeneOrGeneProduct
,	O
as	O
well	O
as	O
the	O
CEACAM	B-GeneOrGeneProduct
,	O
interferon	B-GeneOrGeneProduct
related	O
,	O
and	O
HLA	B-GeneOrGeneProduct
gene	O
families	O
)	O
.	O

Some	O
of	O
these	O
findings	O
were	O
validated	O
by	O
RT	O
-	O
PCR	O
.	O

A	O
similar	O
treatment	O
also	O
modulated	O
numerous	O
microRNAs	O
(	O
miRs	O
)	O
including	O
one	O
regulator	O
of	O
Oct4	B-GeneOrGeneProduct
as	O
well	O
as	O
miRs	O
involved	O
in	O
oncogenesis	O
and	O
/	O
or	O
malignancy	B-DiseaseOrPhenotypicFeature
,	O
with	O
only	O
a	O
few	O
estrogen	B-ChemicalEntity
-	O
induced	O
miRs	O
.	O

Long	O
-	O
term	O
25	O
mM	O
ethanol	B-ChemicalEntity
also	O
induced	O
a	O
5	O
.	O
6	O
-	O
fold	O
upregulation	O
of	O
anchorage	O
-	O
independent	O
growth	O
,	O
an	O
indicator	O
of	O
malignant	O
-	O
like	O
features	O
.	O

Exposure	O
to	O
acetaldehyde	B-ChemicalEntity
resulted	O
in	O
little	O
or	O
no	O
effect	O
comparable	O
to	O
that	O
of	O
ethanol	B-ChemicalEntity
.	O

The	O
previously	O
shown	O
alcohol	B-ChemicalEntity
induction	O
of	O
oncogenic	O
transformation	O
of	O
normal	O
breast	O
cells	O
is	O
now	O
complemented	O
by	O
the	O
current	O
results	O
suggesting	O
alcohol	B-ChemicalEntity
'	O
s	O
potential	O
involvement	O
in	O
malignant	O
progression	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O
Pheochromocytoma	B-DiseaseOrPhenotypicFeature
unmasked	O
by	O
amisulpride	B-ChemicalEntity
and	O
tiapride	B-ChemicalEntity
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	B-DiseaseOrPhenotypicFeature
in	O
a	O
patient	B-OrganismTaxon
treated	O
with	O
amisulpride	B-ChemicalEntity
and	O
tiapride	B-ChemicalEntity
.	O

CASE	O
SUMMARY	O
:	O
A	O
42	O
-	O
year	O
-	O
old	O
white	O
man	B-OrganismTaxon
developed	O
acute	O
hypertension	B-DiseaseOrPhenotypicFeature
with	O
severe	O
headache	B-DiseaseOrPhenotypicFeature
and	O
vomiting	B-DiseaseOrPhenotypicFeature
2	O
hours	O
after	O
the	O
first	O
doses	O
of	O
amisulpride	B-ChemicalEntity
100	O
mg	O
and	O
tiapride	B-ChemicalEntity
100	O
mg	O
.	O

Both	O
drugs	O
were	O
immediately	O
discontinued	O
,	O
and	O
the	O
patient	B-OrganismTaxon
recovered	O
after	O
subsequent	O
nicardipine	B-ChemicalEntity
and	O
verapamil	B-ChemicalEntity
treatment	O
.	O

Abdominal	O
ultrasound	O
showed	O
an	O
adrenal	O
mass	O
,	O
and	O
postoperative	O
histologic	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
pheochromocytoma	B-DiseaseOrPhenotypicFeature
.	O

DISCUSSION	O
:	O
Drug	O
-	O
induced	O
symptoms	O
of	O
pheochromocytoma	B-DiseaseOrPhenotypicFeature
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	B-ChemicalEntity
drugs	I-ChemicalEntity
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

In	O
our	O
case	O
,	O
use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
possible	O
relationship	O
between	O
the	O
hypertensive	B-DiseaseOrPhenotypicFeature
crisis	O
and	O
amisulpride	B-ChemicalEntity
and	O
tiapride	B-ChemicalEntity
therapy	O
.	O

CONCLUSIONS	O
:	O
As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
amisulpride	B-ChemicalEntity
-	O
and	O
tiapride	B-ChemicalEntity
-	O
induced	O
hypertensive	B-DiseaseOrPhenotypicFeature
crisis	O
in	O
a	O
patient	B-OrganismTaxon
with	O
pheochromocytoma	B-DiseaseOrPhenotypicFeature
.	O

Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	O
adverse	O
effect	O
of	O
tiapride	B-ChemicalEntity
and	O
amisulpride	B-ChemicalEntity
.	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
interact	O
to	O
promote	O
generation	O
of	O
CD11c	B-GeneOrGeneProduct
+	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
-	O
producing	O
macrophages	O
.	O

Unraveling	O
the	O
mechanisms	O
of	O
hematopoiesis	O
regulated	O
by	O
multiple	O
cytokines	O
remains	O
a	O
challenge	O
in	O
hematology	O
.	O

IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
is	O
an	O
allergic	O
cytokine	O
with	O
the	O
multilineage	O
potential	O
,	O
while	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
is	O
produced	O
in	O
the	O
steady	O
state	O
with	O
restricted	O
lineage	O
coverage	O
.	O

Here	O
,	O
we	O
uncovered	O
an	O
instructive	O
role	O
of	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
-	O
mediated	O
hematopoiesis	O
.	O

CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
significantly	O
promoted	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
-	O
driven	O
CD11c	B-GeneOrGeneProduct
+	O
cell	O
expansion	O
and	O
dampened	O
basophil	O
and	O
mast	O
cell	O
generation	O
from	O
C57BL	B-CellLine
/	O
6	I-CellLine
bone	O
marrow	O
.	O

Further	O
studies	O
indicated	O
that	O
the	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
/	O
CSF	B-GeneOrGeneProduct
-	O
1R	I-GeneOrGeneProduct
axis	O
contributed	O
significantly	O
to	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
-	O
induced	O
CD11c	B-GeneOrGeneProduct
+	O
cell	O
generation	O
through	O
enhancing	O
c	B-GeneOrGeneProduct
-	O
Fos	I-GeneOrGeneProduct
-	O
associated	O
monopoiesis	O
.	O

CD11c	B-GeneOrGeneProduct
+	O
cells	O
induced	O
by	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
or	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
/	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
were	O
competent	O
in	O
cellular	O
maturation	O
and	O
endocytosis	O
.	O

Both	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
/	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
cells	O
lacked	O
classical	O
dendritic	O
cell	O
appearance	O
and	O
resembled	O
macrophages	O
in	O
morphology	O
.	O

Both	O
populations	O
produced	O
a	O
high	O
level	O
of	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
,	O
in	O
addition	O
to	O
IL	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
and	O
TNFa	B-GeneOrGeneProduct
,	O
in	O
response	O
to	O
LPS	B-ChemicalEntity
,	O
and	O
were	O
relatively	O
poor	O
T	O
cell	O
stimulators	O
.	O

Collectively	O
,	O
these	O
findings	O
reveal	O
a	O
role	O
for	O
CSF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
mediating	O
the	O
IL	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
hematopoietic	O
pathway	O
through	O
monopoiesis	O
,	O
which	O
regulates	O
expansion	O
of	O
CD11c	B-GeneOrGeneProduct
+	O
macrophages	O
.	O
Analysis	O
of	O
Serum	O
Cytokines	O
and	O
Single	O
-	O
Nucleotide	O
Polymorphisms	O
of	O
SOD1	B-GeneOrGeneProduct
,	O
SOD2	B-GeneOrGeneProduct
,	O
and	O
CAT	B-GeneOrGeneProduct
in	O
Erysipelas	B-DiseaseOrPhenotypicFeature
Patients	B-OrganismTaxon
.	O

Increased	O
free	O
radical	O
production	O
had	O
been	O
documented	O
in	O
group	O
A	O
(	O
beta	O
-	O
hemolytic	O
)	O
streptococcus	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
cases	O
.	O

Comparing	O
71	O
erysipelas	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
to	O
55	O
age	O
-	O
matched	O
healthy	O
individuals	O
,	O
we	O
sought	O
for	O
CAT	B-GeneOrGeneProduct
,	O
SOD1	B-GeneOrGeneProduct
,	O
and	O
SOD2	B-GeneOrGeneProduct
single	O
polymorphism	O
mutation	O
(	O
SNPs	O
)	O
interactions	O
with	O
erysipelas	B-DiseaseOrPhenotypicFeature
'	O
predisposition	O
and	O
serum	O
cytokine	O
levels	O
in	O
the	O
acute	O
and	O
recovery	O
phases	O
of	O
erysipelas	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

Whereas	O
female	O
patients	B-OrganismTaxon
had	O
a	O
higher	O
predisposition	O
to	O
erysipelas	B-DiseaseOrPhenotypicFeature
,	O
male	O
patients	B-OrganismTaxon
were	O
prone	O
to	O
having	O
a	O
facial	O
localization	O
of	O
the	O
infection	B-DiseaseOrPhenotypicFeature
.	O

The	O
presence	O
of	O
SOD1	B-GeneOrGeneProduct
G7958	B-SequenceVariant
,	O
SOD2	B-GeneOrGeneProduct
T2734	B-SequenceVariant
,	O
and	O
CAT	B-GeneOrGeneProduct
C262	B-SequenceVariant
alleles	O
was	O
linked	O
to	O
erysipelas	B-DiseaseOrPhenotypicFeature
'	O
predisposition	O
.	O

T	O
and	O
C	O
alleles	O
of	O
SOD2	B-GeneOrGeneProduct
T2734C	B-SequenceVariant
individually	O
were	O
linked	O
to	O
patients	B-OrganismTaxon
with	O
bullous	O
and	O
erythematous	B-DiseaseOrPhenotypicFeature
erysipelas	I-DiseaseOrPhenotypicFeature
,	O
respectively	O
.	O

G	O
and	O
A	O
alleles	O
of	O
SOD1	B-GeneOrGeneProduct
G7958A	B-SequenceVariant
individually	O
were	O
associated	O
with	O
lower	O
limbs	O
and	O
higher	O
body	O
part	O
localizations	O
of	O
the	O
infection	B-DiseaseOrPhenotypicFeature
,	O
respectively	O
.	O

Serum	O
levels	O
of	O
IL	B-GeneOrGeneProduct
-	O
1beta	I-GeneOrGeneProduct
,	O
CCL11	B-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
2Ralpha	I-GeneOrGeneProduct
,	O
CXCL9	B-GeneOrGeneProduct
,	O
TRAIL	B-GeneOrGeneProduct
,	O
PDGF	B-GeneOrGeneProduct
-	O
BB	I-GeneOrGeneProduct
,	O
and	O
CCL4	B-GeneOrGeneProduct
were	O
associated	O
with	O
symptoms	O
accompanying	O
the	O
infection	B-DiseaseOrPhenotypicFeature
,	O
while	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
13	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
15	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
,	O
G	B-GeneOrGeneProduct
-	O
CSF	I-GeneOrGeneProduct
,	O
and	O
VEGF	B-GeneOrGeneProduct
were	O
associated	O
with	O
predisposition	O
and	O
recurrence	O
of	O
erysipelas	B-DiseaseOrPhenotypicFeature
.	O

While	O
variations	O
of	O
IL	B-GeneOrGeneProduct
-	O
1beta	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
7	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
,	O
CCL5	B-GeneOrGeneProduct
,	O
and	O
HGF	B-GeneOrGeneProduct
were	O
associated	O
with	O
the	O
SOD2	B-GeneOrGeneProduct
T2734C	B-SequenceVariant
SNP	O
,	O
variations	O
of	O
PDFG	B-GeneOrGeneProduct
-	O
BB	I-GeneOrGeneProduct
and	O
CCL2	B-GeneOrGeneProduct
were	O
associated	O
with	O
the	O
CAT	B-GeneOrGeneProduct
C262T	B-SequenceVariant
SNP	O
.	O
XRCC1	B-GeneOrGeneProduct
Arg399Gln	B-SequenceVariant
gene	O
polymorphism	O
and	O
the	O
risk	O
of	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
in	O
the	O
Polish	O
population	O
.	O

It	O
has	O
been	O
shown	O
that	O
DNA	O
repair	O
is	O
reduced	O
in	O
patients	B-OrganismTaxon
with	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
(	O
SLE	B-DiseaseOrPhenotypicFeature
)	O
and	O
that	O
the	O
X	B-GeneOrGeneProduct
-	O
ray	I-GeneOrGeneProduct
repair	I-GeneOrGeneProduct
cross	I-GeneOrGeneProduct
-	O
complementing	I-GeneOrGeneProduct
(	O
XRCC1	B-GeneOrGeneProduct
)	O
Arg399Gln	B-SequenceVariant
(	O
rs25487	B-SequenceVariant
)	O
polymorphism	O
may	O
contribute	O
to	O
DNA	O
repair	O
.	O

We	O
evaluated	O
the	O
frequency	O
of	O
the	O
XRCC1	B-GeneOrGeneProduct
Arg399Gln	B-SequenceVariant
substitution	O
in	O
patients	B-OrganismTaxon
with	O
SLE	B-DiseaseOrPhenotypicFeature
(	O
n	O
=	O
265	O
)	O
and	O
controls	O
(	O
n	O
=	O
360	O
)	O
in	O
a	O
sample	O
of	O
the	O
Polish	O
population	O
.	O

The	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
SLE	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
the	O
Gln	O
/	O
Gln	O
versus	O
Gln	O
/	O
Arg	O
or	O
Arg	O
/	O
Arg	O
genotypes	O
was	O
1	O
.	O
553	O
(	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0	O
.	O
9573	O
-	O
2	O
.	O
520	O
;	O
p	O
=	O
0	O
.	O
0729	O
)	O
.	O

OR	O
for	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
was	O
1	O
.	O
551	O
(	O
95%	O
CI	O
=	O
1	O
.	O
122	O
-	O
2	O
.	O
144	O
,	O
p	O
=	O
0	O
.	O
0077	O
)	O
.	O

The	O
OR	O
for	O
the	O
399	B-SequenceVariant
Gln	I-SequenceVariant
allele	O
in	O
patients	B-OrganismTaxon
with	O
SLE	B-DiseaseOrPhenotypicFeature
was	O
1	O
.	O
406	O
(	O
95%	O
CI	O
=	O
1	O
.	O
111	O
-	O
1	O
.	O
779	O
,	O
p	O
=	O
0	O
.	O
0045	O
)	O
.	O

There	O
was	O
also	O
a	O
statistically	O
significant	O
p	O
-	O
value	O
of	O
the	O
(	O
2	O
)	O
test	O
for	O
the	O
trend	O
observed	O
in	O
the	O
XRCC1	B-GeneOrGeneProduct
Arg399Gln	B-SequenceVariant
polymorphism	O
(	O
ptrend	O
=	O
0	O
.	O
0048	O
)	O
.	O

We	O
also	O
found	O
a	O
significant	O
contribution	O
of	O
the	O
Gln	O
/	O
Gln	O
or	O
Arg	O
/	O
Gln	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
to	O
the	O
presence	O
of	O
either	O
the	O
malar	B-DiseaseOrPhenotypicFeature
rash	I-DiseaseOrPhenotypicFeature
or	O
photosensitivity	O
manifestations	O
of	O
SLE	B-DiseaseOrPhenotypicFeature
OR	O
=	O
2	O
.	O
241	O
(	O
1	O
.	O
328	O
-	O
3	O
.	O
781	O
,	O
p	O
=	O
0	O
.	O
0023	O
,	O
pcorr	O
=	O
0	O
.	O
0414	O
)	O
.	O

Moreover	O
,	O
the	O
meta	O
-	O
analysis	O
of	O
Taiwanese	O
Han	O
Chinese	O
,	O
Brazilian	O
,	O
and	O
Polish	O
populations	O
showed	O
that	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
genotype	O
and	O
Gln	O
allele	O
were	O
associated	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
incidence	O
.	O

OR	O
for	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
was	O
1	O
.	O
440	O
(	O
95%	O
CI	O
=	O
1	O
.	O
15	O
-	O
1	O
.	O
80	O
,	O
p	O
=	O
0	O
.	O
0019	O
)	O
and	O
OR	O
for	O
the	O
Gln	O
allele	O
was	O
1	O
.	O
27	O
(	O
95%	O
CI	O
=	O
1	O
.	O
08	O
-	O
1	O
.	O
51	O
,	O
p	O
=	O
0	O
.	O
0051	O
)	O
.	O

Our	O
studies	O
may	O
confirm	O
that	O
the	O
XRCC1	B-GeneOrGeneProduct
Arg399Gln	B-SequenceVariant
polymorphism	O
may	O
increase	O
the	O
risk	O
of	O
incidence	O
of	O
SLE	B-DiseaseOrPhenotypicFeature
and	O
the	O
occurrence	O
of	O
some	O
SLE	B-DiseaseOrPhenotypicFeature
manifestations	O
.	O
Succinylcholine	B-ChemicalEntity
-	O
induced	O
masseter	B-DiseaseOrPhenotypicFeature
muscle	I-DiseaseOrPhenotypicFeature
rigidity	I-DiseaseOrPhenotypicFeature
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Masseter	B-DiseaseOrPhenotypicFeature
muscle	I-DiseaseOrPhenotypicFeature
rigidity	I-DiseaseOrPhenotypicFeature
during	O
general	O
anesthesia	O
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	B-DiseaseOrPhenotypicFeature
hyperthermia	I-DiseaseOrPhenotypicFeature
.	O

The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	B-DiseaseOrPhenotypicFeature
muscle	I-DiseaseOrPhenotypicFeature
rigidity	I-DiseaseOrPhenotypicFeature
.	O

Here	O
,	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	B-DiseaseOrPhenotypicFeature
muscle	I-DiseaseOrPhenotypicFeature
rigidity	I-DiseaseOrPhenotypicFeature
(	O
jaw	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
steel	I-DiseaseOrPhenotypicFeature
)	O
after	O
succinylcholine	B-ChemicalEntity
(	O
Sch	B-ChemicalEntity
)	O
administration	O
during	O
general	O
anesthetic	O
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Anesthesia	O
was	O
continued	O
uneventfully	O
with	O
propofol	B-ChemicalEntity
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	B-DiseaseOrPhenotypicFeature
hyperthermia	I-DiseaseOrPhenotypicFeature
.	O
Evaluation	O
of	O
the	O
Lys198Asn	B-SequenceVariant
and	O
-	O
134delA	I-SequenceVariant
genetic	O
polymorphisms	O
of	O
the	O
endothelin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
.	O

Endothelin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
is	O
a	O
potent	O
vasoconstrictor	O
and	O
shows	O
various	O
pharmacological	O
responses	O
.	O

Two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
(	O
EDN1	B-GeneOrGeneProduct
)	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O

One	O
is	O
the	O
Lys198Asn	B-SequenceVariant
polymorphism	O
,	O
which	O
showed	O
a	O
positive	O
association	O
with	O
BP	O
in	O
overweight	B-DiseaseOrPhenotypicFeature
people	O
.	O

Another	O
is	O
the	O
3A	O
/	O
4A	O
polymorphism	O
(	O
-	O
134delA	I-SequenceVariant
)	O
located	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
Lys198Asn	B-SequenceVariant
polymorphism	O
in	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
vitro	O
,	O
as	O
well	O
as	O
the	O
association	O
between	O
either	O
of	O
the	O
two	O
polymorphisms	O
and	O
the	O
plasma	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
level	O
.	O

We	O
expressed	O
both	O
the	O
major	O
(	O
Lys	O
-	O
type	O
)	O
and	O
minor	O
type	O
(	O
Asn	O
-	O
type	O
)	O
preproET	O
-	O
1	I-GeneOrGeneProduct
in	O
three	O
different	O
cell	O
lines	O
,	O
and	O
measured	O
the	O
levels	O
of	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	O
big	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
the	O
culture	O
supernatant	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
or	O
big	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
between	O
the	O
Asn	B-SequenceVariant
-	O
type	I-SequenceVariant
and	I-SequenceVariant
Lys	I-SequenceVariant
-	O
type	I-SequenceVariant
transfectant	I-SequenceVariant
.	O

In	O
the	O
association	O
study	O
,	O
the	O
plasma	O
levels	O
of	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
54	O
hypertensive	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
having	O
an	O
amino	O
acid	O
substitution	O
from	O
Lys	B-SequenceVariant
to	I-SequenceVariant
Asn	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
198	I-SequenceVariant
were	O
not	O
different	O
from	O
those	O
of	O
hypertensives	B-DiseaseOrPhenotypicFeature
without	O
the	O
substitution	O
.	O

However	O
,	O
we	O
found	O
a	O
significant	O
difference	O
in	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
levels	O
between	O
individuals	O
with	O
the	O
3A	O
/	O
3A	O
and	O
3A	O
/	O
4A	O
genotypes	O
.	O

Our	O
transient	O
expression	O
study	O
indicates	O
that	O
the	O
Lys198Asn	B-SequenceVariant
polymorphism	O
may	O
not	O
directly	O
affect	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	O
big	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
production	O
.	O

Another	O
variant	O
in	O
the	O
EDN1	B-GeneOrGeneProduct
gene	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
Lys198Asn	B-SequenceVariant
polymorphism	O
may	O
be	O
responsible	O
for	O
the	O
association	O
with	O
BP	O
,	O
or	O
the	O
interaction	O
between	O
the	O
EDN1	B-GeneOrGeneProduct
Lys198Asn	B-SequenceVariant
polymorphism	O
and	O
other	O
factors	O
such	O
as	O
obesity	B-DiseaseOrPhenotypicFeature
may	O
be	O
involved	O
in	O
the	O
mechanisms	O
elevating	O
BP	O
in	O
vivo	O
.	O
Polymorphisms	O
in	O
the	O
SLC2A2	B-GeneOrGeneProduct
(	O
GLUT2	B-GeneOrGeneProduct
)	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	B-DiseaseOrPhenotypicFeature
glucose	I-DiseaseOrPhenotypicFeature
tolerance	I-DiseaseOrPhenotypicFeature
to	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
:	O
the	O
Finnish	O
Diabetes	B-DiseaseOrPhenotypicFeature
Prevention	O
Study	O
.	O

Impaired	B-DiseaseOrPhenotypicFeature
insulin	I-DiseaseOrPhenotypicFeature
secretion	I-DiseaseOrPhenotypicFeature
is	O
a	O
fundamental	O
defect	O
in	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
genes	O
regulating	O
insulin	B-GeneOrGeneProduct
secretion	O
(	O
SLC2A2	B-GeneOrGeneProduct
[	O
encoding	O
GLUT2	B-GeneOrGeneProduct
]	O
,	O
GCK	B-GeneOrGeneProduct
,	O
TCF1	B-GeneOrGeneProduct
[	O
encoding	O
HNF	B-GeneOrGeneProduct
-	O
1alpha	I-GeneOrGeneProduct
]	O
,	O
HNF4A	B-GeneOrGeneProduct
,	O
GIP	B-GeneOrGeneProduct
,	O
and	O
GLP1R	B-GeneOrGeneProduct
)	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	B-DiseaseOrPhenotypicFeature
glucose	I-DiseaseOrPhenotypicFeature
tolerance	I-DiseaseOrPhenotypicFeature
(	O
IGT	B-DiseaseOrPhenotypicFeature
)	O
to	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
in	O
participants	O
of	O
the	O
Finnish	O
Diabetes	B-DiseaseOrPhenotypicFeature
Prevention	O
Study	O
.	O

With	O
the	O
exception	O
of	O
SLC2A2	B-GeneOrGeneProduct
,	O
other	O
genes	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O

All	O
four	O
SNPs	O
of	O
SLC2A2	B-GeneOrGeneProduct
predicted	O
the	O
conversion	O
to	O
diabetes	B-DiseaseOrPhenotypicFeature
,	O
and	O
rs5393	B-SequenceVariant
(	O
AA	O
genotype	O
)	O
increased	O
the	O
risk	O
of	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
in	O
the	O
entire	O
study	O
population	O
by	O
threefold	O
(	O
odds	O
ratio	O
3	O
.	O
04	O
,	O
95%	O
CI	O
1	O
.	O
34	O
-	O
6	O
.	O
88	O
,	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
risk	O
for	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
in	O
the	O
AA	O
genotype	O
carriers	O
was	O
increased	O
in	O
the	O
control	O
group	O
(	O
5	O
.	O
56	O
[	O
1	O
.	O
78	O
-	O
17	O
.	O
39	O
]	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
not	O
in	O
the	O
intervention	O
group	O
.	O

We	O
conclude	O
that	O
the	O
SNPs	O
of	O
SLC2A2	B-GeneOrGeneProduct
predict	O
the	O
conversion	O
to	O
diabetes	B-DiseaseOrPhenotypicFeature
in	O
obese	B-DiseaseOrPhenotypicFeature
subjects	O
with	O
IGT	B-DiseaseOrPhenotypicFeature
.	O
Identification	O
of	O
a	O
novel	O
WFS1	B-GeneOrGeneProduct
mutation	O
(	O
AFF344	B-SequenceVariant
-	O
345ins	I-SequenceVariant
)	O
in	O
Japanese	O
patients	B-OrganismTaxon
with	O
Wolfram	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Wolfram	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
WFS	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
early	O
onset	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
,	O
progressive	O
optic	B-DiseaseOrPhenotypicFeature
atrophy	I-DiseaseOrPhenotypicFeature
,	O
sensorineural	B-DiseaseOrPhenotypicFeature
deafness	I-DiseaseOrPhenotypicFeature
and	O
diabetes	B-DiseaseOrPhenotypicFeature
insipidus	I-DiseaseOrPhenotypicFeature
.	O

Affected	O
individuals	O
may	O
also	O
have	O
renal	B-DiseaseOrPhenotypicFeature
tract	I-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
as	O
well	O
as	O
neurogical	O
and	O
psychiatric	B-DiseaseOrPhenotypicFeature
syndromes	I-DiseaseOrPhenotypicFeature
.	O

WFS1	B-GeneOrGeneProduct
encoding	O
a	O
transmembrane	O
protein	O
was	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
WFS	B-DiseaseOrPhenotypicFeature
.	O

We	O
report	O
herein	O
a	O
Japanese	O
family	O
,	O
of	O
which	O
two	O
members	O
had	O
this	O
syndrome	O
.	O

In	O
the	O
WFS1	B-GeneOrGeneProduct
gene	O
of	O
these	O
patients	B-OrganismTaxon
,	O
we	O
identified	O
a	O
novel	O
mutation	O
,	O
a	O
nine	B-SequenceVariant
nucleotide	I-SequenceVariant
insertion	I-SequenceVariant
(	O
AFF344	B-SequenceVariant
-	O
345ins	I-SequenceVariant
)	O
.	O

In	O
addition	O
,	O
one	O
of	O
these	O
patients	B-OrganismTaxon
had	O
preclinical	O
hypopituitarism	B-DiseaseOrPhenotypicFeature
,	O
which	O
is	O
an	O
unusual	O
feature	O
of	O
WFS	B-DiseaseOrPhenotypicFeature
.	O

As	O
only	O
the	O
two	O
family	O
members	O
homozygous	O
for	O
the	O
mutation	O
showed	O
WFS	B-DiseaseOrPhenotypicFeature
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
this	O
mutation	O
is	O
the	O
cause	O
of	O
WFS	B-DiseaseOrPhenotypicFeature
.	O
hOGG1	B-GeneOrGeneProduct
Ser326Cys	B-SequenceVariant
polymorphism	O
and	O
risk	O
of	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
by	O
histological	O
type	O
.	O

Human	B-OrganismTaxon
8	B-GeneOrGeneProduct
-	O
oxoguanine	I-GeneOrGeneProduct
DNA	I-GeneOrGeneProduct
glycosylase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
hOGG1	B-GeneOrGeneProduct
)	O
has	O
a	O
major	O
role	O
in	O
the	O
repair	O
of	O
8	B-ChemicalEntity
-	O
hydroxyguanine	I-ChemicalEntity
,	O
a	O
major	O
promutagenic	O
DNA	O
lesion	O
.	O

The	O
genetic	O
polymorphism	O
rs1052133	B-SequenceVariant
,	O
which	O
leads	O
to	O
substitution	O
of	O
the	O
amino	O
acid	O
at	O
codon	O
326	B-SequenceVariant
from	I-SequenceVariant
Ser	I-SequenceVariant
to	I-SequenceVariant
Cys	I-SequenceVariant
,	O
shows	O
functional	O
differences	O
,	O
namely	O
a	O
decrease	O
in	O
enzyme	O
activity	O
in	O
hOGG1	B-GeneOrGeneProduct
-	O
Cys326	B-SequenceVariant
.	O

Although	O
several	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
rs1052133	B-SequenceVariant
and	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
susceptibility	O
,	O
the	O
effect	O
of	O
this	O
locus	O
on	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
according	O
to	O
histology	O
remains	O
unclear	O
.	O

We	O
therefore	O
conducted	O
a	O
case	O
-	O
control	O
study	O
with	O
515	O
incident	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cases	O
and	O
1030	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
without	O
cancer	B-DiseaseOrPhenotypicFeature
,	O
and	O
further	O
conducted	O
a	O
meta	O
-	O
analysis	O
.	O

In	O
overall	O
analysis	O
,	O
the	O
homozygous	O
Cys	O
/	O
Cys	O
genotype	O
showed	O
a	O
significant	O
association	O
with	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
compared	O
to	O
Ser	O
allele	O
carrier	O
status	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1	O
.	O
31	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
02	O
-	O
1	O
.	O
69	O
)	O
.	O

By	O
histology	O
-	O
based	O
analysis	O
,	O
the	O
Cys	O
/	O
Cys	O
genotype	O
showed	O
a	O
significantly	O
positive	O
association	O
with	O
small	B-DiseaseOrPhenotypicFeature
-	O
cell	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
OR	O
=	O
2	O
.	O
40	O
,	O
95%	O
CI	O
=	O
1	O
.	O
32	O
-	O
4	O
.	O
49	O
)	O
and	O
marginally	O
significant	O
association	O
with	O
adenocarcinoma	B-DiseaseOrPhenotypicFeature
(	O
OR	O
=	O
1	O
.	O
32	O
,	O
95%	O
CI	O
=	O
0	O
.	O
98	O
-	O
1	O
.	O
77	O
)	O
.	O

A	O
meta	O
-	O
analysis	O
of	O
previous	O
and	O
our	O
present	O
study	O
revealed	O
that	O
this	O
polymorphism	O
is	O
positively	O
associated	O
with	O
adenocarcinoma	B-DiseaseOrPhenotypicFeature
,	O
although	O
suggestive	O
associations	O
were	O
also	O
found	O
for	O
squamous	B-DiseaseOrPhenotypicFeature
-	O
and	I-DiseaseOrPhenotypicFeature
small	I-DiseaseOrPhenotypicFeature
-	O
cell	I-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
.	O

These	O
results	O
indicate	O
that	O
rs1052133	B-SequenceVariant
contributes	O
to	O
the	O
risk	O
of	O
adenocarcinoma	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
.	O
Thyroid	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
a	I-GeneOrGeneProduct
mutation	O
causes	O
a	O
severe	O
and	O
thyroxine	B-ChemicalEntity
-	O
resistant	O
skeletal	B-DiseaseOrPhenotypicFeature
dysplasia	I-DiseaseOrPhenotypicFeature
in	O
female	O
mice	B-OrganismTaxon
.	O

A	O
new	O
genetic	O
disorder	O
has	O
been	O
identified	O
that	O
results	O
from	O
mutation	O
of	O
THRA	B-GeneOrGeneProduct
,	O
encoding	O
thyroid	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
a1	I-GeneOrGeneProduct
(	O
TRa1	B-GeneOrGeneProduct
)	O
.	O

Affected	O
children	O
have	O
a	O
high	O
serum	O
T3	B-ChemicalEntity
:	O
T4	B-ChemicalEntity
ratio	O
and	O
variable	O
degrees	O
of	O
intellectual	B-DiseaseOrPhenotypicFeature
deficit	I-DiseaseOrPhenotypicFeature
and	O
constipation	B-DiseaseOrPhenotypicFeature
but	O
exhibit	O
a	O
consistently	O
severe	O
skeletal	B-DiseaseOrPhenotypicFeature
dysplasia	I-DiseaseOrPhenotypicFeature
.	O

In	O
an	O
attempt	O
to	O
improve	O
developmental	B-DiseaseOrPhenotypicFeature
delay	I-DiseaseOrPhenotypicFeature
and	O
alleviate	O
symptoms	O
of	O
hypothyroidism	B-DiseaseOrPhenotypicFeature
,	O
patients	B-OrganismTaxon
are	O
receiving	O
varying	O
doses	O
and	O
durations	O
of	O
T4	B-ChemicalEntity
treatment	O
,	O
but	O
responses	O
have	O
been	O
inconsistent	O
so	O
far	O
.	O

Thra1	B-GeneOrGeneProduct
(	O
PV	O
/	O
+	O
)	O
mice	B-OrganismTaxon
express	O
a	O
similar	O
potent	O
dominant	O
-	O
negative	O
mutant	O
TRa1	B-GeneOrGeneProduct
to	O
affected	O
individuals	O
,	O
and	O
thus	O
represent	O
an	O
excellent	O
disease	O
model	O
.	O

We	O
hypothesized	O
that	O
Thra1	B-GeneOrGeneProduct
(	O
PV	O
/	O
+	O
)	O
mice	B-OrganismTaxon
could	O
be	O
used	O
to	O
predict	O
the	O
skeletal	O
outcome	O
of	O
human	B-OrganismTaxon
THRA	B-GeneOrGeneProduct
mutations	O
and	O
determine	O
whether	O
prolonged	O
treatment	O
with	O
a	O
supraphysiological	O
dose	O
of	O
T4	B-ChemicalEntity
ameliorates	O
the	O
skeletal	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
.	O

Adult	O
female	O
Thra1	B-GeneOrGeneProduct
(	O
PV	O
/	O
+	O
)	O
mice	B-OrganismTaxon
had	O
short	B-DiseaseOrPhenotypicFeature
stature	I-DiseaseOrPhenotypicFeature
,	O
grossly	O
abnormal	O
bone	O
morphology	O
but	O
normal	O
bone	O
strength	O
despite	O
high	O
bone	O
mass	O
.	O

Although	O
T4	B-ChemicalEntity
treatment	O
suppressed	O
TSH	B-GeneOrGeneProduct
secretion	O
,	O
it	O
had	O
no	O
effect	O
on	O
skeletal	O
maturation	O
,	O
linear	O
growth	O
,	O
or	O
bone	O
mineralization	O
,	O
thus	O
demonstrating	O
profound	O
tissue	O
resistance	B-DiseaseOrPhenotypicFeature
to	I-DiseaseOrPhenotypicFeature
thyroid	I-DiseaseOrPhenotypicFeature
hormone	I-DiseaseOrPhenotypicFeature
.	O

Despite	O
this	O
,	O
prolonged	O
T4	B-ChemicalEntity
treatment	O
abnormally	O
increased	O
bone	O
stiffness	O
and	O
strength	O
,	O
suggesting	O
the	O
potential	O
for	O
detrimental	O
consequences	O
in	O
the	O
long	O
term	O
.	O

Our	O
studies	O
establish	O
that	O
TRa1	B-GeneOrGeneProduct
has	O
an	O
essential	O
role	O
in	O
the	O
developing	O
and	O
adult	O
skeleton	O
and	O
predict	O
that	O
patients	B-OrganismTaxon
with	O
different	O
THRA	B-GeneOrGeneProduct
mutations	O
will	O
display	O
variable	O
responses	O
to	O
T4	B-ChemicalEntity
treatment	O
,	O
which	O
depend	O
on	O
the	O
severity	O
of	O
the	O
causative	O
mutation	O
.	O
Variation	O
in	O
IL10	B-GeneOrGeneProduct
and	O
other	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
and	O
in	O
oxidation	O
and	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
recurrence	O
.	O

BACKGROUND	O
:	O
To	O
evaluate	O
the	O
association	O
of	O
variation	O
in	O
genes	O
involved	O
in	O
immune	O
response	O
,	O
including	O
IL10	B-GeneOrGeneProduct
,	O
production	O
and	O
detoxification	O
of	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
,	O
and	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
with	O
risk	O
of	O
recurrence	O
after	O
surgery	O
for	O
localized	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
nested	O
case	O
-	O
control	O
study	O
of	O
men	B-OrganismTaxon
who	O
had	O
a	O
radical	O
prostatectomy	O
in	O
1993	O
to	O
2001	O
.	O

A	O
total	O
of	O
484	O
recurrence	O
cases	O
and	O
484	O
controls	O
were	O
matched	O
on	O
age	O
,	O
race	O
,	O
and	O
pathologic	O
stage	O
and	O
grade	O
.	O

Germline	O
DNA	O
was	O
extracted	O
from	O
paraffin	B-ChemicalEntity
-	O
embedded	O
unaffected	O
lymph	O
nodes	O
.	O

We	O
genotyped	O
candidate	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
IL10	B-GeneOrGeneProduct
,	O
CRP	B-GeneOrGeneProduct
,	O
GPX1	B-GeneOrGeneProduct
,	O
GSR	B-GeneOrGeneProduct
,	O
GSTP1	B-GeneOrGeneProduct
,	O
hOGG1	B-GeneOrGeneProduct
,	O
IL1B	B-GeneOrGeneProduct
,	O
IL1RN	B-GeneOrGeneProduct
,	O
IL6	B-GeneOrGeneProduct
,	O
IL8	B-GeneOrGeneProduct
,	O
MPO	B-GeneOrGeneProduct
,	O
NOS2	B-GeneOrGeneProduct
,	O
NOS3	B-GeneOrGeneProduct
,	O
SOD1	B-GeneOrGeneProduct
,	O
SOD2	B-GeneOrGeneProduct
,	O
SOD3	B-GeneOrGeneProduct
,	O
TLR4	B-GeneOrGeneProduct
,	O
and	O
TNF	B-GeneOrGeneProduct
and	O
tagging	O
SNPs	O
in	O
IL10	B-GeneOrGeneProduct
,	O
CRP	B-GeneOrGeneProduct
,	O
GSR	B-GeneOrGeneProduct
,	O
IL1RN	B-GeneOrGeneProduct
,	O
IL6	B-GeneOrGeneProduct
,	O
NOS2	B-GeneOrGeneProduct
,	O
and	O
NOS3	B-GeneOrGeneProduct
.	O

We	O
used	O
conditional	O
logistic	O
regression	O
to	O
estimate	O
OR	O
and	O
95%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

RESULTS	O
:	O
The	O
minor	O
allele	O
(	O
A	O
)	O
in	O
IL10	B-GeneOrGeneProduct
rs1800872	B-SequenceVariant
,	O
known	O
to	O
produce	O
less	O
interleukin	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
(	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
)	O
,	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
recurrence	O
(	O
OR	O
=	O
1	O
.	O
76	O
,	O
95%	O
CI	O
:	O
1	O
.	O
00	O
-	O
3	O
.	O
10	O
)	O
,	O
and	O
the	O
minor	O
allele	O
(	O
G	O
)	O
in	O
rs1800896	B-SequenceVariant
,	O
known	O
to	O
produce	O
more	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
,	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
recurrence	O
(	O
OR	O
=	O
0	O
.	O
66	O
,	O
95%	O
CI	O
:	O
0	O
.	O
48	O
-	O
0	O
.	O
91	O
)	O
.	O

We	O
also	O
observed	O
associations	O
for	O
candidate	O
SNPs	O
in	O
CRP	B-GeneOrGeneProduct
,	O
GSTP1	B-GeneOrGeneProduct
,	O
and	O
IL1B	B-GeneOrGeneProduct
.	O

A	O
common	O
IL10	B-GeneOrGeneProduct
haplotype	O
and	O
2	O
common	O
NOS2	B-GeneOrGeneProduct
haplotypes	O
were	O
associated	O
with	O
recurrence	O
.	O

CONCLUSION	O
:	O
Variation	O
in	O
IL10	B-GeneOrGeneProduct
,	O
CRP	B-GeneOrGeneProduct
,	O
GSTP1	B-GeneOrGeneProduct
,	O
IL1B	B-GeneOrGeneProduct
,	O
and	O
NOS2	B-GeneOrGeneProduct
was	O
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
recurrence	O
independent	O
of	O
pathologic	O
prognostic	O
factors	O
.	O

IMPACT	O
:	O
This	O
study	O
supports	O
that	O
genetic	O
variation	O
in	O
immune	O
response	O
and	O
oxidation	O
influence	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
recurrence	O
risk	O
and	O
suggests	O
genetic	O
variation	O
in	O
these	O
pathways	O
may	O
inform	O
prognosis	O
.	O
Large	O
contiguous	O
gene	O
deletions	O
in	O
Sjogren	B-DiseaseOrPhenotypicFeature
-	O
Larsson	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Sjogren	B-DiseaseOrPhenotypicFeature
-	O
Larsson	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
SLS	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
ichthyosis	B-DiseaseOrPhenotypicFeature
,	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
,	O
spasticity	B-DiseaseOrPhenotypicFeature
and	O
mutations	O
in	O
the	O
ALDH3A2	B-GeneOrGeneProduct
gene	O
for	O
fatty	B-GeneOrGeneProduct
aldehyde	I-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
fatty	B-ChemicalEntity
aldehyde	I-ChemicalEntity
to	O
fatty	B-ChemicalEntity
acid	I-ChemicalEntity
.	O

More	O
than	O
70	O
mutations	O
have	O
been	O
identified	O
in	O
SLS	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
including	O
small	O
deletions	O
or	O
insertions	O
,	O
missense	O
mutations	O
,	O
splicing	O
defects	O
and	O
complex	O
nucleotide	O
changes	O
.	O

We	O
now	O
describe	O
2	O
SLS	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
whose	O
disease	O
is	O
caused	O
by	O
large	O
contiguous	O
gene	O
deletions	O
of	O
the	O
ALDH3A2	B-GeneOrGeneProduct
locus	O
on	O
17p11	O
.	O
2	O
.	O

The	O
deletions	O
were	O
defined	O
using	O
long	O
distance	O
inverse	O
PCR	O
and	O
microarray	O
-	O
based	O
comparative	O
genomic	O
hybridization	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
SLS	B-DiseaseOrPhenotypicFeature
female	O
was	O
homozygous	O
for	O
a	O
352	B-SequenceVariant
-	O
kb	I-SequenceVariant
deletion	I-SequenceVariant
involving	O
ALDH3A2	B-GeneOrGeneProduct
and	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
contiguous	O
genes	O
including	O
ALDH3A1	B-GeneOrGeneProduct
,	O
which	O
codes	O
for	O
the	O
major	O
soluble	O
protein	O
in	O
cornea	O
.	O

Although	O
lacking	O
corneal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
she	O
showed	O
severe	O
symptoms	O
of	O
SLS	B-DiseaseOrPhenotypicFeature
with	O
uncommon	O
deterioration	O
in	O
oral	O
motor	O
function	O
and	O
loss	O
of	O
ambulation	O
.	O

The	O
other	O
19	O
-	O
month	O
-	O
old	O
female	O
patient	B-OrganismTaxon
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
1	B-SequenceVariant
.	O
44	I-SequenceVariant
-	O
Mb	I-SequenceVariant
contiguous	I-SequenceVariant
gene	I-SequenceVariant
deletion	I-SequenceVariant
and	O
a	O
missense	O
mutation	O
(	O
c	B-SequenceVariant
.	O
407C	I-SequenceVariant
>	O
T	I-SequenceVariant
,	O
P136L	B-SequenceVariant
)	O
in	O
ALDH3A2	B-GeneOrGeneProduct
.	O

These	O
studies	O
suggest	O
that	O
large	O
gene	O
deletions	O
may	O
account	O
for	O
up	O
to	O
5%	O
of	O
the	O
mutant	O
alleles	O
in	O
SLS	B-DiseaseOrPhenotypicFeature
.	O

Geneticists	O
should	O
consider	O
the	O
possibility	O
of	O
compound	O
heterozygosity	O
for	O
large	O
deletions	O
in	O
patients	B-OrganismTaxon
with	O
SLS	B-DiseaseOrPhenotypicFeature
and	O
other	O
inborn	B-DiseaseOrPhenotypicFeature
errors	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
metabolism	I-DiseaseOrPhenotypicFeature
,	O
which	O
has	O
implications	O
for	O
carrier	O
testing	O
and	O
prenatal	O
diagnosis	O
.	O
Pharmacogenetic	O
Analysis	O
of	O
INT	O
0144	O
Trial	O
:	O
Association	O
of	O
Polymorphisms	O
with	O
Survival	O
and	O
Toxicity	B-DiseaseOrPhenotypicFeature
in	O
Rectal	B-DiseaseOrPhenotypicFeature
Cancer	I-DiseaseOrPhenotypicFeature
Patients	B-OrganismTaxon
Treated	O
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
Radiation	O
.	O

PURPOSE	O
:	O
We	O
tested	O
whether	O
18	O
polymorphisms	O
in	O
16	O
genes	O
(	O
GSTP1	B-GeneOrGeneProduct
,	O
COX2	B-GeneOrGeneProduct
,	O
IL10	B-GeneOrGeneProduct
,	O
EGFR	B-GeneOrGeneProduct
,	O
EGF	B-GeneOrGeneProduct
,	O
FGFR4	B-GeneOrGeneProduct
,	O
CCDN1	B-GeneOrGeneProduct
,	O
VEGFR2	B-GeneOrGeneProduct
,	O
VEGF	B-GeneOrGeneProduct
,	O
CXCR2	B-GeneOrGeneProduct
,	O
IL8	B-GeneOrGeneProduct
,	O
MMP3	B-GeneOrGeneProduct
,	O
ICAM1	B-GeneOrGeneProduct
,	O
ERCC1	B-GeneOrGeneProduct
,	O
RAD51	B-GeneOrGeneProduct
,	O
and	O
XRCC3	B-GeneOrGeneProduct
)	O
would	O
predict	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
toxicity	B-DiseaseOrPhenotypicFeature
in	O
the	O
INT0144	O
trial	O
,	O
which	O
was	O
designed	O
to	O
investigate	O
different	O
postoperative	O
regimens	O
of	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
)	O
-	O
based	O
chemoradiation	O
(	O
CRT	O
)	O
in	O
locally	O
advanced	O
rectal	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
:	O
Arm	O
1	O
consisted	O
of	O
bolus	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
followed	O
by	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
protracted	O
venous	O
infusion	O
(	O
PVI	O
)	O
with	O
radiotherapy	O
;	O
arm	O
2	O
was	O
induction	O
and	O
concomitant	O
PVI	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
with	O
radiotherapy	O
and	O
arm	O
3	O
was	O
induction	O
and	O
concomitant	O
bolus	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
with	O
radiotherapy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
DNA	O
from	O
746	O
stage	O
II	O
/	O
III	O
rectal	O
patients	B-OrganismTaxon
enrolled	O
in	O
the	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
S9304	O
phase	O
III	O
trial	O
was	O
analyzed	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
formalin	B-ChemicalEntity
-	O
fixed	O
,	O
paraffin	B-ChemicalEntity
-	O
embedded	O
(	O
FFPE	O
)	O
tumor	B-DiseaseOrPhenotypicFeature
tissue	O
.	O

The	O
polymorphisms	O
were	O
analyzed	O
using	O
direct	O
DNA	O
-	O
sequencing	O
or	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
.	O

RESULTS	O
:	O
GSTP1	B-GeneOrGeneProduct
-	O
Ile105Val	B-SequenceVariant
(	O
rs1695	B-SequenceVariant
)	O
was	O
significantly	O
associated	O
with	O
DFS	O
and	O
OS	O
and	O
its	O
effect	O
did	O
not	O
vary	O
by	O
treatment	O
arm	O
.	O

The	O
five	O
-	O
year	O
DFS	O
and	O
OS	O
were	O
53%	O
and	O
58%	O
,	O
respectively	O
,	O
for	O
G	O
/	O
G	O
,	O
66%	O
and	O
72%	O
for	O
G	O
/	O
A	O
,	O
and	O
57%	O
and	O
66%	O
for	O
A	O
/	O
A	O
patients	B-OrganismTaxon
.	O

In	O
arm	O
2	O
,	O
IL8	B-GeneOrGeneProduct
-	O
251A	I-SequenceVariant
/	O
A	I-SequenceVariant
genotype	O
(	O
rs4073	B-SequenceVariant
)	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
toxicities	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

The	O
VEGFR2	B-GeneOrGeneProduct
H472Q	B-SequenceVariant
Q	O
/	O
Q	O
genotype	O
(	O
rs1870377	B-SequenceVariant
)	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
grade	O
3	O
-	O
5	O
proximal	O
upper	O
gastrointestinal	O
tract	O
(	O
PUGIT	O
)	O
mucositis	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
0	O
.	O
04	O
)	O
in	O
arm	O
2	O
.	O

However	O
,	O
in	O
arm	O
1	O
,	O
this	O
genotype	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
PUGIT	O
mucositis	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

CONCLUSION	O
:	O
rs1695	B-SequenceVariant
may	O
be	O
prognostic	O
in	O
patients	B-OrganismTaxon
with	O
rectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
treated	O
with	O
adjuvant	O
CRT	O
.	O

rs4073	B-SequenceVariant
and	O
rs1870377	B-SequenceVariant
may	O
exhibit	O
different	O
associations	O
with	O
toxicity	B-DiseaseOrPhenotypicFeature
,	O
according	O
to	O
the	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
schedule	O
.	O
Genetic	O
homogeneity	O
for	O
inherited	O
congenital	B-DiseaseOrPhenotypicFeature
microcoria	I-DiseaseOrPhenotypicFeature
loci	O
in	O
an	O
Asian	O
Indian	O
pedigree	O
.	O

PURPOSE	O
:	O
Congenital	B-DiseaseOrPhenotypicFeature
microcoria	I-DiseaseOrPhenotypicFeature
is	O
a	O
rare	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
developmental	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
iris	I-DiseaseOrPhenotypicFeature
associated	O
with	O
myopia	B-DiseaseOrPhenotypicFeature
and	O
juvenile	B-DiseaseOrPhenotypicFeature
open	I-DiseaseOrPhenotypicFeature
angle	I-DiseaseOrPhenotypicFeature
glaucoma	I-DiseaseOrPhenotypicFeature
.	O

Linkage	O
to	O
the	O
chromosomal	O
locus	O
13q31	O
-	O
q32	O
has	O
previously	O
been	O
reported	O
in	O
a	O
large	O
French	O
family	O
.	O

In	O
the	O
current	O
study	O
,	O
a	O
three	O
generation	O
Asian	O
Indian	O
family	O
with	O
15	O
congenital	B-DiseaseOrPhenotypicFeature
microcoria	I-DiseaseOrPhenotypicFeature
(	O
pupils	O
with	O
a	O
diameter	O
<	O
2	O
mm	O
)	O
affected	O
members	O
was	O
studied	O
for	O
linkage	O
to	O
candidate	O
microsatellite	O
markers	O
at	O
the	O
13q31	O
-	O
q32	O
locus	O
.	O

METHODS	O
:	O
Twenty	O
-	O
four	O
members	O
of	O
the	O
family	O
were	O
clinically	O
examined	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O

Microsatellite	O
markers	O
at	O
13q31	O
-	O
q32	O
were	O
PCR	O
amplified	O
and	O
run	O
on	O
an	O
ABI	O
Prism	O
310	O
genetic	O
analyzer	O
and	O
genotyped	O
with	O
the	O
GeneScan	O
analysis	O
.	O

Two	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
using	O
the	O
MLINK	O
and	O
SUPERLINK	O
programs	O
.	O

RESULTS	O
:	O
Peak	O
two	O
point	O
LOD	O
scores	O
of	O
3	O
.	O
5	O
,	O
4	O
.	O
7	O
,	O
and	O
5	O
.	O
3	O
were	O
found	O
co	O
-	O
incident	O
with	O
consecutive	O
markers	O
D13S154	O
,	O
DCT	B-GeneOrGeneProduct
,	O
and	O
D13S1280	O
.	O

Multipoint	O
analysis	O
revealed	O
a	O
4	O
cM	O
region	O
encompassing	O
D13S1300	O
to	O
D13S1280	O
where	O
the	O
LOD	O
remains	O
just	O
over	O
6	O
.	O
0	O
Thus	O
we	O
confirm	O
localization	O
of	O
the	O
congenital	B-DiseaseOrPhenotypicFeature
microcoria	I-DiseaseOrPhenotypicFeature
locus	O
to	O
chromosomal	O
locus	O
13q31	O
-	O
q32	O
.	O

In	O
addition	O
,	O
eight	O
individuals	O
who	O
had	O
both	O
microcoria	B-DiseaseOrPhenotypicFeature
and	O
glaucoma	B-DiseaseOrPhenotypicFeature
were	O
screened	O
for	O
glaucoma	B-DiseaseOrPhenotypicFeature
genes	O
:	O
myocilin	B-GeneOrGeneProduct
(	O
MYOC	B-GeneOrGeneProduct
)	O
,	O
optineurin	B-GeneOrGeneProduct
(	O
OPTN	B-GeneOrGeneProduct
)	O
and	O
CYP1B1	B-GeneOrGeneProduct
.	O

Using	O
direct	O
sequencing	O
a	O
point	O
mutation	O
(	O
144	B-SequenceVariant
G	I-SequenceVariant
>	O
A	I-SequenceVariant
)	O
resulting	O
in	O
a	O
Q48H	B-SequenceVariant
substitution	O
in	O
exon	O
1	O
of	O
the	O
MYOC	B-GeneOrGeneProduct
gene	O
was	O
observed	O
in	O
five	O
of	O
the	O
eight	O
glaucoma	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
but	O
not	O
in	O
unaffected	O
family	O
members	O
and	O
100	O
unrelated	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
confirmed	O
the	O
localization	O
of	O
the	O
congenital	B-DiseaseOrPhenotypicFeature
microcoria	I-DiseaseOrPhenotypicFeature
locus	O
(	O
MCOR	B-GeneOrGeneProduct
)	O
to	O
13q31	O
-	O
q32	O
in	O
a	O
large	O
Asian	O
Indian	O
family	O
and	O
conclude	O
that	O
current	O
information	O
suggests	O
this	O
is	O
a	O
single	O
locus	O
disorder	O
and	O
genetically	O
homogeneous	O
.	O

When	O
combined	O
with	O
the	O
initial	O
linkage	O
paper	O
our	O
haplotype	O
and	O
linkage	O
data	O
map	O
the	O
MCOR	B-GeneOrGeneProduct
locus	O
to	O
a	O
6	O
-	O
7	O
cM	O
region	O
between	O
D13S265	O
and	O
D13S1280	O
.	O

The	O
DCT	B-GeneOrGeneProduct
locus	O
,	O
a	O
member	O
of	O
the	O
tyrosinase	B-GeneOrGeneProduct
family	O
involved	O
in	O
pigmentation	B-DiseaseOrPhenotypicFeature
,	O
maps	O
within	O
this	O
region	O
.	O

Data	O
presented	O
here	O
supports	O
the	O
hypothesis	O
that	O
congenital	B-DiseaseOrPhenotypicFeature
microcoria	I-DiseaseOrPhenotypicFeature
is	O
a	O
potential	O
risk	O
factor	O
for	O
glaucoma	B-DiseaseOrPhenotypicFeature
,	O
although	O
this	O
observation	O
is	O
complicated	O
by	O
the	O
partial	O
segregation	O
of	O
MYOC	B-GeneOrGeneProduct
Q48H	B-SequenceVariant
(	O
1q24	O
.	O
3	O
-	O
q25	O
.	O
2	O
)	O
,	O
a	O
mutation	O
known	O
to	O
be	O
associated	O
with	O
glaucoma	B-DiseaseOrPhenotypicFeature
in	O
India	O
.	O

Fine	O
mapping	O
and	O
candidate	O
gene	O
analysis	O
continues	O
with	O
the	O
hope	O
that	O
characterizing	O
the	O
micocoria	B-GeneOrGeneProduct
gene	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
microcoria	B-DiseaseOrPhenotypicFeature
and	O
glaucoma	B-DiseaseOrPhenotypicFeature
causation	O
.	O

The	O
relationship	O
between	O
microcoria	B-DiseaseOrPhenotypicFeature
,	O
glaucoma	B-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
MYOC	B-GeneOrGeneProduct
Q48H	B-SequenceVariant
mutation	O
in	O
this	O
family	O
is	O
discussed	O
.	O
Chemokine	O
CCL2	B-GeneOrGeneProduct
and	O
its	O
receptor	O
CCR2	B-GeneOrGeneProduct
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Neuroinflammation	B-DiseaseOrPhenotypicFeature
occurs	O
after	O
seizures	B-DiseaseOrPhenotypicFeature
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O

CCR2	B-GeneOrGeneProduct
is	O
a	O
chemokine	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
for	O
CCL2	B-GeneOrGeneProduct
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	B-DiseaseOrPhenotypicFeature
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O

In	O
this	O
work	O
CCR2	B-GeneOrGeneProduct
and	O
CCL2	B-GeneOrGeneProduct
expression	O
were	O
examined	O
following	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
(	O
SE	B-DiseaseOrPhenotypicFeature
)	O
induced	O
by	O
pilocarpine	B-ChemicalEntity
injection	O
.	O

METHODS	O
:	O
SE	B-DiseaseOrPhenotypicFeature
was	O
induced	O
by	O
pilocarpine	B-ChemicalEntity
injection	O
.	O

Control	O
rats	B-OrganismTaxon
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	B-ChemicalEntity
.	O

Five	O
days	O
after	O
SE	B-DiseaseOrPhenotypicFeature
,	O
CCR2	B-GeneOrGeneProduct
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O

The	O
number	O
of	O
CCR2	B-GeneOrGeneProduct
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O

CCL2	B-GeneOrGeneProduct
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay	O
.	O

RESULTS	O
:	O
Increased	O
CCR2	B-GeneOrGeneProduct
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B-DiseaseOrPhenotypicFeature
.	O

Seizures	B-DiseaseOrPhenotypicFeature
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	B-GeneOrGeneProduct
.	O

Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	B-GeneOrGeneProduct
was	O
observed	O
following	O
SE	B-DiseaseOrPhenotypicFeature
.	O

Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2	B-GeneOrGeneProduct
-	O
labeled	O
cells	O
in	O
SE	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
.	O

In	O
addition	O
,	O
rats	B-OrganismTaxon
that	O
experienced	O
SE	B-DiseaseOrPhenotypicFeature
exhibited	O
CCR2	B-GeneOrGeneProduct
-	O
labeling	O
in	O
populations	O
of	O
hypertrophied	O
astrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O

These	O
CCR2	B-GeneOrGeneProduct
+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats	B-OrganismTaxon
.	O

Examination	O
of	O
CCL2	B-GeneOrGeneProduct
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	B-GeneOrGeneProduct
and	O
CCL2	B-GeneOrGeneProduct
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
SE	B-DiseaseOrPhenotypicFeature
.	O

Seizures	B-DiseaseOrPhenotypicFeature
also	O
result	O
in	O
changes	O
to	O
CCR2	B-GeneOrGeneProduct
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O

These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	B-DiseaseOrPhenotypicFeature
changes	O
that	O
occur	O
following	O
seizures	B-DiseaseOrPhenotypicFeature
.	O
Ubiquitin	B-GeneOrGeneProduct
carboxyl	I-GeneOrGeneProduct
-	O
terminal	I-GeneOrGeneProduct
esterase	I-GeneOrGeneProduct
L1	I-GeneOrGeneProduct
(	O
UCHL1	B-GeneOrGeneProduct
)	O
is	O
associated	O
with	O
stem	O
-	O
like	O
cancer	B-DiseaseOrPhenotypicFeature
cell	O
functions	O
in	O
pediatric	O
high	O
-	O
grade	O
glioma	B-DiseaseOrPhenotypicFeature
.	O

Pediatric	O
high	O
-	O
grade	O
gliomas	B-DiseaseOrPhenotypicFeature
represent	O
8	O
-	O
12%	O
of	O
all	O
primary	O
tumors	B-DiseaseOrPhenotypicFeature
of	O
the	O
nervous	O
system	O
in	O
children	O
.	O

Five	O
-	O
year	O
survival	O
for	O
these	O
pediatric	O
aggressive	O
tumors	B-DiseaseOrPhenotypicFeature
is	O
poor	O
(	O
15	O
-	O
35%	O
)	O
indicating	O
the	O
need	O
to	O
develop	O
better	O
treatments	O
for	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
work	O
we	O
used	O
SF188	B-CellLine
and	O
SJ	B-CellLine
-	O
GBM2	I-CellLine
cell	O
lines	O
to	O
study	O
the	O
function	O
of	O
the	O
ubiquitin	B-GeneOrGeneProduct
carboxyl	I-GeneOrGeneProduct
-	O
terminal	I-GeneOrGeneProduct
esterase	I-GeneOrGeneProduct
L1	I-GeneOrGeneProduct
(	O
UCHL1	B-GeneOrGeneProduct
)	O
,	O
a	O
deubiquitinase	O
de	O
-	O
regulated	O
in	O
several	O
cancers	B-DiseaseOrPhenotypicFeature
,	O
in	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-DiseaseOrPhenotypicFeature
.	O

UCHL1	B-GeneOrGeneProduct
depletion	O
in	O
SF188	B-CellLine
and	O
SJ	B-CellLine
-	O
GBM2	I-CellLine
glioma	B-DiseaseOrPhenotypicFeature
cells	O
was	O
associated	O
with	O
decreased	O
cell	O
proliferation	O
and	O
invasion	O
,	O
along	O
with	O
a	O
reduced	O
ability	O
to	O
grow	O
in	O
soft	O
agar	B-ChemicalEntity
and	O
to	O
form	O
spheres	O
(	O
i	O
.	O
e	O
.	O

self	O
-	O
renewal	O
measure	O
)	O
.	O

A	O
70%	O
reduction	O
in	O
Wnt	B-GeneOrGeneProduct
signaling	O
was	O
also	O
observed	O
in	O
the	O
SF188	B-CellLine
and	O
SJ	B-CellLine
-	O
GBM2	I-CellLine
UCHL1	B-GeneOrGeneProduct
knockdowns	O
(	O
KDs	O
)	O
using	O
a	O
TCF	B-GeneOrGeneProduct
-	O
dependent	O
TOPflash	O
reporter	O
assay	O
.	O

Transcriptome	O
comparisons	O
of	O
UCHL1	B-GeneOrGeneProduct
KDs	O
versus	O
vector	O
control	O
identified	O
a	O
list	O
of	O
306	O
differentially	O
expressed	O
genes	O
(	O
at	O
least	O
2	O
-	O
fold	O
change	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
which	O
included	O
genes	O
known	O
to	O
be	O
involved	O
in	O
cancer	B-DiseaseOrPhenotypicFeature
like	O
ACTA2	B-GeneOrGeneProduct
,	O
POSTN	B-GeneOrGeneProduct
,	O
LIF	B-GeneOrGeneProduct
,	O
FBXL7	B-GeneOrGeneProduct
,	O
FBXW11	B-GeneOrGeneProduct
,	O
GDF15	B-GeneOrGeneProduct
,	O
HEY2	B-GeneOrGeneProduct
,	O
but	O
also	O
potential	O
novel	O
genes	O
such	O
us	O
IGLL5	B-GeneOrGeneProduct
,	O
ABCA4	B-GeneOrGeneProduct
,	O
AQP3	B-GeneOrGeneProduct
,	O
AQP4	B-GeneOrGeneProduct
,	O
CALB1	B-GeneOrGeneProduct
,	O
and	O
ALK	B-GeneOrGeneProduct
.	O

Bioinformatics	O
gene	O
ontology	O
(	O
GO	O
)	O
analysis	O
of	O
these	O
306	O
genes	O
revealed	O
significant	O
enrichment	O
in	O
""""	O
signal	O
peptides	O
""""	O
,	O
""""	O
extracellular	O
matrix	O
""""	O
and	O
""""	O
secreted	O
proteins	O
""""	O
GO	O
Terms	O
.	O

""""	O
Angiogenesis	O
and	O
blood	O
vessel	O
development	O
""""	O
,	O
""""	O
neuron	O
differentiation	O
/	O
development	O
""""	O
,	O
cell	O
adhesion	O
""""	O
,	O
and	O
""""	O
cell	O
migration	O
""""	O
also	O
showed	O
significant	O
enrichment	O
in	O
our	O
GO	O
analysis	O
.	O

Top	O
canonical	O
pathways	O
identified	O
by	O
Ingenuity	O
Pathway	O
Analysis	O
(	O
IPA	O
)	O
included	O
""""	O
Clathrin	B-GeneOrGeneProduct
-	O
mediated	O
Endocytosis	O
Signaling	O
""""	O
(	O
p	O
=	O
5	O
.	O
14x10	O
-	O
4	O
)	O
,	O
""""	O
Virus	O
Entry	O
via	O
Endocytic	O
Pathways	O
""""	O
(	O
p	O
=	O
6	O
.	O
15x	O
10	O
-	O
4	O
)	O
,	O
and	O
""""	O
High	B-GeneOrGeneProduct
Mobility	I-GeneOrGeneProduct
Group	I-GeneOrGeneProduct
-	O
Box	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
HMGB1	B-GeneOrGeneProduct
)	O
Signaling	O
""""	O
(	O
p	O
=	O
6	O
.	O
15x10	O
-	O
4	O
)	O
.	O

While	O
FGF2	B-GeneOrGeneProduct
,	O
IL1B	B-GeneOrGeneProduct
,	O
TNF	B-GeneOrGeneProduct
and	O
PDGFB	B-GeneOrGeneProduct
were	O
predicted	O
as	O
top	O
upstream	O
regulators	O
(	O
p	O
<	O
2x10	O
-	O
16	O
)	O
of	O
the	O
UCHL1	B-GeneOrGeneProduct
KD	O
-	O
associated	O
transcriptome	O
.	O

Aberrant	O
expression	O
of	O
UCHL1	B-GeneOrGeneProduct
in	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-DiseaseOrPhenotypicFeature
may	O
promote	O
cell	O
invasion	O
,	O
transformation	O
,	O
and	O
self	O
-	O
renewal	O
properties	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
modulating	O
Wnt	B-GeneOrGeneProduct
/	O
Beta	B-GeneOrGeneProduct
catenin	I-GeneOrGeneProduct
activity	O
.	O

UCHL1	B-GeneOrGeneProduct
might	O
act	O
as	O
an	O
oncogene	O
in	O
glioma	B-DiseaseOrPhenotypicFeature
within	O
the	O
gene	O
network	O
that	O
imparts	O
stem	O
-	O
like	O
characteristics	O
to	O
these	O
cancer	B-DiseaseOrPhenotypicFeature
cells	O
.	O
Langerin	B-GeneOrGeneProduct
,	O
a	O
novel	O
C	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
lectin	I-GeneOrGeneProduct
specific	O
to	O
Langerhans	O
cells	O
,	O
is	O
an	O
endocytic	O
receptor	O
that	O
induces	O
the	O
formation	O
of	O
Birbeck	O
granules	O
.	O

We	O
have	O
identified	O
a	O
type	B-GeneOrGeneProduct
II	I-GeneOrGeneProduct
Ca2	I-GeneOrGeneProduct
+	O
-	O
dependent	I-GeneOrGeneProduct
lectin	I-GeneOrGeneProduct
displaying	O
mannose	B-ChemicalEntity
-	O
binding	O
specificity	O
,	O
exclusively	O
expressed	O
by	O
Langerhans	O
cells	O
(	O
LC	O
)	O
,	O
and	O
named	O
Langerin	B-GeneOrGeneProduct
.	O

LC	O
are	O
uniquely	O
characterized	O
by	O
Birbeck	O
granules	O
(	O
BG	O
)	O
,	O
which	O
are	O
organelles	O
consisting	O
of	O
superimposed	O
and	O
zippered	O
membranes	O
.	O

Here	O
,	O
we	O
have	O
shown	O
that	O
Langerin	B-GeneOrGeneProduct
is	O
constitutively	O
associated	O
with	O
BG	O
and	O
that	O
antibody	O
to	O
Langerin	B-GeneOrGeneProduct
is	O
internalized	O
into	O
these	O
structures	O
.	O

Remarkably	O
,	O
transfection	O
of	O
Langerin	B-GeneOrGeneProduct
cDNA	O
into	O
fibroblasts	O
created	O
a	O
compact	O
network	O
of	O
membrane	O
structures	O
with	O
typical	O
features	O
of	O
BG	O
.	O

Langerin	B-GeneOrGeneProduct
is	O
thus	O
a	O
potent	O
inducer	O
of	O
membrane	O
superimposition	O
and	O
zippering	O
leading	O
to	O
BG	O
formation	O
.	O

Our	O
data	O
suggest	O
that	O
induction	O
of	O
BG	O
is	O
a	O
consequence	O
of	O
the	O
antigen	O
-	O
capture	O
function	O
of	O
Langerin	B-GeneOrGeneProduct
,	O
allowing	O
routing	O
into	O
these	O
organelles	O
and	O
providing	O
access	O
to	O
a	O
nonclassical	O
antigen	O
-	O
processing	O
pathway	O
.	O
Polymorphism	O
of	O
the	O
PEMT	B-GeneOrGeneProduct
gene	O
and	O
susceptibility	O
to	O
nonalcoholic	B-DiseaseOrPhenotypicFeature
fatty	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
NAFLD	B-DiseaseOrPhenotypicFeature
)	O
.	O

Phosphatidylethanolamine	B-GeneOrGeneProduct
N	I-GeneOrGeneProduct
-	O
methyltransferase	I-GeneOrGeneProduct
(	O
PEMT	B-GeneOrGeneProduct
)	O
catalyzes	O
phosphatidylcholine	B-ChemicalEntity
synthesis	O
.	O

PEMT	B-GeneOrGeneProduct
knockout	O
mice	B-OrganismTaxon
have	O
fatty	B-DiseaseOrPhenotypicFeature
livers	I-DiseaseOrPhenotypicFeature
,	O
and	O
it	O
is	O
possible	O
that	O
,	O
in	O
humans	B-OrganismTaxon
,	O
nonalcoholic	B-DiseaseOrPhenotypicFeature
fatty	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
NAFLD	B-DiseaseOrPhenotypicFeature
)	O
might	O
be	O
associated	O
with	O
PEMT	B-GeneOrGeneProduct
gene	O
polymorphisms	O
.	O

DNA	O
samples	O
from	O
59	O
humans	B-OrganismTaxon
without	O
fatty	B-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
and	O
from	O
28	O
humans	B-OrganismTaxon
with	O
NAFLD	B-DiseaseOrPhenotypicFeature
were	O
genotyped	O
for	O
a	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
8	O
of	O
PEMT	B-GeneOrGeneProduct
,	O
which	O
leads	O
to	O
a	O
V175M	B-SequenceVariant
substitution	O
.	O

V175M	B-SequenceVariant
is	O
a	O
loss	O
of	O
function	O
mutation	O
,	O
as	O
determined	O
by	O
transiently	O
transfecting	O
McArdle	B-CellLine
-	O
RH7777	I-CellLine
cells	O
with	O
constructs	O
of	O
wild	O
-	O
type	O
PEMT	B-GeneOrGeneProduct
open	O
reading	O
frame	O
or	O
the	O
V175M	B-SequenceVariant
mutant	O
.	O

Met	B-SequenceVariant
/	O
Met	I-SequenceVariant
at	I-SequenceVariant
residue	I-SequenceVariant
175	I-SequenceVariant
(	O
loss	O
of	O
function	O
SNP	O
)	O
occurred	O
in	O
67	O
.	O
9%	O
of	O
the	O
NAFLD	B-DiseaseOrPhenotypicFeature
subjects	O
and	O
in	O
only	O
40	O
.	O
7%	O
of	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
03	O
)	O
.	O

For	O
the	O
first	O
time	O
we	O
report	O
that	O
a	O
polymorphism	O
of	O
the	O
human	B-OrganismTaxon
PEMT	B-GeneOrGeneProduct
gene	O
(	O
V175M	B-SequenceVariant
)	O
is	O
associated	O
with	O
diminished	O
activity	O
and	O
may	O
confer	O
susceptibility	O
to	O
NAFLD	B-DiseaseOrPhenotypicFeature
.	O
Mutation	O
screening	O
of	O
the	O
GUCA1B	B-GeneOrGeneProduct
gene	O
in	O
patients	B-OrganismTaxon
with	O
autosomal	O
dominant	O
cone	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
cone	I-DiseaseOrPhenotypicFeature
rod	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
.	O

Background	O
:	O
Heterozygous	O
mutations	O
in	O
GUCA1A	B-GeneOrGeneProduct
(	O
MIM	O
#	O
600364	O
)	O
have	O
been	O
identified	O
to	O
cause	O
autosomal	O
dominantly	O
inherited	O
cone	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
,	O
cone	B-DiseaseOrPhenotypicFeature
rod	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
and	O
macular	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
the	O
role	O
of	O
GUCA1B	B-GeneOrGeneProduct
gene	O
mutations	O
in	O
inherited	O
retinal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
has	O
been	O
controversial	O
.	O

We	O
therefore	O
performed	O
a	O
mutation	O
analysis	O
of	O
the	O
GUCA1B	B-GeneOrGeneProduct
gene	O
in	O
a	O
clinically	O
well	O
characterized	O
group	O
of	O
patients	B-OrganismTaxon
of	O
European	O
and	O
North	O
-	O
American	O
geographical	O
origin	O
with	O
autosomal	O
dominantly	O
inherited	O
cone	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
and	O
cone	B-DiseaseOrPhenotypicFeature
rod	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
.	O

Material	O
and	O
Methods	O
:	O
Twenty	O
-	O
four	O
unrelated	O
patients	B-OrganismTaxon
diagnosed	O
with	O
cone	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
or	O
cone	B-DiseaseOrPhenotypicFeature
rod	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
according	O
to	O
standard	O
diagnostic	O
criteria	O
and	O
a	O
family	O
history	O
consistent	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
were	O
included	O
in	O
the	O
study	O
.	O

Mutation	O
analysis	O
of	O
all	O
coding	O
exons	O
of	O
the	O
GUCA1B	B-GeneOrGeneProduct
gene	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
genomic	O
DNA	O
and	O
subsequent	O
DNA	O
sequencing	O
.	O

Results	O
:	O
Three	O
different	O
sequence	O
variants	O
,	O
c	B-SequenceVariant
.	O
-	O
17T	I-SequenceVariant
>	O
C	I-SequenceVariant
,	O
c	B-SequenceVariant
.	O
171T	I-SequenceVariant
>	O
C	I-SequenceVariant
,	O
c	B-SequenceVariant
.	O
465G	I-SequenceVariant
>	O
T	I-SequenceVariant
were	O
identified	O
.	O

The	O
sequence	O
variant	O
c	B-SequenceVariant
.	O
465G	I-SequenceVariant
>	O
T	I-SequenceVariant
encodes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
,	O
p	B-SequenceVariant
.	O
Glu155Asp	I-SequenceVariant
,	O
located	O
in	O
EF	O
-	O
hand	O
4	O
,	O
the	O
calcium	B-ChemicalEntity
binding	O
site	O
of	O
GCAP2	B-GeneOrGeneProduct
protein	O
.	O

All	O
sequence	O
variants	O
were	O
previously	O
reported	O
in	O
healthy	O
subjects	O
.	O

Conclusion	O
:	O
The	O
absence	O
of	O
clearly	O
pathogenic	O
mutations	O
in	O
the	O
selected	O
patient	B-OrganismTaxon
group	O
suggests	O
that	O
the	O
GUCA1B	B-GeneOrGeneProduct
gene	O
is	O
a	O
minor	O
cause	O
for	O
retinal	B-DiseaseOrPhenotypicFeature
degenerations	I-DiseaseOrPhenotypicFeature
in	O
Europeans	O
or	O
North	O
-	O
Americans	O
.	O
Negative	O
Selection	O
and	O
Chromosome	B-DiseaseOrPhenotypicFeature
Instability	I-DiseaseOrPhenotypicFeature
Induced	O
by	O
Mad2	B-GeneOrGeneProduct
Overexpression	O
Delay	O
Breast	B-DiseaseOrPhenotypicFeature
Cancer	I-DiseaseOrPhenotypicFeature
but	O
Facilitate	O
Oncogene	O
-	O
Independent	O
Outgrowth	O
.	O

Chromosome	B-DiseaseOrPhenotypicFeature
instability	I-DiseaseOrPhenotypicFeature
(	O
CIN	B-DiseaseOrPhenotypicFeature
)	O
is	O
associated	O
with	O
poor	O
survival	O
and	O
therapeutic	O
outcome	O
in	O
a	O
number	O
of	O
malignancies	B-DiseaseOrPhenotypicFeature
.	O

Despite	O
this	O
correlation	O
,	O
CIN	B-DiseaseOrPhenotypicFeature
can	O
also	O
lead	O
to	O
growth	O
disadvantages	O
.	O

Here	O
,	O
we	O
show	O
that	O
simultaneous	O
overexpression	O
of	O
the	O
mitotic	O
checkpoint	O
protein	O
Mad2	B-GeneOrGeneProduct
with	O
Kras	B-GeneOrGeneProduct
(	O
G12D	B-GeneOrGeneProduct
)	O
or	O
Her2	B-GeneOrGeneProduct
in	O
mammary	O
glands	O
of	O
adult	O
mice	B-OrganismTaxon
results	O
in	O
mitotic	O
checkpoint	O
overactivation	O
and	O
a	O
delay	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
onset	O
.	O

Time	O
-	O
lapse	O
imaging	O
of	O
organotypic	O
cultures	O
and	O
pathologic	O
analysis	O
prior	O
to	O
tumor	B-DiseaseOrPhenotypicFeature
establishment	O
reveals	O
error	O
-	O
prone	O
mitosis	O
,	O
mitotic	O
arrest	O
,	O
and	O
cell	O
death	O
.	O

Nonetheless	O
,	O
Mad2	B-GeneOrGeneProduct
expression	O
persists	O
and	O
increases	O
karyotype	O
complexity	O
in	O
Kras	B-GeneOrGeneProduct
tumors	B-DiseaseOrPhenotypicFeature
.	O

Faced	O
with	O
the	O
selective	O
pressure	O
of	O
oncogene	O
withdrawal	O
,	O
Mad2	B-GeneOrGeneProduct
-	O
positive	O
tumors	B-DiseaseOrPhenotypicFeature
have	O
a	O
higher	O
frequency	O
of	O
developing	O
persistent	O
subclones	O
that	O
avoid	O
remission	O
and	O
continue	O
to	O
grow	O
.	O
Neuroprotective	O
effect	O
of	O
neuroserpin	B-GeneOrGeneProduct
in	O
oxygen	B-ChemicalEntity
-	O
glucose	B-ChemicalEntity
deprivation	O
-	O
and	O
reoxygenation	O
-	O
treated	O
rat	B-OrganismTaxon
astrocytes	O
in	O
vitro	O
.	O

Neuroserpin	B-GeneOrGeneProduct
(	O
NSP	B-GeneOrGeneProduct
)	O
reportedly	O
exerts	O
neuroprotective	O
effects	O
in	O
cerebral	B-DiseaseOrPhenotypicFeature
ischemic	I-DiseaseOrPhenotypicFeature
animal	O
models	O
and	O
patients	B-OrganismTaxon
;	O
however	O
,	O
the	O
mechanism	O
of	O
protection	O
is	O
poorly	O
understood	O
.	O

We	O
thus	O
attempted	O
to	O
confirm	O
neuroprotective	O
effects	O
of	O
NSP	B-GeneOrGeneProduct
on	O
astrocytes	O
in	O
the	O
ischemic	B-DiseaseOrPhenotypicFeature
state	O
and	O
then	O
explored	O
the	O
relative	O
mechanisms	O
.	O

Astrocytes	O
from	O
neonatal	O
rats	B-OrganismTaxon
were	O
treated	O
with	O
oxygen	B-ChemicalEntity
-	O
glucose	B-ChemicalEntity
deprivation	O
(	O
OGD	O
)	O
followed	O
by	O
reoxygenation	O
(	O
OGD	O
/	O
R	O
)	O
.	O

To	O
confirm	O
the	O
neuroprotective	O
effects	O
of	O
NSP	B-GeneOrGeneProduct
,	O
we	O
measured	O
the	O
cell	O
survival	O
rate	O
,	O
relative	O
lactate	B-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
(	O
LDH	B-GeneOrGeneProduct
)	O
release	O
;	O
we	O
also	O
performed	O
morphological	O
methods	O
,	O
namely	O
Hoechst	O
33342	O
staining	O
and	O
Annexin	B-GeneOrGeneProduct
V	I-GeneOrGeneProduct
assay	O
.	O

To	O
explore	O
the	O
potential	O
mechanisms	O
of	O
NSP	B-GeneOrGeneProduct
,	O
the	O
release	O
of	O
nitric	B-ChemicalEntity
oxide	I-ChemicalEntity
(	O
NO	B-ChemicalEntity
)	O
and	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
related	O
to	O
NSP	B-GeneOrGeneProduct
administration	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
proteins	O
related	O
to	O
the	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
,	O
ERK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
,	O
and	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
pathways	O
were	O
investigated	O
by	O
Western	O
blotting	O
.	O

To	O
verify	O
the	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
neuroprotection	O
and	O
the	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
pathway	O
,	O
a	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
pathway	O
inhibitor	O
sc3060	B-ChemicalEntity
was	O
employed	O
to	O
observe	O
the	O
effects	O
of	O
NSP	B-GeneOrGeneProduct
-	O
induced	O
neuroprotection	O
.	O

We	O
found	O
that	O
NSP	B-GeneOrGeneProduct
significantly	O
increased	O
the	O
cell	O
survival	O
rate	O
and	O
reduced	O
LDH	B-GeneOrGeneProduct
release	O
in	O
OGD	O
/	O
R	O
-	O
treated	O
astrocytes	O
.	O

It	O
also	O
reduced	O
NO	B-ChemicalEntity
/	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
release	O
.	O

Western	O
blotting	O
showed	O
that	O
the	O
protein	O
levels	O
of	O
p	O
-	O
IKKBalpha	B-GeneOrGeneProduct
/	O
beta	I-GeneOrGeneProduct
and	O
P65	B-GeneOrGeneProduct
were	O
upregulated	O
by	O
the	O
OGD	O
/	O
R	O
treatment	O
and	O
such	O
effects	O
were	O
significantly	O
inhibited	O
by	O
NSP	B-GeneOrGeneProduct
administration	O
.	O

The	O
NSP	B-GeneOrGeneProduct
-	O
induced	O
inhibition	O
could	O
be	O
significantly	O
reversed	O
by	O
administration	O
of	O
the	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
pathway	O
inhibitor	O
sc3060	B-ChemicalEntity
,	O
whereas	O
,	O
expressions	O
of	O
p	O
-	O
ERK1	B-GeneOrGeneProduct
,	O
p	O
-	O
ERK2	B-GeneOrGeneProduct
,	O
and	O
p	O
-	O
AKT	B-GeneOrGeneProduct
were	O
upregulated	O
by	O
the	O
OGD	O
/	O
R	O
treatment	O
;	O
however	O
,	O
their	O
levels	O
were	O
unchanged	O
by	O
NSP	B-GeneOrGeneProduct
administration	O
.	O

Our	O
results	O
thus	O
verified	O
the	O
neuroprotective	O
effects	O
of	O
NSP	B-GeneOrGeneProduct
in	O
ischemic	B-DiseaseOrPhenotypicFeature
astrocytes	O
.	O

The	O
potential	O
mechanisms	O
include	O
inhibition	O
of	O
the	O
release	O
of	O
NO	B-ChemicalEntity
/	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
and	O
repression	O
of	O
the	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
signaling	O
pathways	O
.	O

Our	O
data	O
also	O
indicated	O
that	O
NSP	B-GeneOrGeneProduct
has	O
little	O
influence	O
on	O
the	O
MAPK	B-GeneOrGeneProduct
and	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
pathways	O
.	O

Genotype	O
rs8099917	B-SequenceVariant
near	O
the	O
IL28B	B-GeneOrGeneProduct
gene	O
and	O
amino	O
acid	O
substitution	O
at	O
position	O
70	O
in	O
the	O
core	O
region	O
of	O
the	O
hepatitis	B-OrganismTaxon
C	I-OrganismTaxon
virus	I-OrganismTaxon
are	O
determinants	O
of	O
serum	O
apolipoprotein	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
concentration	O
in	O
chronic	B-DiseaseOrPhenotypicFeature
hepatitis	I-DiseaseOrPhenotypicFeature
C	I-DiseaseOrPhenotypicFeature
.	O

The	O
life	O
cycle	O
of	O
the	O
hepatitis	B-OrganismTaxon
C	I-OrganismTaxon
virus	I-OrganismTaxon
(	O
HCV	B-OrganismTaxon
)	O
is	O
closely	O
related	O
to	O
host	O
lipoprotein	O
metabolism	O
.	O

Serum	O
levels	O
of	O
lipid	B-ChemicalEntity
are	O
associated	O
with	O
the	O
response	O
to	O
pegylated	B-GeneOrGeneProduct
interferon	I-GeneOrGeneProduct
plus	O
ribavirin	B-ChemicalEntity
(	O
PEG	B-GeneOrGeneProduct
-	O
IFN	I-GeneOrGeneProduct
/	O
RBV	B-ChemicalEntity
)	O
therapy	O
,	O
while	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
around	O
the	O
human	B-OrganismTaxon
interleukin	B-GeneOrGeneProduct
28B	I-GeneOrGeneProduct
(	O
IL28B	B-GeneOrGeneProduct
)	O
gene	O
locus	O
and	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	B-OrganismTaxon
have	O
been	O
reported	O
to	O
affect	O
the	O
efficacy	O
of	O
PEG	B-GeneOrGeneProduct
-	O
IFN	I-GeneOrGeneProduct
/	O
RBV	B-ChemicalEntity
therapy	O
in	O
chronic	B-DiseaseOrPhenotypicFeature
hepatitis	I-DiseaseOrPhenotypicFeature
with	O
HCV	B-DiseaseOrPhenotypicFeature
genotype	I-DiseaseOrPhenotypicFeature
1b	I-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
relationship	O
between	O
serum	O
lipid	B-ChemicalEntity
and	O
factors	O
that	O
are	O
able	O
to	O
predict	O
the	O
efficacy	O
of	O
PEG	B-GeneOrGeneProduct
-	O
IFN	I-GeneOrGeneProduct
/	O
RB	B-ChemicalEntity
therapy	O
,	O
with	O
specific	O
focus	O
on	O
apolipoprotein	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
(	O
apoB	B-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
)	O
in	O
148	O
subjects	O
with	O
chronic	O
HCV	B-DiseaseOrPhenotypicFeature
G1b	I-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

Our	O
results	O
demonstrated	O
that	O
both	O
the	O
aa	O
70	O
substitution	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	B-OrganismTaxon
and	O
the	O
rs8099917	B-SequenceVariant
SNP	O
located	O
proximal	O
to	O
the	O
IL28B	B-GeneOrGeneProduct
were	O
independent	O
factors	O
in	O
determining	O
serum	O
apoB	B-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
and	O
low	B-ChemicalEntity
-	O
density	I-ChemicalEntity
lipoprotein	I-ChemicalEntity
(	O
LDL	I-ChemicalEntity
)	O
cholesterol	I-ChemicalEntity
levels	O
.	O

A	O
significant	O
association	O
was	O
noted	O
between	O
higher	O
levels	O
of	O
apoB	B-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
(	O
P	O
=	O
1	O
.	O
1	O
10	O
(	O
-	O
3	O
)	O
)	O
and	O
LDL	B-ChemicalEntity
cholesterol	I-ChemicalEntity
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
the	O
subjects	O
having	O
Arg70	B-SequenceVariant
.	O

A	O
significant	O
association	O
was	O
also	O
observed	O
between	O
subjects	O
carrying	O
the	O
rs8099917	B-SequenceVariant
TT	O
responder	O
genotype	O
and	O
higher	O
levels	O
of	O
apoB	B-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
(	O
P	O
=	O
6	O
.	O
4	O
10	O
(	O
-	O
3	O
)	O
)	O
and	O
LDL	B-ChemicalEntity
cholesterol	I-ChemicalEntity
(	O
P	O
=	O
4	O
.	O
2	O
10	O
(	O
-	O
3	O
)	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
apoB	B-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
and	O
LDL	B-ChemicalEntity
cholesterol	I-ChemicalEntity
are	O
markers	O
of	O
impaired	O
cellular	O
lipoprotein	O
pathways	O
and	O
/	O
or	O
host	O
endogenous	O
interferon	O
response	O
to	O
HCV	B-OrganismTaxon
in	O
chronic	O
HCV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

In	O
particular	O
,	O
serum	O
apoB	B-GeneOrGeneProduct
-	O
100	I-GeneOrGeneProduct
concentration	O
might	O
be	O
an	O
informative	O
marker	O
for	O
judging	O
changes	O
in	O
HCV	B-OrganismTaxon
-	O
associated	O
intracellular	O
lipoprotein	O
metabolism	O
in	O
patients	B-OrganismTaxon
carrying	O
the	O
rs8099917	B-SequenceVariant
responder	O
genotype	O
.	O
Randomized	O
comparison	O
of	O
olanzapine	B-ChemicalEntity
versus	O
risperidone	B-ChemicalEntity
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	B-DiseaseOrPhenotypicFeature
:	O
4	O
-	O
month	O
outcomes	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4	O
-	O
month	O
treatment	O
outcomes	O
for	O
olanzapine	B-ChemicalEntity
versus	O
risperidone	B-ChemicalEntity
in	O
patients	O
with	O
first	O
-	O
episode	O
schizophrenia	B-DiseaseOrPhenotypicFeature
spectrum	O
disorders	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70%	O
male	O
;	O
mean	O
age	O
=	O
23	O
.	O
3	O
years	O
[	O
SD	O
=	O
5	O
.	O
1	O
]	O
)	O
with	O
first	O
-	O
episode	O
schizophrenia	B-DiseaseOrPhenotypicFeature
(	O
75%	O
)	O
,	O
schizophreniform	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
(	O
17%	O
)	O
,	O
or	O
schizoaffective	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
(	O
8%	O
)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	B-ChemicalEntity
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	B-ChemicalEntity
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O

RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	B-ChemicalEntity
(	O
43	O
.	O
7%	O
,	O
95%	O
CI	O
=	O
28	O
.	O
8%	O
-	O
58	O
.	O
6%	O
)	O
and	O
risperidone	B-ChemicalEntity
(	O
54	O
.	O
3%	O
,	O
95%	O
CI	O
=	O
39	O
.	O
9%	O
-	O
68	O
.	O
7%	O
)	O
.	O

Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	B-ChemicalEntity
group	O
(	O
40	O
.	O
9%	O
,	O
95%	O
CI	O
=	O
16	O
.	O
8%	O
-	O
65	O
.	O
0%	O
)	O
than	O
in	O
the	O
risperidone	B-ChemicalEntity
group	O
(	O
18	O
.	O
9%	O
,	O
95%	O
CI	O
=	O
0%	O
-	O
39	O
.	O
2%	O
)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O

Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B-DiseaseOrPhenotypicFeature
and	O
akathisia	B-DiseaseOrPhenotypicFeature
did	O
not	O
differ	O
between	O
medications	O
.	O

Extrapyramidal	B-DiseaseOrPhenotypicFeature
symptom	I-DiseaseOrPhenotypicFeature
severity	O
scores	O
were	O
1	O
.	O
4	O
(	O
95%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
risperidone	B-ChemicalEntity
and	O
1	O
.	O
2	O
(	O
95%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
olanzapine	B-ChemicalEntity
.	O

Significantly	O
more	O
weight	B-DiseaseOrPhenotypicFeature
gain	I-DiseaseOrPhenotypicFeature
occurred	O
with	O
olanzapine	B-ChemicalEntity
than	O
with	O
risperidone	B-ChemicalEntity
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17	O
.	O
3%	O
(	O
95%	O
CI	O
=	O
14	O
.	O
2%	O
-	O
20	O
.	O
5%	O
)	O
with	O
olanzapine	B-ChemicalEntity
and	O
11	O
.	O
3%	O
(	O
95%	O
CI	O
=	O
8	O
.	O
4%	O
-	O
14	O
.	O
3%	O
)	O
with	O
risperidone	B-ChemicalEntity
.	O

Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24	O
.	O
3	O
(	O
95%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzapine	B-ChemicalEntity
and	O
23	O
.	O
9	O
(	O
95%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperidone	B-ChemicalEntity
.	O

CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	B-ChemicalEntity
were	O
equal	O
to	O
those	O
with	O
olanzapine	B-ChemicalEntity
,	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O

Olanzapine	B-ChemicalEntity
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O

Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B-DiseaseOrPhenotypicFeature
gain	I-DiseaseOrPhenotypicFeature
,	O
but	O
weight	B-DiseaseOrPhenotypicFeature
gain	I-DiseaseOrPhenotypicFeature
was	O
greater	O
with	O
olanzapine	B-ChemicalEntity
.	O
Association	O
between	O
an	O
endoglin	B-GeneOrGeneProduct
gene	O
polymorphism	O
and	O
systemic	B-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
-	O
related	O
pulmonary	B-DiseaseOrPhenotypicFeature
arterial	I-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
.	O

Systemic	B-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
(	O
SSc	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
connective	O
tissue	O
disorder	O
characterized	O
by	O
early	O
generalized	O
microangiopathy	B-DiseaseOrPhenotypicFeature
with	O
disturbed	O
angiogenesis	O
.	O

Endoglin	B-GeneOrGeneProduct
gene	O
(	O
ENG	B-GeneOrGeneProduct
)	O
encodes	O
a	O
transmembrane	O
glycoprotein	B-GeneOrGeneProduct
which	O
acts	O
as	O
an	O
accessory	O
receptor	O
for	O
the	O
transforming	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
(	O
TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
)	O
superfamily	O
,	O
and	O
is	O
crucial	O
for	O
maintaining	O
vascular	O
integrity	O
.	O

A	O
6	B-SequenceVariant
-	O
base	I-SequenceVariant
insertion	I-SequenceVariant
in	O
intron	O
7	O
(	O
6bINS	B-SequenceVariant
)	O
of	O
ENG	B-GeneOrGeneProduct
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
microvascular	O
disturbance	O
.	O

OBJECTIVES	O
:	O
Our	O
objective	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
6bINS	B-SequenceVariant
and	O
the	O
vascular	B-DiseaseOrPhenotypicFeature
complication	I-DiseaseOrPhenotypicFeature
pulmonary	B-DiseaseOrPhenotypicFeature
arterial	I-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
(	O
PAH	B-DiseaseOrPhenotypicFeature
)	O
in	O
SSc	B-DiseaseOrPhenotypicFeature
in	O
a	O
French	O
Caucasian	O
population	O
.	O

METHODS	O
:	O
Two	O
hundred	O
eighty	O
SSc	B-DiseaseOrPhenotypicFeature
cases	O
containing	O
29	O
/	O
280	O
having	O
PAH	B-DiseaseOrPhenotypicFeature
diagnosed	O
by	O
catheterism	O
were	O
compared	O
with	O
140	O
patients	B-OrganismTaxon
with	O
osteoarthritis	B-DiseaseOrPhenotypicFeature
.	O

Genotyping	O
was	O
performed	O
by	O
polymerase	O
-	O
chain	O
-	O
reaction	O
-	O
based	O
fluorescence	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
The	O
polymorphism	O
was	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

We	O
observed	O
a	O
significant	O
lower	O
frequency	O
of	O
6bINS	B-SequenceVariant
allele	O
in	O
SSc	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
associated	O
PAH	B-DiseaseOrPhenotypicFeature
compared	O
with	O
controls	O
[	O
10	O
.	O
3	O
vs	O
23	O
.	O
9%	O
,	O
P	O
=	O
0	O
.	O
01	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
0	O
.	O
37	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
15	O
-	O
0	O
.	O
89	O
]	O
,	O
and	O
a	O
trend	O
in	O
comparison	O
with	O
SSc	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
without	O
PAH	B-DiseaseOrPhenotypicFeature
(	O
10	O
.	O
3	O
vs	O
20	O
.	O
3%	O
,	O
P	O
=	O
0	O
.	O
05	O
;	O
OR	O
:	O
0	O
.	O
45	O
,	O
95%	O
CI	O
:	O
0	O
.	O
19	O
-	O
1	O
.	O
08	O
)	O
.	O

Genotypes	O
carrying	O
allele	O
6bINS	B-SequenceVariant
were	O
also	O
less	O
frequent	O
in	O
SSc	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
PAH	B-DiseaseOrPhenotypicFeature
than	O
in	O
controls	O
(	O
20	O
.	O
7	O
vs	O
42	O
.	O
9%	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

CONCLUSIONS	O
:	O
Thus	O
the	O
frequency	O
of	O
6bINS	B-SequenceVariant
differs	O
between	O
SSc	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
or	O
without	O
PAH	B-DiseaseOrPhenotypicFeature
,	O
suggesting	O
the	O
implication	O
of	O
ENG	B-GeneOrGeneProduct
in	O
this	O
devastating	O
vascular	B-DiseaseOrPhenotypicFeature
complication	I-DiseaseOrPhenotypicFeature
of	O
SSc	B-DiseaseOrPhenotypicFeature
.	O
Screening	O
for	O
exonic	O
copy	O
number	O
mutations	O
at	O
MSH2	B-GeneOrGeneProduct
and	O
MLH1	B-GeneOrGeneProduct
by	O
MAPH	O
.	O

BACKGROUND	O
:	O
Exonic	O
deletions	O
in	O
MSH2	B-GeneOrGeneProduct
and	O
MLH1	B-GeneOrGeneProduct
are	O
significant	O
contributors	O
to	O
the	O
mutation	O
spectrum	O
in	O
HNPCC	B-DiseaseOrPhenotypicFeature
,	O
and	O
heterozygous	O
changes	O
in	O
exon	O
copy	O
number	O
are	O
not	O
detected	O
by	O
conventional	O
mutation	O
screening	O
methods	O
.	O

AIMS	O
:	O
We	O
aimed	O
to	O
develop	O
methods	O
for	O
screening	O
copy	O
number	O
changes	O
in	O
all	O
the	O
exons	O
of	O
the	O
MLH1	B-GeneOrGeneProduct
and	O
MSH2	B-GeneOrGeneProduct
genes	O
using	O
a	O
single	O
multiplex	O
amplifiable	O
probe	O
hybridisation	O
(	O
MAPH	O
)	O
assay	O
.	O

METHODS	O
:	O
We	O
developed	O
a	O
probe	O
set	O
consisting	O
of	O
probes	O
from	O
the	O
19	O
exons	O
of	O
MLH1	B-GeneOrGeneProduct
and	O
16	O
exons	O
of	O
MSH2	B-GeneOrGeneProduct
,	O
and	O
3	O
control	O
probes	O
,	O
and	O
applied	O
it	O
to	O
screening	O
for	O
deletions	O
and	O
duplications	O
using	O
fluorescent	O
detection	O
of	O
amplified	O
fragments	O
.	O

RESULTS	O
:	O
We	O
tested	O
73	O
DNA	O
samples	O
from	O
controls	O
and	O
50	O
from	O
HNPCC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
whom	O
no	O
point	O
mutations	O
had	O
been	O
found	O
,	O
and	O
detected	O
10	O
copy	O
number	O
changes	O
among	O
the	O
patient	B-OrganismTaxon
samples	O
.	O

A	O
deletion	O
of	O
about	O
1	O
.	O
4	O
kb	O
including	O
exon	O
3	O
of	O
MSH2	B-GeneOrGeneProduct
was	O
confirmed	O
by	O
amplification	O
of	O
a	O
junction	O
fragment	O
,	O
and	O
was	O
shown	O
to	O
be	O
the	O
result	O
of	O
an	O
unequal	O
recombination	O
between	O
intronic	O
Alu	O
elements	O
.	O

CONCLUSIONS	O
:	O
MAPH	O
can	O
detect	O
exonic	O
copy	O
number	O
changes	O
in	O
MLH1	B-GeneOrGeneProduct
and	O
MSH2	B-GeneOrGeneProduct
in	O
DNA	O
from	O
HNPCC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Since	O
finding	O
an	O
exonic	O
deletion	O
or	O
duplication	O
makes	O
full	O
sequence	O
analysis	O
unnecessary	O
,	O
it	O
may	O
be	O
most	O
cost	O
-	O
effective	O
to	O
pre	O
-	O
screen	O
samples	O
by	O
MAPH	O
or	O
MLPA	O
before	O
screening	O
for	O
point	O
mutations	O
.	O
